var title_f21_1_21520="Long axis mitral stenosis";
var content_f21_1_21520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two dimensional echocardiogram of mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The precordial long axis during diastole from a two dimensional echocardiogram of a patient with mitral stenosis shows a very small, flow limiting orifice that is maximally opened (arrow). The flexible portion of the valve leaflet domes (assumes a knee bend appearance) under the continually elevated left atrial (LA) pressure and lowered left ventricular (LV) diastolic pressure. The LA and right ventricle (RV) are large and the LV small.",
"    <div class=\"footnotes\">",
"     Ao: aorta.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21520=[""].join("\n");
var outline_f21_1_21520=null;
var title_f21_1_21521="Calculator: Friedewald Equation for Low Density Lipoprotein (LDL-C)";
var content_f21_1_21521=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"Friedewald_form\" name=\"Friedewald_form\" onkeydown=\"clrResults();\" onkeyup=\"Friedewald_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Friedewald Equation for Low Density Lipoprotein (LDL-C)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         LDL = TotalChol - (Triglyceride / 5) - HDL",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Total Chol",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Total_Chol_param\" onblur=\"Friedewald_fx(); minMaxCheck();\" onchange=\"Friedewald_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Total_Chol_unit\" onchange=\"Friedewald_fx();\" style=\"width:105px;\">",
"             <option value=\"100|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"1000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"1|0|mg%\">",
"              mg%",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"100|0|mg/mL\">",
"              mg/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             HDL",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"HDL_param\" onblur=\"Friedewald_fx(); minMaxCheck();\" onchange=\"Friedewald_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"HDL_unit\" onchange=\"Friedewald_fx();\" style=\"width:105px;\">",
"             <option value=\"100|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"1000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"1|0|mg%\">",
"              mg%",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"100|0|mg/mL\">",
"              mg/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Triglyceride",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Triglyceride_param\" onblur=\"Friedewald_fx(); minMaxCheck();\" onchange=\"Friedewald_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Triglyceride_unit\" onchange=\"Friedewald_fx();\" style=\"width:105px;\">",
"             <option value=\"100|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"1000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"1|0|mg%\">",
"              mg%",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"100|0|mg/mL\">",
"              mg/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Result:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             LDL",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"LDL_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"LDL_unit\" onchange=\"Friedewald_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"Friedewald_fx();\">",
"             <option selected=\"selected\">",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option>",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      In the formula above",
"      <b>",
"       LDL",
"      </b>",
"      represents LDL-C and",
"      <b>",
"       HDL",
"      </b>",
"      represents HDL-C.",
"     </li>",
"     <li>",
"      This calculation is not valid when the",
"      <b>",
"       Triglyceride",
"      </b>",
"      level is &gt;= 400 mg/dL.",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.",
"       <i>",
"        Clin Chem",
"       </i>",
"       . 1972, 18;499-502.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21521=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function Friedewald_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.Friedewald_form){",
"",
"",
"doCalc = true;",
"if (Total_Chol_param.value.indexOf(',') >= 0){ Total_Chol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Total_Chol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Total_Chol_unit.options[Total_Chol_unit.selectedIndex].value.split('|');",
"Total_Chol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (HDL_param.value.indexOf(',') >= 0){ HDL_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(HDL_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = HDL_unit.options[HDL_unit.selectedIndex].value.split('|');",
"HDL = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Triglyceride_param.value.indexOf(',') >= 0){ Triglyceride_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Triglyceride_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Triglyceride_unit.options[Triglyceride_unit.selectedIndex].value.split('|');",
"Triglyceride = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"LDL =  Total_Chol - (Triglyceride / 5) - HDL;",
"",
"unit_parts = LDL_unit.options[LDL_unit.selectedIndex].value.split('|');",
"if (doCalc) LDL_param.value = fixDP((LDL - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Friedewald_form){",
"",
"if (Triglyceride_param.value && Triglyceride < 0) {",
"Triglyceride = 0;",
"Triglyceride_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Triglyceride is 0 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Triglyceride_param.value && Triglyceride > 400) {",
"Triglyceride_param.value = \"\";",
"clrResults();",
"Triglyceride = 0;",
"doCalc = false;",
"alert(\"The maximum value for Triglyceride is 400 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Friedewald_form){",
"",
"LDL_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f21_1_21521=null;
var title_f21_1_21522="Patient information: Giardia (The Basics)";
var content_f21_1_21522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15896\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/22/10595\">",
"         Patient information: Food poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/0/28673\">",
"         Patient information: Giardia (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Giardia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/giardia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28412652\">",
"      <span class=\"h1\">",
"       What is Giardia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Giardia is an infection of the digestive system (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). The infection can cause diarrhea, nausea, and stomach ache. It is very common.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28412659\">",
"      <span class=\"h1\">",
"       What are the symptoms of Giardia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Giardia infections do not always cause symptoms. Some people carry the parasite that causes Giardia without ever knowing it. When symptoms do happen, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Diarrhea that comes on suddenly and that can start off watery",
"       </li>",
"       <li>",
"        Feeling ill",
"       </li>",
"       <li>",
"        Having bowel movements that are fatty and smell worse than usual",
"       </li>",
"       <li>",
"        Belly cramps, gas, and bloating",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28412666\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends. See your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have severe diarrhea, meaning it happens many times in a day",
"       </li>",
"       <li>",
"        Have severe belly pain",
"       </li>",
"       <li>",
"        Cannot eat or drink",
"       </li>",
"       <li>",
"        Have a fever higher than 100.4&deg;F (38&deg;C)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Young children and older adults with symptoms should make sure to see their doctor or nurse. That&rsquo;s because these groups can get dehydrated more easily than other people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28412673\">",
"      <span class=\"h1\">",
"       How did I catch Giardia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Giardia infections can spread in 3 ways:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        From person to person &mdash; The parasite that causes Giardia lives in bowel movements of people who are infected. You can catch Giardia from another person if they do not wash their hands after a bowel movement and then touch you. The same is true for someone who changes a diaper on a child or an adult and then does not wash his or her hands. It is also possible to catch Giardia through anal sex. &nbsp;",
"       </li>",
"       <li>",
"        Through food &mdash; The parasite that causes Giardia can live on food. Cooking kills it. But if food is not cooked or not handled the right way, it can carry Giardia.",
"       </li>",
"       <li>",
"        Through water &mdash; The parasite that causes Giardia can live in water sources that people drink from. For instance, Giardia can live in streams or drinking wells. People who camp and hike are at risk of getting Giardia if they drink water from lakes or streams without treating the water properly first.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28412680\">",
"      <span class=\"h1\">",
"       Is there a test for Giardia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse thinks you might have Giardia, he or she will ask you for a bowel movement sample. At the lab, the sample can be checked for Giardia and other infections that can cause the same symptoms as Giardia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28412687\">",
"      <span class=\"h1\">",
"       How is Giardia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for Giardia involves taking an antibiotic medicine for several days. In most cases, that gets rid of the infection and its symptoms. In some cases, though, Giardia does not get better with the first round of antibiotics. If that happens, doctors usually suggest changing the type or dose of antibiotic, or increasing the length of time a person is treated.",
"     </p>",
"     <p>",
"      If you do not have symptoms of Giardia, you might not need antibiotics&mdash;even if your test shows you have the infection. Some people with Giardia can beat the infection without treatment. But children in daycare and people who work with food should be treated for Giardia, even if they have no symptoms. This helps prevent the spread of infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28412694\">",
"      <span class=\"h1\">",
"       Can Giardia be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, it can. The most important thing is to be clean. Follow these tips:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash your hands with soap and water after using the bathroom, and teach children to do the same",
"       </li>",
"       <li>",
"        Wash your hands with soap and water after changing diapers or after touching anyone who can&rsquo;t control his or her bowels &nbsp;",
"       </li>",
"       <li>",
"        Throw away dirty diapers right away in sealed trash bins",
"       </li>",
"       <li>",
"        Wash clothes that could have even small amounts of bowel movement on them",
"       </li>",
"       <li>",
"        Try not to swallow water when swimming",
"       </li>",
"       <li>",
"        Kill the germs and parasites in your drinking water when traveling or hiking. You can do this by doing 1 of these things:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Boiling drinking water for at least 10 minutes at a hard boil",
"       </li>",
"       <li>",
"        Adding 5 drops of tincture of iodine to 4 cups of water and waiting 30 minutes. Tincture of iodine is a liquid you can buy at most pharmacies or camping goods stores. People also use it on cuts to kill germs. It is much better at killing Giardia than bleach.",
"       </li>",
"       <li>",
"        Using a good water filtering system (you can learn about good filtering systems by searching on &ldquo;water filter&rdquo; at this Web site:",
"        <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/\">",
"         file://wwwnc.cdc.gov/travel/",
"        </a>",
"        ) &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28412806\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=see_link\">",
"       Patient information: Food poisoning (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/0/28673?source=see_link\">",
"       Patient information: Giardia (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/1/21522?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15896 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-C266496ECC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21522=[""].join("\n");
var outline_f21_1_21522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28412652\">",
"      What is Giardia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28412659\">",
"      What are the symptoms of Giardia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28412666\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28412673\">",
"      How did I catch Giardia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28412680\">",
"      Is there a test for Giardia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28412687\">",
"      How is Giardia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28412694\">",
"      Can Giardia be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28412806\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15896\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=related_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/0/28673?source=related_link\">",
"      Patient information: Giardia (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_1_21523="Nodular basal cell carcinomas";
var content_f21_1_21523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A typical nodular basal cell carcinoma presents as a well-circumscribed nodule with a translucent or pearly appearance and telangiectasias (most evident in the left panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21523=[""].join("\n");
var outline_f21_1_21523=null;
var title_f21_1_21524="Pancreatic pseudocyst 2";
var content_f21_1_21524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pancreatic pseudocyst (arrow) in a patient with a history of acute pancreatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin McGrath, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21524=[""].join("\n");
var outline_f21_1_21524=null;
var title_f21_1_21525="Raltitrexed: Drug information";
var content_f21_1_21525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Raltitrexed: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/37/26196?source=see_link\">",
"    see \"Raltitrexed: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tomudex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F217009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should be administered only if WBC &gt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ANC &gt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and platelets &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Colorectal cancer, advanced:",
"     </b>",
"     I.V.: 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malignant pleural mesothelioma (unlabeled use):",
"     </b>",
"     I.V.: 3 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with cisplatin) (van Meerbeeck, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F217010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;65 mL/minute: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     55-65 mL/minute: Administer 75% of dose every 4 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-54 mL/minute: Administer percentage of dose equivalent to Cl",
"     <sub>",
"      cr",
"     </sub>",
"     every 4 weeks (eg, 25% of dose for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     of 25 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute: Do not administer (use is contraindicated in severe renal impairment).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F217011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required for mild-to-moderate hepatic insufficiency. Use is contraindicated in severe hepatic impairment and not recommended in clinical jaundice or decompensated liver disease. Patients who develop hepatic toxicity should have treatment held until returns to grade 2.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F217033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Delay dose in subsequent cycles until recovery from toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Grade 4 gastrointestinal toxicity (diarrhea or mucositis) or grade 3 gastrointestinal toxicity in combination with grade 4 hematologic toxicity: Discontinue therapy and manage with supportive measures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Grade 3 hematologic toxicity (neutropenia or thrombocytopenia) or grade 2 gastrointestinal toxicity (diarrhea or mucositis): Reduce dose by 25%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Grade 4 hematologic toxicity (neutropenia or thrombocytopenia) or grade 3 gastrointestinal toxicity (diarrhea or mucositis): Reduce dose by 50%.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F11391901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution, as disodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tomudex&reg;: 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F216987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer via I.V. infusion over 15 minutes. Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F217039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS. Do not mix with other medications.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced colorectal cancer",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F11392664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of malignant pleural mesothelioma (in combination with cisplatin)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Raltitrexed may be confused with methotrexate, PEMEtrexed, PRALAtrexate",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (2% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (58%; grades 3/4: 12%), diarrhea (38%; grades 3/4: 11%), vomiting (38%; grades 3/4: 12%), anorexia (26% to 28%), abdominal pain (18%), constipation (13% to 15%), mucositis/stomatitis (12%; grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (20% to 22%; grade 3/4: 12% to 13%; nadir within 7-14 days, recovery by 21 days); anemia (15% to 18%; grades 3/4: 7% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (14% to 18%; grades 3/4: 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (46% to 49%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (10%), arrhythmias (3%), CHF (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6%), dizziness (4% to 5%), chills (4%), malaise (4%), pain (4%), insomnia (3% to 4%), depression (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (6%), cellulitis (3%), pruritus (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (6% to 7%), hypokalemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (6%), taste perversion (6%), weight loss (6%), flatulence (2% to 3%), xerostomia (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (5% to 6%; grades 3/4: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (2% to 3%), bilirubin increased (2% to 3%; grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (2% to 3%), myalgia (3%), arthralgia (&lt;2%), hypertonia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (5%), dyspnea (4% to 5%), pharyngitis (4% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (6% to 8%), diaphoresis (3% to 4%), infection (3%), sepsis (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Desquamation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to raltitrexed or any component of the formulation; severe renal or hepatic impairment; pregnancy or breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Neutropenia, leukopenia, anemia, and thrombocytopenia may occur. Use with caution in patients with pre-existing marrow suppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal toxicity: Nausea, vomiting and diarrhea are common; mucositis and stomatitis may also occur. Severe diarrhea with concomitant hematologic toxicity (neutropenia) may be life-threatening and may require discontinuation or subsequent dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malaise/weakness: May cause malaise/weakness; caution patients concerning operation of machinery/driving.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment (contraindicated in severe impairment and not recommended in clinical jaundice or decompensated liver disease). Therapy interruption is required in patients with hepatotoxicity; may reintroduce therapy only with decrease in hepatic enzymes to grade 2. Asymptomatic and self-limiting increases (reversible) in ALT and AST may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with mild-to-moderate renal impairment (contraindicated in severe impairment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Folic acid/folate-containing medications: Folinic acid (leucovorin calcium), folic acid, or folate-containing medications (eg, multivitamins) may interfere with raltitrexed; do not administer immediately prior to or concurrently with raltitrexed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use in this patient population is not recommended by manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy recipients: Use with caution in patients who have received prior radiation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Folic Acid: May diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levomefolate: May diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Raltitrexed. Specifically, the folic acid contained in multivitamins is responsible for this potential interaction.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F217003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid folic acid and multivitamins with folic acid close to and during administration.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in women who are or may become pregnant during treatment. Pregnancy should be excluded prior to treatment, and should be avoided during treatment and for 6 months following treatment (including women with male partners receiving treatment). Pregnant women should not handle this medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F216993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid folic acid, folinic acid (leucovorin calcium), and multivitamins with folic acid close to and during administration.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F216982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (at baseline, prior to each treatment, or weekly if GI toxicity observed); hepatic function tests and serum creatinine (at baseline and prior to each treatment); signs of GI toxicity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F216994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tomudex (AR, AT, AU, BE, BG, BR, CH, CZ, EE, ES, FR, GB, HN, HU, IE, IT, LU, MX, NL, NO, PL, PT, RU, SG, TR, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Raltitrexed is a folate analogue that inhibits thymidylate synthase, blocking purine synthesis. This results in an overall inhibition of DNA synthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 548 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes extensive intracellular metabolism to active polyglutamate forms; appears to be little or no systemic metabolism of the drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Triphasic; Beta: 2 hours; Terminal: 198 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~50% as unchanged drug); feces (~15%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bottomley A, Coens C, Efficace F, et al, &ldquo;Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(36):5770-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21525/abstract-text/18089874/pubmed\" id=\"18089874\" target=\"_blank\">",
"        18089874",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bottomley A, Gaafar R, Manegold C, et al, &ldquo;Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(9):1435-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21525/abstract-text/16446322/pubmed\" id=\"16446322\" target=\"_blank\">",
"        16446322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Massacesi C, Santini D, Rocchi MB, et al, &ldquo;Raltitrexed-Induced Hepatotoxicity: Multivariate Analysis of Predictive Factors,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 2003, 14(7):533-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21525/abstract-text/12960737/pubmed\" id=\"12960737\" target=\"_blank\">",
"        12960737",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Cutsem E, Cunningham D, Maroun J, et al, \"Raltitrexed: Current Clinical Status and Future Directions,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2002, 13(4):513-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21525/abstract-text/12056700/pubmed\" id=\"12056700\" target=\"_blank\">",
"        12056700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Meerbeeck JP, Gaafar R, Manegold C, et al, &ldquo;Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(28):6881-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21525/abstract-text/16192580/pubmed\" id=\"16192580\" target=\"_blank\">",
"        16192580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10087 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21525=[""].join("\n");
var outline_f21_1_21525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217007\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217032\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217009\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062197\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217010\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217011\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217033\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391901\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234288\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216987\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217039\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216986\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11392664\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977831\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217030\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216990\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216974\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299979\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216978\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217003\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216992\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217017\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216993\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216982\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216994\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216973\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216989\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10087\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10087|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/37/26196?source=related_link\">",
"      Raltitrexed: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_1_21526="The Δanion gap/ΔHCO3 ratio in patients with a high anion gap metabolic acidosis";
var content_f21_1_21526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21526/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21526/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21526/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21526/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21526/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21526/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/1/21526/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     NORMAL SERUM ANION GAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of the serum anion gap (AG) is an important step in approaching the differential diagnosis of metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the adult with metabolic acidosis\", section on 'Serum anion gap and differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum AG is calculated from the following formula, which represents the difference between the primary measured cation (Na) and the primary measured anions (Cl and HCO3):",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Serum AG &nbsp;= &nbsp;Na &nbsp;- &nbsp;(Cl &nbsp;+ &nbsp;HCO3)",
"   </p>",
"   <p>",
"    Some physicians also include the serum potassium in the formula; when this is done, the normal range increases by about 4",
"    <span class=\"nowrap\">",
"     meq/L:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Serum AG &nbsp;= &nbsp;(Na &nbsp;+ &nbsp;K) &nbsp;- &nbsp;(Cl &nbsp;+ &nbsp;HCO3)",
"   </p>",
"   <p>",
"    Historically, the normal range for the serum AG was 7 to 13",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    However, newer autoanalyzers measure a higher serum chloride concentration, resulting in a lower normal range of 3 to 9",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As a result, knowing the normal range in a particular laboratory is essential for accurate interpretation of the serum AG.",
"   </p>",
"   <p>",
"    In normal subjects, negatively charged plasma proteins, particularly albumin, are responsible for most of the serum AG. As a result, the expected normal values for the AG must be adjusted downward in patients with hypoalbuminemia, with the AG falling by about 2.3 to 2.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    reduction in the serum albumin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. On the other hand, the expected normal values for the AG must be adjusted upward using the same calculations in patients with hyperalbuminemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The determinants and utility of the delta",
"    <span class=\"nowrap\">",
"     AG/delta",
"    </span>",
"    HCO3 ratio in patients with metabolic acidosis and the potential effect of alterations in unmeasured ions other than albumin will be reviewed here. The serum AG may also be increased, decreased, or even negative in conditions other than metabolic acidosis. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36533?source=see_link\">",
"     \"Serum anion gap in conditions other than metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DELTA AG/DELTA HCO3 RATIO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum anion gap (AG) is elevated in those forms of metabolic acidosis in which the anion accompanying the hydrogen ion is not chloride. The most common causes of an acute high AG acidosis are lactic acidosis and ketoacidosis. The degree to which the anion gap rises in relation to the fall in bicarbonate varies with the cause of the acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Determinants",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the extracellular fluid were an isolated compartment, the addition of lactic acid (HL) or ketoacids would lead to buffering of the excess acid by bicarbonate according to the following equation:",
"   </p>",
"   <p>",
"    HL &nbsp;+ &nbsp;NaHCO3 &nbsp;&rarr; &nbsp;NaL &nbsp;+ &nbsp;H2CO3 &nbsp;&rarr; &nbsp;CO2 &nbsp;+ &nbsp;H2O",
"   </p>",
"   <p>",
"    In this setting, the increase in serum lactate and therefore the serum AG would exactly match the decrease in serum HCO3 caused by buffering of the hydrogen ion. These opposite changes in the serum AG and HCO3 concentration would result in a",
"    <span class=\"nowrap\">",
"     &Delta;AG/&Delta;HCO3",
"    </span>",
"    ratio of 1:1.",
"   </p>",
"   <p>",
"    However, two major additional factors influence the",
"    <span class=\"nowrap\">",
"     &Delta;AG/&Delta;HCO3",
"    </span>",
"    ratio:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The buffering reaction is not limited to the extracellular fluid, and the space of distribution of hydrogen ions is different from that of lactate or ketoacid anions [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/4,7,9,10\">",
"       4,7,9,10",
"      </a>",
"      ]. Most of the anions remain in the extracellular space, thereby raising the AG. In contrast, more than 50 percent of the excess hydrogen ions are buffered in the cells and in bone, a proportion that increases as the serum HCO3 falls [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/10\">",
"       10",
"      </a>",
"      ]. Buffering hydrogen ions outside the extracellular fluid will not lower the serum bicarbonate concentration. Thus, the serum AG will increase more than the HCO3 concentration will fall, raising the",
"      <span class=\"nowrap\">",
"       &Delta;AG/&Delta;HCO3",
"      </span>",
"      ratio above 1:1. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Lactic acidosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The renal excretion of the anions and hydrogen ions occur at different rates. This applies more to ketoacidosis than hypoperfusion-induced lactic acidosis in which there is typically little or no renal function. To the extent that ketoacid anions are excreted with sodium or potassium, the serum AG will fall without a concomitant increase in serum HCO3, lowering the",
"      <span class=\"nowrap\">",
"       &Delta;AG/&Delta;HCO3",
"      </span>",
"      ratio below 1:1 and resulting in the development of a hyperchloremic (ie, normal AG) acidosis after insulin therapy is initiated and extracellular volume repletion has been achieved. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ketoacidosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lactic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In lactic acidosis, the lactic acid (hydrogen lactate [HL]) is buffered by bicarbonate according to the following equation:",
"   </p>",
"   <p>",
"    HL &nbsp;+ &nbsp;NaHCO3 &nbsp;&rarr; &nbsp;NaL &nbsp;+ &nbsp;H2CO3 &nbsp;&rarr; &nbsp;CO2 &nbsp;+ &nbsp;H2O",
"   </p>",
"   <p>",
"    The ensuing increase in the unmeasured anion lactate will raise the AG. From this equation, it might be assumed that there is a 1:1 relationship between the increase in serum AG",
"    <span class=\"nowrap\">",
"     (&Delta;AG)",
"    </span>",
"    and the fall in serum bicarbonate",
"    <span class=\"nowrap\">",
"     (&Delta;HCO3).",
"    </span>",
"    However, most of the lactate anions remain in the extracellular fluid, and urinary lactate excretion is limited in hypoperfusion-induced lactic acidosis in which there is typically little or no renal function. In contrast, more than 50 percent of the excess hydrogen ions are buffered in the cells and bone in mild metabolic acidosis and a higher proportion in more severe metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect of the larger space of distribution of hydrogen ions compared to lactate anions and the low rate of lactate excretion is that the",
"    <span class=\"nowrap\">",
"     &Delta;AG/&Delta;HCO3",
"    </span>",
"    ratio is typically greater than 1 in lactic acidosis, and is usually about 1.6 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/3,4,7,9,11,12\">",
"     3,4,7,9,11,12",
"    </a>",
"    ]. Thus, a patient with lactic acidosis and a serum bicarbonate concentration of 14",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    below normal) should have a serum AG of approximately 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (16",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    above normal if the normal value is approximately 9",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    However, hydrogen ion buffering in cells and bone may take several hours to reach completion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. Thus, the ratio will initially be close to 1:1 with acute lactic acidosis and then increase with time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Urinary loss of unmeasured anions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary excretion of unmeasured anions (ie, not chloride or bicarbonate) can affect the",
"    <span class=\"nowrap\">",
"     &Delta;AG/&Delta;HCO3",
"    </span>",
"    ratio. This most often occurs in patients with ketoacidosis but can also be seen in D-lactic acidosis and toluene intoxication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Ketoacidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     &Delta;AG/&Delta;HCO3",
"    </span>",
"    ratio in patients with ketoacidosis averages about 1:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ]. This is in contrast to the average ratio of 1.6 described in the preceding section in lactic acidosis due to hypoperfusion. An important reason for this difference is the relative maintenance of renal function in ketoacidosis, which allows ketoacid anions (beta-hydroxybutyrate and acetoacetate) to be lost in the urine as the sodium and potassium salts. The loss of ketoacid anions lowers the AG without affecting the serum bicarbonate concentration, thereby reducing the",
"    <span class=\"nowrap\">",
"     &Delta;AG/&Delta;HCO3",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The quantity of ketoacid anions excreted in patients with ketoacidosis depends upon the degree to which glomerular filtration is maintained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with impaired renal function (due to underlying diabetic nephropathy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      volume depletion) will retain a greater fraction of the ketoacid anions and have a relatively high anion gap in relation to the fall in the serum bicarbonate concentration, similar to that seen in hypoperfusion-induced lactic acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/1,13,14\">",
"       1,13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who maintain relatively normal renal function (including those with alcoholic or fasting ketoacidosis) can lose large quantities of ketoacids in the urine and may have a",
"      <span class=\"nowrap\">",
"       &Delta;AG/&Delta;HCO3",
"      </span>",
"      ratio",
"      <strong>",
"       below 1",
"      </strong>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/9,13,14\">",
"       9,13,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The urinary loss of ketoacid anions as the sodium or potassium salts represents the loss of what has been called \"potential bicarbonate\" since, if they had not been excreted, the metabolism of these anions would have resulted in the regeneration of bicarbonate and reversal of the acidosis. In addition, the loss of sodium and potassium with the ketoacid anions contributes to both extracellular fluid volume depletion and potassium depletion. Following the institution of appropriate therapy for the ketoacidosis, correction of hypovolemia with intravenous saline will initially result in increased excretion of ketoacid anions, while insulin therapy will slow ketogenesis and promote metabolism of the ketoacids.",
"   </p>",
"   <p>",
"    As a result of the urinary loss of potential bicarbonate, almost all patients with diabetic ketoacidosis who have relatively intact renal function develop a",
"    <strong>",
"     hyperchloremic (normal AG) metabolic acidosis",
"    </strong>",
"    following insulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/9,13,14\">",
"     9,13,14",
"    </a>",
"    ]. The findings are different in patients with advanced chronic kidney disease. In this setting, there is only limited loss of ketoacid anions (potential bicarbonate) in the urine and insulin therapy will return the serum HCO3 to values close to those at baseline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Anion gap'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the tubular reabsorption of some of the filtered beta-hydroxybutyrate and acetoacetate in ketoacidosis, there is limited or no reabsorption of D-lactate or hippurate (generated from toluene metabolism). As a result, these anions will be more rapidly eliminated from the plasma, potentially normalizing the anion gap in D-lactic acidosis or after toluene inhalation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     D-lactic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;D-lactic acidosis is a rare disorder that most often occurs in patients with jejunoileal bypass or a short-bowel syndrome. It is caused by the combination of bacterial overgrowth and increased glucose and starch delivery into the colon (due to lack of normal absorption in the small intestine). As a result, dietary carbohydrate is converted to D-lactate, rather than the physiologically occurring L-lactate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=see_link\">",
"     \"D-Lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sodium-L-lactate cotransporter in the proximal tubule is stereospecific and does not bind D-lactate. Thus, filtered D-lactate is rapidly excreted in the urine and the serum AG is increased less than expected from the degree of fall in serum bicarbonate and may be normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=see_link\">",
"     \"D-Lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Toluene inhalation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary anion loss is even more rapid after toluene inhalation due, for example, to glue-sniffing. Toluene is converted in part into hippuric acid, which will initially tend to cause a high AG acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, hippurate is both filtered across the glomerulus and secreted into the tubular lumen by the proximal tubular cells. The net effect is that almost all of the hippurate presented to the kidney is excreted (largely as the sodium and potassium salts). Thus, most patients with toluene ingestion present with volume depletion, hypokalemia that is often severe, and a normal AG acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33753?source=see_link\">",
"     \"Inhalant abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other causes of a low &Delta;AG/&Delta;HCO3 ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions other than those associated with urinary loss of unmeasured anions can lead to metabolic acidosis and a",
"    <span class=\"nowrap\">",
"     &Delta;AG/&Delta;HCO3",
"    </span>",
"    ratio of 1:1 or less.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In chronic kidney disease, tubular damage may result in increased excretion of filtered anions while the degree of hydrogen secretion is limited [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link\">",
"       \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a combined high and normal AG acidosis, as might occur if diarrhea were superimposed upon any high AG metabolic acidosis or if severe diarrhea led to reduced tissue perfusion and lactic acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     &Delta;AG/&Delta;HCO3 greater than expected",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with a high AG metabolic acidosis have a",
"    <span class=\"nowrap\">",
"     &Delta;AG/&Delta;HCO3",
"    </span>",
"    ratio that is higher than expected (ie, more than 1.6:1 in lactic acidosis or more than 1:1 in ketoacidosis occurring in patients with preserved renal function). These patients have a mixed acid-base disorder in which the serum HCO3 concentration is higher than expected due to concurrent metabolic alkalosis, as with vomiting, or to the compensatory increase in serum HCO3 induced by preexisting chronic respiratory acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POTENTIAL SOURCES OF ERROR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of the",
"    <span class=\"nowrap\">",
"     &Delta;AG/&Delta;HCO3",
"    </span>",
"    ratio in patients with a high anion gap (AG) metabolic acidosis is dependent upon several assumptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      That the baseline serum AG can be accurately estimated, an issue that is particularly important in view of the lower normal serum AG with newer autoanalyzers [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Evaluation of recent previous blood test results, if available, provide the best way of determining the usual serum AG for a specific patient. In addition, normal values for the AG must be adjusted downward in patients with hypoalbuminemia, with the serum AG falling by about 2.3 to 2.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      for every 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (10",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      reduction in the serum albumin concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/2,8\">",
"       2,8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Normal serum anion gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      That the accumulating anions are derived from acids that are responsible for the acidemia. In some cases, unmeasured anions accumulate in the plasma that are unrelated to the metabolic acidosis. As an example, severe diarrhea can induce both hyperproteinemia due to hemoconcentration and hyperphosphatemia due to acidosis-induced movement of phosphate from the cells into the extracellular fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/19\">",
"       19",
"      </a>",
"      ]. The net effect will be an elevation in AG, even though diarrhea alone produces a normal AG acidosis (unless the volume losses are so large that lactic acidosis is superimposed). Hyperphosphatemia may also contribute to a high AG in patients with diabetic ketoacidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum phosphate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Changes in the concentration of other unmeasured anions (eg, hypoalbuminemia) or of unmeasured cations (potassium, calcium, or magnesium) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21526/abstract/7\">",
"       7",
"      </a>",
"      ]. As an example, both hypoalbuminemia (decreased unmeasured anions) and hyperkalemia (increased unmeasured cations) can lower the AG. Thus, a patient with one or both of these disorders may have a baseline AG of 4 rather than 8",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      In this setting, an AG of 13",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      which is mildly above \"normal,\" represents a true elevation in the AG of 9",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      As a result, calculation of the",
"      <span class=\"nowrap\">",
"       &Delta;AG/&Delta;HCO3",
"      </span>",
"      is most accurate when the pre-acidosis AG is known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SERUM AG WITHOUT METABOLIC ACIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the serum anion gap is primarily measured in patients with metabolic acidosis, it can be increased, low, or even negative in conditions other than metabolic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36533?source=see_link\">",
"     \"Serum anion gap in conditions other than metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assuming that the baseline serum AG is known or can be accurately estimated, the",
"      <span class=\"nowrap\">",
"       &Delta;AG/&Delta;HCO3",
"      </span>",
"      ratio in an uncomplicated high AG metabolic acidosis (eg, shock-induced lactic acidosis) should be between",
"      <strong>",
"       1 and 2",
"      </strong>",
"      . (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Lactic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      However, a lower value (in which the",
"      <span class=\"nowrap\">",
"       &Delta;AG",
"      </span>",
"      is less than expected from the",
"      <span class=\"nowrap\">",
"       &Delta;HCO3)",
"      </span>",
"      can be seen in a number of settings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In ketoacidosis, D-lactic acidosis, or toluene intoxication, the organic acid anions that accumulate are excreted by the kidney as sodium",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      potassium salts. In these disorders, the",
"      <span class=\"nowrap\">",
"       &Delta;AG/&Delta;HCO3",
"      </span>",
"      ratio is often below 1, and the serum AG may be normal. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Urinary loss of unmeasured anions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with early-stage chronic kidney disease may have relatively well preserved glomerular filtration but more severe tubular damage. This can result in preserved excretion of filtered acid anions but simultaneous impairment of hydrogen secretion, mainly due to reduced ammonium synthesis and excretion. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Other causes of a low &Delta;AG/&Delta;HCO3 ratio'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some clinical disorders, such as severe diarrhea, can generate a combined high and normal AG acidosis. This is due to a hyperchloremic acidosis resulting from the loss of bicarbonate salts in the stool in combination with a lactic acidosis resulting from hypovolemia and reduced tissue perfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On the other hand, a higher value",
"      <span class=\"nowrap\">",
"       (&Delta;AG/&Delta;HCO3",
"      </span>",
"      ratio above 2) usually reflects a mixed acid-base disorder in which the serum HCO3 concentration is higher than would be expected based upon the large anion gap. The high bicarbonate concentration may be due to a preexisting or concurrent metabolic alkalosis, as with vomiting or diuretic use, or may reflect the compensatory increase in serum HCO3 induced by a preexisting chronic respiratory acidosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       '&Delta;AG/&Delta;HCO3 greater than expected'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 583-590.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/2\">",
"      Emmett M, Narins RG. Clinical use of the anion gap. Medicine (Baltimore) 1977; 56:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/3\">",
"      Gabow PA. Disorders associated with an altered anion gap. Kidney Int 1985; 27:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/4\">",
"      Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol 2007; 2:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/5\">",
"      Rastegar A. Use of the DeltaAG/DeltaHCO3- ratio in the diagnosis of mixed acid-base disorders. J Am Soc Nephrol 2007; 18:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/6\">",
"      Winter SD, Pearson JR, Gabow PA, et al. The fall of the serum anion gap. Arch Intern Med 1990; 150:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/7\">",
"      Salem MM, Mujais SK. Gaps in the anion gap. Arch Intern Med 1992; 152:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/8\">",
"      Feldman M, Soni N, Dickson B. Influence of hypoalbuminemia or hyperalbuminemia on the serum anion gap. J Lab Clin Med 2005; 146:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/9\">",
"      Oh MS, Carroll HJ, Goldstein DA, Fein IA. Hyperchloremic acidosis during the recovery phase of diabetic ketosis. Ann Intern Med 1978; 89:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/10\">",
"      Fernandez PC, Cohen RM, Feldman GM. The concept of bicarbonate distribution space: the crucial role of body buffers. Kidney Int 1989; 36:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/11\">",
"      Orringer CE, Eustace JC, Wunsch CD, Gardner LB. Natural history of lactic acidosis after grand-mal seizures. A model for the study of an anion-gap acidosis not associated with hyperkalemia. N Engl J Med 1977; 297:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/12\">",
"      Madias NE, Homer SM, Johns CA, Cohen JJ. Hypochloremia as a consequence of anion gap metabolic acidosis. J Lab Clin Med 1984; 104:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/13\">",
"      Adrogu&eacute; HJ, Eknoyan G, Suki WK. Diabetic ketoacidosis: role of the kidney in the acid-base homeostasis re-evaluated. Kidney Int 1984; 25:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/14\">",
"      Adrogu&eacute; HJ, Wilson H, Boyd AE 3rd, et al. Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med 1982; 307:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/15\">",
"      Carlisle EJ, Donnelly SM, Vasuvattakul S, et al. Glue-sniffing and distal renal tubular acidosis: sticking to the facts. J Am Soc Nephrol 1991; 1:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/16\">",
"      Dickson RP, Luks AM. Toluene toxicity as a cause of elevated anion gap metabolic acidosis. Respir Care 2009; 54:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/17\">",
"      Wallia R, Greenberg A, Piraino B, et al. Serum electrolyte patterns in end-stage renal disease. Am J Kidney Dis 1986; 8:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/18\">",
"      Narins RG, Emmett M. Simple and mixed acid-base disorders: a practical approach. Medicine (Baltimore) 1980; 59:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/19\">",
"      Wang F, Butler T, Rabbani GH, Jones PK. The acidosis of cholera. Contributions of hyperproteinemia, lactic acidemia, and hyperphosphatemia to an increased serum anion gap. N Engl J Med 1986; 315:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21526/abstract/20\">",
"      Kebler R, McDonald FD, Cadnapaphornchai P. Dynamic changes in serum phosphorus levels in diabetic ketoacidosis. Am J Med 1985; 79:571.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2292 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-85AC9C56DE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21526=[""].join("\n");
var outline_f21_1_21526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      NORMAL SERUM ANION GAP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DELTA AG/DELTA HCO3 RATIO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Determinants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Urinary loss of unmeasured anions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - D-lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Toluene inhalation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other causes of a low &Delta;AG/&Delta;HCO3 ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      &Delta;AG/&Delta;HCO3 greater than expected",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POTENTIAL SOURCES OF ERROR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SERUM AG WITHOUT METABOLIC ACIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=related_link\">",
"      D-Lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33753?source=related_link\">",
"      Inhalant abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36533?source=related_link\">",
"      Serum anion gap in conditions other than metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_1_21527="Pathogenesis of ascites in patients with cirrhosis";
var content_f21_1_21527=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of ascites in patients with cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21527/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21527/contributors\">",
"     Jos&eacute; Such, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21527/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21527/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21527/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21527/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21527/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/1/21527/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascites is defined as the pathologic accumulation of fluid in the peritoneal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/1\">",
"     1",
"    </a>",
"    ]. It is the most common complication of cirrhosis, which is the most common cause of ascites in the United States, accounting for approximately 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/1\">",
"     1",
"    </a>",
"    ]. Within 10 years after the diagnosis of compensated cirrhosis, about 50 percent of patients will have developed ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of ascites is the final consequence of a series of anatomic, pathophysiologic, and biochemical abnormalities occurring in patients with cirrhosis. The two older theories of ascites formation, the underfill theory [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/3\">",
"     3",
"    </a>",
"    ] and the overflow theory [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/4\">",
"     4",
"    </a>",
"    ], appear to be relevant at different stages of the natural history of cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the most recent theory, the arterial vasodilation hypothesis, appears to match best with the actual hemodynamic data, and has become the most widely accepted theory [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The formation of ascites is governed by the same principles as edema formation at other sites: net capillary permeability and the hydraulic and oncotic pressure gradients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PORTAL HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of portal hypertension (PHT) is the first step toward fluid retention in the setting of cirrhosis. Patients with cirrhosis but without PHT do not develop ascites or edema [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/7\">",
"     7",
"    </a>",
"    ]. A portal pressure &gt;12 mmHg appears to be required for fluid retention [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]; on the other hand, ascites will usually disappear if portal pressure is reduced below 12 mmHg, eg, after a surgical or radiologic portosystemic shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/9\">",
"     9",
"    </a>",
"    ]. Sinusoidal hypertension appears to be required for fluid retention to occur; presinusoidal portal hypertension, as in portal vein thrombosis, does not result in ascites formation in the absence of another predisposing factor.",
"   </p>",
"   <p>",
"    PHT leads to profound changes in the splanchnic circulation. Although it was formerly thought that PHT was due solely to a mechanical obstruction to portal flow, data from animal models provide evidence for a component of increased portal venous inflow as a consequence of splanchnic arterial vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with cirrhosis and clinically significant PHT have several circulatory, vascular, functional, and biochemical abnormalities that contribute to the pathogenesis of fluid retention (",
"    <a class=\"graphic graphic_table graphicRef62128 \" href=\"UTD.htm?26/63/27644\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vasodilation and hyperdynamic circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cirrhosis and ascites usually have a marked reduction in systemic vascular resistance (SVR) and in mean arterial pressure (MAP) plus an increase in cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These abnormalities result in a hyperdynamic circulation which can be found in patients and experimental animals with cirrhosis before the development of ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vascular territory where the reduced SVR is most obvious is the arterial splanchnic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/6\">",
"     6",
"    </a>",
"    ]. The presence of this abnormality in other vascular territories is less obvious and the subject of controversy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanisms of vasodilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable effort has been made to elucidate the exact mechanism(s) of arterial vasodilation and the hyperdynamic circulation of cirrhosis (",
"    <a class=\"graphic graphic_algorithm graphicRef81659 \" href=\"UTD.htm?4/63/5104\">",
"     algorithm 1",
"    </a>",
"    ). Anatomic and functional liver-related causes have been considered in order to explain the presence of vasodilation.",
"   </p>",
"   <p>",
"    The opening of portasystemic collaterals, a frequent finding in cirrhosis, helps explain the presence of vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/13\">",
"     13",
"    </a>",
"    ]. The performance of portocaval shunts in these patients further decreases SVR [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although portosystemic collaterals may contribute, most of the studies which have examined the vasodilation in patients with cirrhosis have focused on increased levels of circulating vasodilators. Glucagon has been one of the most widely studied [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], although its role in the pathogenesis of vasodilation has not been precisely defined [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. Other vasodilators have been considered, such as vasoactive intestinal peptide, substance P, platelet-activating-factor or prostaglandins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased synthesis of systemic prostacyclin has been observed in patients with cirrhosis even before they develop ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/20\">",
"     20",
"    </a>",
"    ]. The synthesis of renal prostacyclin is increased in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/21\">",
"     21",
"    </a>",
"    ] and contributes to maintenance of the glomerular filtration rate (as evidenced by reductions in glomerular filtration rate and renal plasma flow following the administration of a nonsteroidal antiinflammatory drug) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/22\">",
"     22",
"    </a>",
"    ]. Renal prostaglandin synthesis decreases with advanced liver disease and may contribute to the marked renal vasoconstriction in patients with hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H2#H2\">",
"     \"Hepatorenal syndrome\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cirrhosis but without portal hypertension (eg, patients after portasystemic shunt) also show increased levels of systemic prostacyclin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/23\">",
"     23",
"    </a>",
"    ]. It is possible that this activation is related to the presence of endotoxemia, since selective intestinal decontamination with nonabsorbable antibiotics significantly decreases the synthesis of systemic prostacyclin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the above factors may play a contributory role, much of the recent literature has focused on the possible role of nitric oxide (NO) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The following observations suggest that NO is the primary mediator of vasodilation in cirrhosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The activity of endothelial NO synthase (which promotes the synthesis of NO from L-arginine) is increased in the arterial vessels of cirrhotic rats with ascites [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The serum levels of nitrite and nitrate, an index of in vivo NO synthesis, are significantly higher in patients with cirrhosis than in controls [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhibition of the synthesis of NO in rats with cirrhosis significantly increases the arterial pressure and SVR, decreases the cardiac index [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/28\">",
"       28",
"      </a>",
"      ] and reverses the impaired response to vasopressors [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possible factors responsible for the increased NO synthesis in cirrhosis have been intensively studied. Nitric oxide production may be stimulated by endotoxin or other bacterial products, such as bacterial DNA from the gastrointestinal tract, which are less efficiently cleared due to portal-systemic shunting and decreased reticuloendothelial cell function in cirrhosis. The increased synthesis of NO is mediated by both the endothelial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/31\">",
"     31",
"    </a>",
"    ] and inducible forms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/32\">",
"     32",
"    </a>",
"    ]. This hypothesis is supported by the following observations (",
"    <a class=\"graphic graphic_algorithm graphicRef81659 \" href=\"UTD.htm?4/63/5104\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/24,27\">",
"     24,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NO concentrations in blood collected from portal vein are higher than those of peripheral veins [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A significant correlation has been noted between serum nitrite and nitrate levels and endotoxin [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral administration of the antibiotic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      to patients with cirrhosis significantly reduces plasma endotoxin levels and the serum concentration of nitrite and nitrate [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/33\">",
"       33",
"      </a>",
"      ], and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      increases systemic vascular resistance and decreases plasma renin in a subgroup of patients with ascites [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fragments of bacterial DNA in blood and ascitic fluid have been described in one-third of patients with cirrhosis and ascites and up to two-thirds of patients with refractory ascites [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]. Bacterial DNA is rarely present in patients with cirrhosis who do not have ascites. Bacterial DNA induces the synthesis of nitric oxide by peritoneal macrophages, suggesting that it may be related to the hemodynamic derangement observed in patients with advanced cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/32\">",
"       32",
"      </a>",
"      ]. In addition, bacterial DNA may further impair the endothelial dysfunction commonly found in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/38\">",
"       38",
"      </a>",
"      ]. Some data suggest that its presence is correlated with a poor prognosis, but more studies are needed [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Animal models of cirrhosis have shown that the presence of bacterial DNA in biological fluids is invariably associated with its simultaneous presence in mesenteric lymph nodes, either as viable (culture-positive) or nonviable (culture-negative) forms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/40\">",
"     40",
"    </a>",
"    ]. These observations have led to the modification of the concept of bacterial translocation to include the presence of bacterial products in mesenteric lymph nodes, and not only a positive culture",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF VASODILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progressive vasodilation seen in cirrhosis leads to the activation of endogenous vasoconstrictors, sodium and water retention, and increasing renal vasoconstriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Activation of endogenous vasoconstrictor agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduction in pressure (or stretch) at the carotid and renal baroreceptors induced by cirrhotic vasodilation results in activation of the sodium-retaining neurohumoral mechanisms in an attempt to restore perfusion pressure to normal (",
"    <a class=\"graphic graphic_algorithm graphicRef81659 \" href=\"UTD.htm?4/63/5104\">",
"     algorithm 1",
"    </a>",
"    ). These include the renin-angiotensin-aldosterone system, sympathetic nervous system, and antidiuretic hormone (vasopressin). The secretion of these \"hypovolemic\" hormones is proportional to the severity of the hemodynamic insufficiency (",
"    <a class=\"graphic graphic_figure graphicRef74244 \" href=\"UTD.htm?36/51/37693\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is avid sodium and water retention because the patient is effectively volume depleted even though extracellular sodium stores, the plasma volume, and the cardiac output are increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sodium retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retention of sodium and water increases the plasma volume. If this were adequate to refill the intravascular space, the activity of the endogenous vasoconstrictor systems would decrease, with a progressive normalization of the excretion of sodium and water (",
"    <a class=\"graphic graphic_algorithm graphicRef80443 \" href=\"UTD.htm?5/21/5471\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/7\">",
"     7",
"    </a>",
"    ]. However, impaired sodium excretion after a saline load [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/44\">",
"     44",
"    </a>",
"    ] and a reduction in central blood volume [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/45\">",
"     45",
"    </a>",
"    ] have been demonstrated in patients with cirrhosis who have not yet developed ascites. This unstable equilibrium can be affected by infections, drugs, or progressive impairment in liver function. In advanced disease, sodium excretion often falls to less than 10",
"    <span class=\"nowrap\">",
"     mEq/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, sodium retention is a sensitive marker of the overall status of the patient with cirrhosis. A significant nonlinear relationship has been identified between urinary sodium excretion and the aminopyrine breath test, a measurement of true liver function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/46\">",
"     46",
"    </a>",
"    ]; the presence of sodium retention was indicative of at least a 50 percent reduction in liver function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/46\">",
"     46",
"    </a>",
"    ]. Fluid overload is an important landmark in the natural history of these patients, and the degree of sodium retention is inversely related to survival. In one series, for example, patients with ascites and urinary sodium excretion below 10",
"    <span class=\"nowrap\">",
"     mEq/day",
"    </span>",
"    had a mean survival rate as low as five to six months, in comparison to over two years in those with ascites and a higher rate of sodium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Water retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water excretion is usually normal in patients with cirrhosis before the development of ascites and then becomes increasingly impaired as the liver disease progresses. This abnormality is largely related to the increased release of antidiuretic hormone (ADH) described above [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/41-43\">",
"     41-43",
"    </a>",
"    ], since suppression of ADH release is required to excrete a water load. The pathogenetic importance of ADH in water retention in cirrhosis has been demonstrated in rats with cirrhosis in which the administration of an ADH receptor antagonist restores near normal water excretory ability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/47\">",
"     47",
"    </a>",
"    ]. The inability to excrete water regularly leads to the development of hyponatremia and hypoosmolality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link\">",
"     \"Hyponatremia in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, patients with cirrhosis and ascites usually demonstrate urinary sodium retention, increased total body sodium, and dilutional hyponatremia. It can be challenging to explain to patients and their families (and even to some clinicians) that the hyponatremia does not indicate a deficiency of sodium.",
"   </p>",
"   <p>",
"    Because the increase in ADH secretion (and therefore the degree of water retention) is roughly proportional to the severity of the cirrhosis (",
"    <a class=\"graphic graphic_figure graphicRef74244 \" href=\"UTD.htm?36/51/37693\">",
"     figure 1",
"    </a>",
"    ), the degree of hyponatremia parallels the severity of the liver disease and is, along with the degree of sodium retention, of prognostic value. The severity of hyponatremia correlates with worsening survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal vasoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activation of vasoconstrictor systems tends to reduce renal blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/53\">",
"     53",
"    </a>",
"    ]. Renal perfusion may initially be maintained due to vasodilators such as prostaglandins and perhaps nitric oxide (",
"    <a class=\"graphic graphic_algorithm graphicRef80443 \" href=\"UTD.htm?5/21/5471\">",
"     algorithm 2",
"    </a>",
"    ). However, the natural progression of liver disease overcomes these protective mechanisms, leading to progressive renal hypoperfusion, a gradual decline in the glomerular filtration rate, and, in some patients, the hepatorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/15,54\">",
"     15,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H2#H2\">",
"     \"Hepatorenal syndrome\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of splanchnic vasodilation in the genesis of renal ischemia has been indirectly illustrated by the response to ornipressin and terlipressin, analogs of antidiuretic hormone (arginine vasopressin) that are preferential splanchnic vasoconstrictors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/11,55,56\">",
"     11,55,56",
"    </a>",
"    ]. In patients with advanced cirrhosis, the administration of ornipressin or terlipressin raised the mean arterial pressure, increased renal blood flow, glomerular filtration rate, and urinary sodium excretion and volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link&amp;anchor=H5672085#H5672085\">",
"     \"Hepatorenal syndrome\", section on 'Terlipressin plus albumin where available'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reduction in glomerular filtration rate in patients with liver disease is often masked clinically. Both urea and creatinine production may be substantially reduced in this setting, due to the liver disease and to decreased muscle mass. The net effect is that a serum creatinine concentration that appears to be within the normal range (1 to 1.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 88 to 115",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    may, depending primarily upon muscle mass, be associated with a glomerular filtration rate that ranges from as low as 20 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    to a clearly normal value above 100",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21527/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15625663\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ascites is defined as the pathologic accumulation of fluid in the peritoneal cavity. It is most commonly caused by cirrhosis.",
"     </li>",
"     <li>",
"      The development of portal hypertension (PHT) is the first step toward fluid retention in the setting of cirrhosis. Patients with cirrhosis but without PHT do not develop ascites or edema. A portal pressure &gt;12 mmHg appears to be required for fluid retention.",
"     </li>",
"     <li>",
"      Patients with cirrhosis and clinically significant PHT have several circulatory, vascular, functional, and biochemical abnormalities that contribute to the pathogenesis of fluid retention (",
"      <a class=\"graphic graphic_table graphicRef62128 \" href=\"UTD.htm?26/63/27644\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Portal hypertension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352628841\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/1\">",
"      Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/2\">",
"      Gin&eacute;s P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/3\">",
"      SHERLOCK S, SHALDON S. The aetiology and management of ascites in patients with hepatic cirrhosis: a review. Gut 1963; 4:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/4\">",
"      Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: The overflow theory of ascites formation. Ann NY Acad Sci 1970; 170:292.",
"     </a>",
"    </li>",
"    <li>",
"     Runyon, BA. Ascites and spontaneous bacterial peritonitis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Treatment, Feldman, M, Friedman, LS, Brandt, LJ (Eds), WB Saunders, Philadelphia 2010. p.1517.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/6\">",
"      Sol&agrave; E, Gin&egrave;s P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010; 53:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/7\">",
"      Gin&egrave;s P, Fern&aacute;ndez-Esparrach G, Arroyo V, Rod&eacute;s J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/8\">",
"      Morali GA, Sniderman KW, Deitel KM, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992; 16:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/9\">",
"      Reichle FA, Owen OE. Hemodynamic patterns in human hepatic cirrhosis: a prospective randomized study of the hemodynamic sequelae of distal splenorenal (Warren) and mesocaval shunts. Ann Surg 1979; 190:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/10\">",
"      Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87:1120.",
"     </a>",
"    </li>",
"    <li>",
"     Cardenas A, Gines P. Pathobiology, Evaluation, and Treatment. In: Portal Hypertension, Sanyal AJ, Shah VH (Eds), Humana Press, 2005. p.65.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/12\">",
"      Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 1994; 20:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/13\">",
"      Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/14\">",
"      KOWALSKI HJ, ABELMANN WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/15\">",
"      Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/16\">",
"      Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/17\">",
"      Maroto A, Gin&egrave;s P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/18\">",
"      Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986; 6:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/19\">",
"      Kravetz D, Arderiu M, Bosch J, et al. Hyperglucagonemia and hyperkinetic circulation after portocaval shunt in the rat. Am J Physiol 1987; 252:G257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/20\">",
"      Guarner C, Colina I, Guarner F, et al. Renal prostaglandins in cirrhosis of the liver. Clin Sci (Lond) 1986; 70:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/21\">",
"      Guarner F, Guarner C, Prieto J, et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. Gastroenterology 1986; 90:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/22\">",
"      Wong F, Massie D, Hsu P, Dudley F. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology 1993; 104:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/23\">",
"      Guarner C, Soriano G, Such J, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992; 102:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/24\">",
"      Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/25\">",
"      Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43:S121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/26\">",
"      Ros J, Jim&eacute;nez W, Lamas S, et al. Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology 1995; 21:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/27\">",
"      Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/28\">",
"      Cl&agrave;ria J, Jim&eacute;nez W, Ros J, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 1992; 15:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/29\">",
"      Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993; 104:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/30\">",
"      Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992; 103:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/31\">",
"      Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/32\">",
"      Franc&eacute;s R, Mu&ntilde;oz C, Zapater P, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/33\">",
"      Battista S, Bar F, Mengozzi G, et al. Systemic and portal nitric oxide and endothelin-1 levels in cirrhotic patients. J Hepatol 1995; Suppl 1:73 (A).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/34\">",
"      Albillos A, de la Hera A, Gonz&aacute;lez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/35\">",
"      Angeli P, Brun P, Cesari M, et, al. Prevalence of bacteria DNA in patients with cirrhosis and refractory ascites and its role in the development of caridac and renal dysfunction. Hepatology 2010; 52:342A (abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/36\">",
"      Such J, Franc&eacute;s R, Mu&ntilde;oz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/37\">",
"      Franc&eacute;s R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/38\">",
"      Bellot P, Garc&iacute;a-Pag&aacute;n JC, Franc&eacute;s R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010; 52:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/39\">",
"      Zapater P, Frances R, Gonzalez-Navajas JM, et, al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2010; 48:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/40\">",
"      Guarner C, Gonz&aacute;lez-Navajas JM, S&aacute;nchez E, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006; 44:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/41\">",
"      Asbert M, Gin&egrave;s A, Gin&egrave;s P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/42\">",
"      Henriksen JH, Bendtsen F, Gerbes AL, et al. Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/43\">",
"      Arroyo V, Bosch J, Gaya-Beltr&aacute;n J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/44\">",
"      Wong F, Massie D, Hsu P, Dudley F. Renal response to a saline load in well-compensated alcoholic cirrhosis. Hepatology 1994; 20:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/45\">",
"      Wong F, Liu P, Tobe S, et al. Central blood volume in cirrhosis: measurement with radionuclide angiography. Hepatology 1994; 19:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/46\">",
"      Wensing G, Lotterer E, Link I, et al. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function. Hepatology 1997; 26:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/47\">",
"      Tsuboi Y, Ishikawa S, Fujisawa G, et al. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994; 46:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/48\">",
"      Arroyo V, Cl&agrave;ria J, Sal&oacute; J, Jim&eacute;nez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994; 14:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/49\">",
"      Papadakis MA, Fraser CL, Arieff AI. Hyponatraemia in patients with cirrhosis. Q J Med 1990; 76:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/50\">",
"      Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/51\">",
"      Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/52\">",
"      Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/53\">",
"      Sacerdoti D, Bolognesi M, Merkel C, et al. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 1993; 17:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/54\">",
"      BALDUS WP, FEICHTER RN, SUMMERSKILL WH. THE KIDNEY IN CIRRHOSIS. I. CLINICAL AND BIOCHEMICAL FEATURES OF AZOTEMIA IN HEPATIC FAILURE. Ann Intern Med 1964; 60:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/55\">",
"      Guevara M, Gin&egrave;s P, Fern&aacute;ndez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/56\">",
"      Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/57\">",
"      Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21527/abstract/58\">",
"      Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52:605.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1259 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-B88327F15F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21527=[""].join("\n");
var outline_f21_1_21527=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15625663\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PORTAL HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vasodilation and hyperdynamic circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanisms of vasodilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONSEQUENCES OF VASODILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Activation of endogenous vasoconstrictor agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sodium retention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Water retention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal vasoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15625663\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H352628841\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1259\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1259|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?4/63/5104\" title=\"algorithm 1\">",
"      Hemodynamics in cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?5/21/5471\" title=\"algorithm 2\">",
"      Compensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1259|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/51/37693\" title=\"figure 1\">",
"      Hormonal response to cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1259|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/63/27644\" title=\"table 1\">",
"      Abnormalities cirrhotic ascites",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_1_21528="Overview of the treatment of renal cell carcinoma";
var content_f21_1_21528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of renal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21528/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21528/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21528/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21528/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/1/21528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1056313379\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. Urothelial (transitional cell) carcinomas of the renal pelvis account for approximately 8 percent of kidney tumors, and other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare. Nephroblastoma (Wilms' tumor) is common in children (5 to 6 percent of primary renal tumors). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=see_link\">",
"     \"Malignancies of the renal pelvis and ureter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When patients with RCC present with localized disease, surgical resection can be curative. Unfortunately, many RCCs are clinically silent for much of their natural history. Thus, the diagnosis is frequently not made until disease is either locally advanced and unresectable or metastatic. Furthermore, many patients who initially are resectable eventually recur. The prognosis for long-term disease-free survival for patients with locally advanced or metastatic RCC is generally poor.",
"   </p>",
"   <p>",
"    An overview of the approach to treatment is presented here; more detailed discussions of specific aspects of treatment are discussed in other topics, as noted below. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311476\">",
"    <span class=\"h1\">",
"     LOCALIZED (RESECTABLE) RCC",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311484\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is curative in the majority of patients without metastatic RCC and is therefore the preferred treatment for patients with stages I, II, and III disease (",
"    <a class=\"graphic graphic_table graphicRef50004 \" href=\"UTD.htm?35/0/35851\">",
"     table 1",
"    </a>",
"    ). Treatment can involve either a radical nephrectomy or a variety of renal-sparing approaches (partial nephrectomy or ablative techniques) in carefully selected patients, depending upon the extent of disease. Surgery may be carried out through a conventional approach or by laparoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link\">",
"     \"Surgical management of localized renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In carefully selected patients who present with a resectable primary tumor and a concurrent single metastasis, surgical resection of the metastasis, in conjunction with radical nephrectomy, may be curative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=see_link\">",
"     \"Role of surgery in patients with metastatic renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056313976\">",
"    <span class=\"h2\">",
"     Active surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients and those with significant comorbidity may not be candidates for surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/1\">",
"     1",
"    </a>",
"    ]. Although nonsurgical procedures (cryoablation, RFA) may be useful, most small tumors grow slowly and do not become symptomatic or metastasize [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. In addition, up to 40 percent of tumors less than 1 cm in size may be benign [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/7\">",
"     7",
"    </a>",
"    ]. In this setting, observation with periodic reevaluation is a reasonable option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H29#H29\">",
"     \"Surgical management of localized renal cell carcinoma\", section on 'Active surveillance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056313897\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to improve on the results with surgery alone for localized RCC include adjuvant therapy, with either immunotherapy or molecularly targeted agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311491\">",
"    <span class=\"h3\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of immunotherapy to induce objective tumor responses in some patients with advanced RCCs has led to the evaluation of various immunotherapeutic strategies as adjuvant therapy following surgical resection. However, multiple randomized trials have",
"    <strong>",
"     not",
"    </strong>",
"    demonstrated a survival benefit from any of these approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H34#H34\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Adjuvant immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311498\">",
"    <span class=\"h3\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon demonstrated activity in patients with metastatic RCC, several clinical trials are currently examining the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    compared to placebo in patients with resected intermediate or high-risk RCC (NCT00326898, NCT00375674) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/8\">",
"     8",
"    </a>",
"    ]. These trials are not anticipated to yield mature data before 2012. Until data from these trials support this approach, such treatments should not be used in the adjuvant setting except as part of a formal clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311505\">",
"    <span class=\"h2\">",
"     Surveillance after resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful surveillance following surgical resection is important to permit early diagnosis of relapse when the tumor burden is limited. The response to immunotherapy of patients who relapse is best in patients with a good performance status and less tumor-associated immune suppression. Furthermore, some patients who have a solitary recurrence may be cured with surgical metastasectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32360?source=see_link\">",
"     \"Surveillance for metastatic disease after nephrectomy for renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314147\">",
"    <span class=\"h1\">",
"     ADVANCED DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350647569\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecularly targeted therapy has largely replaced the use of immunotherapy for patients with advanced renal cell carcinoma. However, immunotherapy remains an option for select patients. The choice between immunotherapy and molecularly targeted therapy can be stratified by whether patients were or were not treated for advanced renal cell carcinoma:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350647576\">",
"    <span class=\"h2\">",
"     Previously untreated patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a good Karnofsky performance status (KPS) (&ge;80 percent) (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ) and intact organ function, we suggest high-dose interleukin-2 (IL-2) rather than targeted therapy, provided there is access to this treatment. IL-2 can induce durable long-term remissions in approximately 10 percent of patients. (See",
"      <a class=\"local\" href=\"#H1056314219\">",
"       'Immunotherapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H2#H2\">",
"       \"Immunotherapy of renal cell carcinoma\", section on 'Interleukin-2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are not candidates for IL-2 (including those patients without access to IL-2 therapy and those who decline treatment), we recommend molecularly targeted therapy. (See",
"      <a class=\"local\" href=\"#H1056314281\">",
"       'Molecularly targeted therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350647584\">",
"    <span class=\"h2\">",
"     Previously treated patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who progressed after cytokine therapy (ie, IL-2 or interferon-alfa), we recommend treatment with a VEGFR inhibitor. A choice between available agents is based on patient considerations (ie, comorbidities) and drug availability. (See",
"      <a class=\"local\" href=\"#H1056311533\">",
"       'Anti-angiogenic (VEGF pathway)'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have progressed after a VEGF pathway inhibitor, mTOR inhibitors or use of a different VEGF pathway inhibitor are reasonable options. In the absence of prospective trials, a decision to use either agent is based on individual patient considerations, such as tumor response to the prior VEGF pathway inhibitor. (See",
"      <a class=\"local\" href=\"#H1056314281\">",
"       'Molecularly targeted therapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link&amp;anchor=H3#H3\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'VEGF TK inhibitors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link&amp;anchor=H26#H26\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'mTOR inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beyond these choices, additional options, including surgery and radiation therapy, may be used in carefully selected patients. Chemotherapy and hormonal therapy have limited use in clear cell carcinoma. (See",
"    <a class=\"local\" href=\"#H350647762\">",
"     'Other options'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evidence to support these recommendations is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314219\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the development of active, molecularly targeted agents, immunotherapy with either interleukin-2 or interferon alfa represented the primary modalities for the treatment of patients with metastatic RCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link\">",
"     \"Immunotherapy of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314226\">",
"    <span class=\"h3\">",
"     Interleukin-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunotherapy with high-dose bolus interleukin-2 (IL-2) can activate an immune response against RCC that results in tumor regressions in a minority of patients. Although treatment is associated with severe toxicity, responses often persist for many years, even in the absence of additional therapy, and the majority of complete responders remain free of relapse long-term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H2#H2\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Interleukin-2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High-dose IL-2 remains an important option for carefully selected patients who are able to tolerate the toxicity associated with this approach and who have access to this treatment, because of its ability to induce durable long-term remissions in approximately 10 percent of patients. Efforts to better identify the group of patients who achieve major benefit from IL-2 therapy are ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314233\">",
"    <span class=\"h3\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activity of monotherapy with interferon alfa (IFNa) in metastatic RCC has been extensively evaluated. Using a variety of preparations, doses, and schedules, the overall response rate may be as high as 15 percent; the median time to response is about four months, and most responses are partial and rarely persist beyond one year. A meta-analysis based upon four studies that included a total of 644 patients found that treatment with IFNa was associated with an average median improvement in survival of almost four months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H18#H18\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Interferon alfa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of IFNa has largely been replaced by molecularly targeted agents that have demonstrated improved efficacy compared to IFNa without additional toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H18#H18\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Interferon alfa'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314281\">",
"    <span class=\"h2\">",
"     Molecularly targeted therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the pathogenesis of RCC at the molecular level has identified the vascular endothelial growth factor (VEGF) pathway and the mammalian target of rapamycin (mTOR) as targets for therapeutic intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311533\">",
"    <span class=\"h3\">",
"     Anti-angiogenic (VEGF pathway)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two different approaches have clinical activity in blocking the VEGF pathway (",
"    <a class=\"graphic graphic_figure graphicRef65979 \" href=\"UTD.htm?14/4/14408\">",
"     figure 1",
"    </a>",
"    ): the use of small molecule tyrosine kinase (TK) inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    , tivozanib) to block the intracellular domain of the VEGF receptor and a monoclonal antibody (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ) to bind circulating VEGF and prevent its activating the VEGF receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Randomized clinical trials have established the role of the VEGF receptor inhibitors for the initial management of advanced RCC and for the treatment of patients with disease progression after cytokine therapy.",
"     </li>",
"     <li>",
"      An alternative approach to interrupting the VEGF pathway uses the anti-VEGF monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , which has significant activity in both untreated patients and those who have failed cytokine therapy. The activity of bevacizumab in treatment-naive patients was demonstrated in two phase III trials in combination with IFNa compared to IFNa alone, leaving unclear to what extent the concomitant IFNa administration contributed to the activity of the combination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link&amp;anchor=H24#H24\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'Bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056314296\">",
"    <span class=\"h3\">",
"     mTOR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mammalian target of rapamycin (mTOR) pathway is downstream of the phosphoinositide 3-kinase and Akt pathway that is regulated by the PTEN tumor suppressor gene (",
"    <a class=\"graphic graphic_figure graphicRef65979 \" href=\"UTD.htm?14/4/14408\">",
"     figure 1",
"    </a>",
"    ). Inhibition of the mTOR pathway has the potential to inhibit tumor progression at multiple levels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       Temsirolimus",
"      </a>",
"      , an inhibitor of mTOR, significantly increased survival of poor-prognosis patients in a phase III trial when used as the initial treatment for patients with advanced disease. Temsirolimus is an alternative to VEGF receptor inhibition, particularly in poor-risk patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link&amp;anchor=H26#H26\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'mTOR inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       Everolimus",
"      </a>",
"      , another inhibitor of mTOR, significantly increased progression-free survival compared to placebo in a phase III trial in patients who have progressed after treatment with a VEGF-targeted agent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link&amp;anchor=H26#H26\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'mTOR inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350647762\">",
"    <span class=\"h2\">",
"     Other options",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311562\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy does not have an established role in the management of patients with advanced or metastatic RCC, in contrast to other malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/12\">",
"     12",
"    </a>",
"    ]. A review of early studies reported that fluorinated pyrimidines were the most active agents, but the objective response rate was only 5 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/13\">",
"     13",
"    </a>",
"    ]. Subsequent studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and a formulation of the 5-fluorouracil prodrug tegafur have also shown evidence of at least some activity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/14\">",
"     14",
"    </a>",
"    ], as have studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Recently reported phase II studies using combinations of gemcitabine plus capecitabine have reported response rates of 8 to 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/18-22\">",
"     18-22",
"    </a>",
"    ], and at least one study has suggested that this combination may be more effective when given in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/23\">",
"     23",
"    </a>",
"    ]. Additional clinical trials will be required to determine whether this approach may have a role in patients who are no longer responsive to molecularly targeted therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311583\">",
"    <span class=\"h3\">",
"     Hormonal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestational agents have been extensively evaluated in patients with advanced RCC, but do not appear to have antitumor activity. Medroxyprogesterone is the most widely studied. Despite occasional reports of responses, a review of medroxyprogesterone treatment concluded that RCCs are neither hormone-dependent nor hormone-responsive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/24\">",
"     24",
"    </a>",
"    ], although some patients with severe anorexia may derive symptomatic benefit from hormonal therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacologic management of cancer anorexia/cachexia\", section on 'Progesterone analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence that other hormonal agents (eg, androgens, antiestrogens, or combinations of hormones and chemotherapy) are any more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350648486\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350648467\">",
"    <span class=\"h4\">",
"     Cytoreductive nephrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of the primary tumor (cytoreductive or debulking nephrectomy) is useful prior to initiating immunotherapy in some patients who present with advanced RCC. Randomized clinical trials demonstrated that patients who undergo a cytoreductive nephrectomy prior to IFNa immunotherapy had improved survival compared to those with an intact primary tumor. Careful patient selection is critical to avoid surgery in patients who will not be able to subsequently receive immunotherapy. In the absence of clinical trials data, the general consensus is that cytoreductive nephrectomy should be performed in all patients where it is clinically feasible and justifiable (75 percent debulking possible, no symptomatic metastatic disease, etc) before initiating systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H26#H26\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Cytoreductive (debulking) nephrectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of cytoreductive nephrectomy in patients who receive molecularly targeted agents is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311590\">",
"    <span class=\"h4\">",
"     Metastasectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection of a single or limited number of metastases can be curative in carefully selected patients. This occasionally is done in conjunction with a radical nephrectomy, but may also be performed following a relapse after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=see_link\">",
"     \"Role of surgery in patients with metastatic renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, in patients who have had a major but less than complete response to systemic immunotherapy, surgery can be useful to convert a partial response to a complete response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H2#H2\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Interleukin-2'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311597\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the characterization of RCC as a radioresistant tumor, conventional and stereotactic radiation therapy (RT) are frequently useful to treat a single or limited number of metastases. In these settings, the utility of RT is similar to that in other metastases from other tumor types.",
"   </p>",
"   <p>",
"    Examples of situations where RT is useful to include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Painful bone metastases (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=see_link\">",
"       \"Radiation therapy for the management of painful bone metastases\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Brain metastases (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"       \"Treatment of brain metastases in favorable prognosis patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link\">",
"       \"Treatment of brain metastases in poor prognosis patients\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Painful recurrences in the renal bed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RT has also been used as an adjuvant following nephrectomy in patients at high risk for local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], but its role in this setting remains unproven and is generally to be discouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350649038\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350648315\">",
"    <span class=\"h2\">",
"     Multiple primary RCCs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral RCCs are more common among patients with inherited conditions (eg, von Hippel-Lindau disease, tuberous sclerosis, papillary RCC) and occasionally are seen in those with sporadic tumors. In these situations, we recommend surgery. However, proper management includes attempting to spare as much renal parenchyma as possible during the initial therapy and monitoring for the development of additional RCCs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=see_link\">",
"     \"Hereditary kidney cancer syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H20#H20\">",
"     \"Surgical management of localized renal cell carcinoma\", section on 'Nephron-sparing approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350648051\">",
"    <span class=\"h2\">",
"     Nonclear cell RCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the data are limited, patients with nonclear cell RCC do not appear to respond to immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H10#H10\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Predictors of response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The activity of molecularly targeted agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    ) in patients with non-clear cell RCC has yet to be formally evaluated, although preliminary results and subset analyses from various clinical trials suggest that these agents have some activity. In addition, treatment with an inhibitor of the MET oncogene may have activity, specifically in papillary renal cell carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link&amp;anchor=H35#H35\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'Non-clear cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsets of non-clear cell tumors occasionally respond to chemotherapy. Major responses have been reported with various combinations of platinum agents, taxanes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    in patients with collecting duct tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/32-35\">",
"     32-35",
"    </a>",
"    ] and sarcomatoid RCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Renal medullary carcinoma may also be responsive to platinum-based combination chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], anthracyclines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/41\">",
"     41",
"    </a>",
"    ], or to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21528/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311611\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311618\">",
"    <span class=\"h2\">",
"     Localized disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a resectable stage I, II, or III RCC, we recommend surgery as the primary treatment approach (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link\">",
"     \"Surgical management of localized renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radical nephrectomy has been the most widely used approach and remains the preferred procedure when there is evidence of invasion into the adrenal, renal vein, or perinephric fat. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H9#H9\">",
"       \"Surgical management of localized renal cell carcinoma\", section on 'Radical nephrectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Partial nephrectomy (either open or laparoscopic) is an alternative for smaller tumors and is particularly valuable in patients with bilateral or multiple lesions, those with inherited syndromes in whom there is an increased risk of an additional primary tumor, and those with impaired renal function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H20#H20\">",
"       \"Surgical management of localized renal cell carcinoma\", section on 'Nephron-sparing approaches'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For elderly patients and those with significant comorbid disease, ablative techniques (cryoablation, radiofrequency ablation) are an alternative. Active surveillance may be an option for patients with small asymptomatic lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=see_link\">",
"       \"Radiofrequency ablation and cryoablation for renal cell carcinoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H29#H29\">",
"       \"Surgical management of localized renal cell carcinoma\", section on 'Active surveillance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1056311625\">",
"    <span class=\"h2\">",
"     Advanced disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350648855\">",
"    <span class=\"h3\">",
"     Previously untreated patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a good performance status and intact organ function, we suggest high-dose interleukin-2 (IL-2) rather than targeted therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1056314219\">",
"       'Immunotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H2#H2\">",
"       \"Immunotherapy of renal cell carcinoma\", section on 'Interleukin-2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are not candidates for IL-2 (including those patients without access to IL-2 therapy and those who decline treatment), we recommend molecularly targeted therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1056314281\">",
"       'Molecularly targeted therapy'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350648686\">",
"    <span class=\"h3\">",
"     Previously treated patients",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who progressed after cytokine therapy (ie, IL-2 or interferon-alfa), we recommend treatment with a VEGF inhibitor (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1056311533\">",
"       'Anti-angiogenic (VEGF pathway)'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have progressed after a VEGF pathway inhibitor, mTOR inhibitors or use of a different VEGF pathway inhibitor are reasonable options. In the absence of prospective trials, a decision to use either agent is based on individual patient considerations, such as tumor response to the prior VEGF pathway inhibitor. (See",
"      <a class=\"local\" href=\"#H1056314281\">",
"       'Molecularly targeted therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link&amp;anchor=H3#H3\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'VEGF TK inhibitors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=see_link&amp;anchor=H26#H26\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'mTOR inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemotherapy and hormonal therapy have limited use in clear cell carcinoma. (See",
"      <a class=\"local\" href=\"#H350647762\">",
"       'Other options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional options, including surgery and radiation therapy, may be used in carefully selected patients. (See",
"      <a class=\"local\" href=\"#H350647762\">",
"       'Other options'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350649060\">",
"    <span class=\"h2\">",
"     Special considerations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with multiple primary RCCs, we recommend surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Surgery should be planned to spare as much of normal renal parenchyma as possible. (See",
"      <a class=\"local\" href=\"#H350648315\">",
"       'Multiple primary RCCs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest molecularly targeted therapy rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, some types of nonclear cell RCC are reported to be chemosensitive (including collecting duct, sarcomatoid, and medullary RCC). (See",
"      <a class=\"local\" href=\"#H350648051\">",
"       'Nonclear cell RCC'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/1\">",
"      Santos Arrontes D, Fern&aacute;ndez Ace&ntilde;ero MJ, Garc&iacute;a Gonz&aacute;lez JI, et al. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 2008; 179:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/2\">",
"      Lamb GW, Bromwich EJ, Vasey P, Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome. Urology 2004; 64:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/3\">",
"      Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology 1995; 197:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/4\">",
"      Volpe A, Panzarella T, Rendon RA, et al. The natural history of incidentally detected small renal masses. Cancer 2004; 100:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/5\">",
"      Rendon RA, Stanietzky N, Panzarella T, et al. The natural history of small renal masses. J Urol 2000; 164:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/6\">",
"      Wehle MJ, Thiel DD, Petrou SP, et al. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology 2004; 64:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/7\">",
"      Rybicki FJ, Shu KM, Cibas ES, et al. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. AJR Am J Roentgenol 2003; 180:1281.",
"     </a>",
"    </li>",
"    <li>",
"     ClinicalTrials.gov file://www.clinicaltrials.gov/ (Accessed on October 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/9\">",
"      Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; :CD001425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/10\">",
"      Atkins MB. Management of advanced renal cancer. Kidney Int 2005; 67:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/11\">",
"      Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/12\">",
"      Vogelzang NJ. Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol 2010; 28:5017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/13\">",
"      Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/14\">",
"      Naito S, Eto M, Shinohara N, et al. Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2010; 28:5022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/15\">",
"      Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1993; 4:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/16\">",
"      De Mulder PH, Weissbach L, Jakse G, et al. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996; 37:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/17\">",
"      Casali M, Marcellini M, Casali A, et al. Gemcitabine in pre-treated advanced renal carcinoma: a feasibility study. J Exp Clin Cancer Res 2001; 20:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/18\">",
"      Chung EK, Posadas EM, Kasza K, et al. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol 2011; 34:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/19\">",
"      Tannir NM, Thall PF, Ng CS, et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008; 180:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/20\">",
"      Waters JS, Moss C, Pyle L, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004; 91:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/21\">",
"      Stadler WM, Halabi S, Rini B, et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 2006; 107:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/22\">",
"      Van Veldhuizen PJ, Hussey M, Lara PN Jr, et al. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol 2009; 32:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/23\">",
"      Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010; 11:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/24\">",
"      Kjaer M. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma. Cancer Treat Rev 1988; 15:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/25\">",
"      Oh WK, Manola J, George DJ, et al. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest 2002; 20:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/26\">",
"      Stahl M, Wilke H, Schmoll HJ, et al. A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann Oncol 1992; 3:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/27\">",
"      Rafla S. Renal cell carcinoma. Natural history and results of treatment. Cancer 1970; 25:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/28\">",
"      Finney R. The value of radiotherapy in the treatment of hypernephroma--a clinical trial. Br J Urol 1973; 45:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/29\">",
"      Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987; 13:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/30\">",
"      Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/31\">",
"      Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005; 28:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/32\">",
"      Gollob JA, Upton MP, DeWolf WC, Atkins MB. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 2001; 58:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/33\">",
"      Milowsky MI, Rosmarin A, Tickoo SK, et al. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 2002; 94:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/34\">",
"      Peyromaure M, Thiounn N, Scott&eacute; F, et al. Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 2003; 170:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/35\">",
"      Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-G&eacute;nitales) study. J Urol 2007; 177:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/36\">",
"      Rashid MH, Welsh CT, Bissada NK, Chaudhary UB. Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma. Am J Clin Oncol 2005; 28:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/37\">",
"      Fujiwara Y, Kiura K, Tabata M, et al. Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anticancer Drugs 2008; 19:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/38\">",
"      Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2011; 28:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/39\">",
"      Strouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 2005; 44:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/40\">",
"      Walsh A, Kelly DR, Vaid YN, et al. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer 2010; 55:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/41\">",
"      Schaeffer EM, Guzzo TJ, Furge KA, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int 2010; 106:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/42\">",
"      Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22:3720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21528/abstract/43\">",
"      Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol 2006; 24:e14.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15719 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21528=[""].join("\n");
var outline_f21_1_21528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1056311611\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1056313379\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311476\">",
"      LOCALIZED (RESECTABLE) RCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311484\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056313976\">",
"      Active surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056313897\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311491\">",
"      - Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311498\">",
"      - Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311505\">",
"      Surveillance after resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314147\">",
"      ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350647569\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350647576\">",
"      Previously untreated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350647584\">",
"      Previously treated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314219\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314226\">",
"      - Interleukin-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314233\">",
"      - Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314281\">",
"      Molecularly targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311533\">",
"      - Anti-angiogenic (VEGF pathway)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056314296\">",
"      - mTOR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350647762\">",
"      Other options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311562\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311583\">",
"      - Hormonal agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H350648486\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H350648467\">",
"      Cytoreductive nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1056311590\">",
"      Metastasectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311597\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H350649038\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350648315\">",
"      Multiple primary RCCs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350648051\">",
"      Nonclear cell RCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311611\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311618\">",
"      Localized disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1056311625\">",
"      Advanced disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H350648855\">",
"      - Previously untreated patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H350648686\">",
"      - Previously treated patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350649060\">",
"      Special considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15719\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15719|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/4/14408\" title=\"figure 1\">",
"      Bio pathways thera targets in RCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15719|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/0/35851\" title=\"table 1\">",
"      Five year survival by stage RCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=related_link\">",
"      Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=related_link\">",
"      Hereditary kidney cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=related_link\">",
"      Pharmacologic management of cancer anorexia/cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26310?source=related_link\">",
"      Radiofrequency ablation and cryoablation for renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22630?source=related_link\">",
"      Role of surgery in patients with metastatic renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=related_link\">",
"      Surgical management of localized renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32360?source=related_link\">",
"      Surveillance for metastatic disease after nephrectomy for renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=related_link\">",
"      Treatment of brain metastases in poor prognosis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_1_21529="Ketorolac (systemic): Drug information";
var content_f21_1_21529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketorolac (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/33/3606?source=see_link\">",
"    see \"Ketorolac (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/22/1385?source=see_link\">",
"    see \"Ketorolac (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8320258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8345791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ketorolac Injectable&reg;;",
"     </li>",
"     <li>",
"      Apo-Ketorolac&reg; Tablet;",
"     </li>",
"     <li>",
"      Ketorolac Tromethamine Injection, USP;",
"     </li>",
"     <li>",
"      Novo-Ketorolac;",
"     </li>",
"     <li>",
"      Nu-Ketorolac;",
"     </li>",
"     <li>",
"      Toradol&reg;;",
"     </li>",
"     <li>",
"      Toradol&reg; IM",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8347268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral;",
"     </li>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8349402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Pain management (acute; moderately-severe):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     The maximum combined duration of treatment (for parenteral and oral) is 5 days; do not increase dose or frequency; supplement with low dose opioids if needed for breakthrough pain. For patients &lt;50 kg and/or &ge;65 years of age, see Elderly dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"     60 mg as a single dose or 30 mg every 6 hours (maximum daily dose: 120 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     30 mg as a single dose or 30 mg every 6 hours (maximum daily dose: 120 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     Critically-ill patients: 30 mg once, followed by 15-30 mg every 6 hours for up to 5 days (maximum daily dose: 120 mg) (Barr, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     20 mg, followed by 10 mg every 4-6 hours; do not exceed 40 mg/day; oral dosing is intended to be a continuation of I.M. or I.V. therapy only",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8349401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/22/1385?source=see_link\">",
"      see \"Ketorolac (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Pain management (acute; moderately-severe):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;16 years and &lt;50 kg:",
"     <i>",
"      I.V.:",
"     </i>",
"     Refer to elderly dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;16 years and &ge;50 kg:",
"     <i>",
"      I.V.:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;17 years and &lt;50 kg:",
"     <i>",
"      Oral:",
"     </i>",
"     Refer to elderly dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;17 years and &ge;50 kg:",
"     <i>",
"      Oral:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8349403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Dosage adjustments in elderly (&ge;65 years), renal insufficiency, or low body weight (&lt;50 kg):",
"     <b>",
"      Note:",
"     </b>",
"     These groups have an increased incidence of GI bleeding, ulceration, and perforation. The maximum combined duration of treatment (for parenteral and oral) is 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: 30 mg as a single dose or 15 mg every 6 hours (maximum daily dose: 60 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: 15 mg as a single dose or 15 mg every 6 hours (maximum daily dose: 60 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 10 mg, followed by 10 mg every 4-6 hours; do not exceed 40 mg/day; oral dosing is intended to be a continuation of I.M. or I.V. therapy only",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8350484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with advanced renal impairment. Patients with moderately-elevated serum creatinine should use half the recommended dose, not to exceed 60 mg/day I.M./I.V.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8350485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution, may cause elevation of liver enzymes; discontinue if clinical signs and symptoms of liver disease develop.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8353206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as tromethamine: 15 mg/mL (1 mL, 2 mL); 30 mg/mL (1 mL, 2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as tromethamine: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8345793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8345784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089165.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089165.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8352025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May take with food to reduce GI upset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer slowly and deeply into the muscle. Analgesia begins in 30 minutes and maximum effect within 2 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer I.V. bolus over a minimum of 15 seconds; onset within 30 minutes; peak analgesia within 2 hours.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8349369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, cisatracurium, dexmedetomidine, fentanyl, hetastarch in lactated electrolyte injection (Hextend&reg;), hydromorphone, methadone, morphine, pantoprazole, remifentanil, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Azithromycin, fenoldopam, haloperidol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dexamethasone sodium phosphate, dimenhydrinate, metoclopramide, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Haloperidol, hydroxyzine, nalbuphine, prochlorperazine edisylate, promethazine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diazepam, hydromorphone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8345794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Short-term (&le;5 days) management of moderate-to-severe acute pain requiring analgesia at the opioid level",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8320263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ketorolac may be confused with Ketalar&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Toradol&reg; may be confused with Foradil&reg;, Inderal&reg;, TEGretol&reg;, traMADol, tromethamine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Toradol [Canada and multiple international markets] may be confused with Theradol brand name for tramadol [Netherlands]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8346958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Frequencies noted for parenteral administration:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gastrointestinal pain (13%), dyspepsia (12%), nausea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (4%), hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (7%), drowsiness (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, purpura, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (7%), constipation, flatulence, GI bleeding, GI fullness, GI perforation, GI ulcer, heartburn, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal function abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal thinking, acute pancreatitis, acute renal failure, agranulocytosis, alopecia, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, aplastic anemia, arrhythmia, aseptic meningitis, asthma, azotemia, blurred vision, bradycardia, bronchospasm, bruising, chest pain, CHF, cholestatic jaundice, coma, confusion, conjunctivitis, cough, cystitis, depression, dyspnea, dysuria, eosinophilia, epistaxis, eructation, erythema multiforme, esophagitis, euphoria, excessive thirst, exfoliative dermatitis, extrapyramidal symptoms, fever, flank pain, flushing, gastritis, GI hemorrhage, glossitis, hallucinations, hearing loss, hematemesis, hematuria, hemolytic anemia, hemolytic uremic syndrome, hepatitis, hyperglycemia, hyperkalemia, hyperkinesis, hypersensitivity reactions, hyponatremia, hypotension, inability to concentrate, infection, infertility, inflammatory bowel disease exacerbation, insomnia, interstitial nephritis, jaundice, laryngeal edema, leukopenia, liver failure, Lyell's syndrome, lymphadenopathy, maculopapular rash, melena, MI, nephritis, nervousness, oliguria, pallor, palpitation, pancytopenia, paresthesia, photosensitivity, pneumonia, polyuria, proteinuria, psychosis, pulmonary edema, rectal bleeding, renal failure, respiratory depression, rhinitis, seizure, sepsis, somnolence, Stevens-Johnson syndrome, stomatitis (ulcerative), stupor, syncope, tachycardia, thrombocytopenia, tongue edema, toxic epidermal necrolysis, tremor, urinary frequency increased, urinary retention, urticaria, vasculitis, vertigo, weakness, weight gain, wound hemorrhage (postoperative), xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8345801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketorolac, aspirin, other NSAIDs, or any component of the formulation; active or history of peptic ulcer disease; recent or history of GI bleeding or perforation; patients with advanced renal disease or risk of renal failure (due to volume depletion); prophylaxis before major surgery; suspected or confirmed cerebrovascular bleeding; hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding; concurrent ASA or other NSAIDs; concomitant probenecid or pentoxifylline; epidural or intrathecal administration; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; labor and delivery; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8345802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding:",
"     <b>",
"      [U.S. Boxed Warning]: May inhibit platelet function; contraindicated in patients with cerebrovascular bleeding (suspected or confirmed), hemorrhagic diathesis, incomplete hemostasis and patients at high risk for bleeding.",
"     </b>",
"     Effects on platelet adhesion and aggregation may prolong bleeding time. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding, ulcers, inflammatory bowel disease), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly, or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Even in patients without prior exposure, hypersensitivity including bronchospasm and anaphylactic shock, may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"     <b>",
"      [U.S. Boxed Warning]: Ketorolac injection is contraindicated in patients with prior hypersensitivity reaction to aspirin or NSAIDs.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery/major surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated as prophylactic analgesic before any major surgery and is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery. Wound bleeding and postoperative hematomas have been associated with ketorolac use in the perioperative setting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment or a history of liver disease. Closely monitor patients with any abnormal LFT. Rarely, severe hepatic reactions (eg, fulminant hepatitis, hepatic necrosis, liver failure) have occurred with NSAID use; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Ketorolac is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion.",
"     </b>",
"     NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Use with caution in patients with impaired renal function or history of kidney disease. Dosage adjustment is required in patients with moderate elevation in serum creatinine. Acute renal failure, interstitial nephritis, and nephrotic syndrome have been reported with ketorolac use; papillary necrosis and renal injury have been reported with the use of NSAIDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin/other NSAIDs:",
"     <b>",
"      [U.S. Boxed Warning]: Concurrent use of ketorolac with aspirin or other NSAIDs is contraindicated due to the increased risk of adverse reactions.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly:",
"     <b>",
"      [U.S. Boxed Warning]: Dosage adjustment is required for patients &ge;65 years of age.",
"     </b>",
"     Avoid use in older adults; use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Labor and delivery/breast-feeding:",
"     <b>",
"      [U.S. Boxed Warning]: May inhibit uterine contractions (increasing the risk for uterine hemorrhage) and affect fetal circulation; inhibition of prostaglandin synthesis may adversely affect neonates; use is contraindicated in labor and delivery and breast-feeding women.",
"     </b>",
"     Avoid use in late pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Low body weight:",
"     <b>",
"      [U.S. Boxed Warning]: Dosage adjustment is required for patients weighing &lt;50 kg (&lt;110 pounds).",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Oral ketorolac is not indicated for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral:",
"     <b>",
"      [U.S. Boxed Warning]: Oral therapy is only indicated for use as continuation treatment, following parenteral ketorolac and is not indicated for minor or chronic painful conditions. The maximum daily oral dose is 40 mg (adults); doses above 40 mg/day do not improve efficacy but may increase the risk of serious adverse effects.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral/injectable:",
"     <b>",
"      [U.S. Boxed Warning]: Systemic ketorolac is indicated for short term (&le;5 days) use in adults for treatment of moderately severe acute pain requiring opioid-level analgesia.",
"     </b>",
"     The combined therapy duration (oral and parenteral) should not exceed 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injectable:",
"     <b>",
"      [U.S. Boxed Warning]: Ketorolac injection is contraindicated for epidural or intrathecal administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8347281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants: Ketorolac (Systemic) may diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Ketorolac (Systemic) may enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Ketorolac (Systemic) may enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Ketorolac (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: Ketorolac (Systemic) may enhance the adverse/toxic effect of Pentoxifylline. Specifically, the risk of bleeding may be increased with this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Ketorolac (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8349365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Oral: High-fat meals may delay time to peak (by &sim;1 hour) and decrease peak concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, and white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8345796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8345797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies ketorolac as pregnancy category C. Ketorolac crosses the placenta. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians).",
"     <b>",
"      [U.S. Boxed Warning]: Ketorolac is contraindicated during labor and delivery (may inhibit uterine contractions and adversely affect fetal circulation).",
"     </b>",
"     The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8345799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated (per manufacturer's labeling)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8345800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low concentrations of ketorolac are found in breast milk (milk concentrations were &lt;1% of the weight-adjusted maternal dose in one study).",
"     <b>",
"      [U.S. Boxed Warning]: Inhibition of prostaglandin synthesis may adversely affect neonates; use of systemic ketorolac is contraindicated in breast-feeding women.",
"     </b>",
"     The manufacturer of the ophthalmic product recommends that caution be used if administered to a breast-feeding woman. The maternal pharmacokinetics of ketorolac were not found to change immediately postpartum.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8350489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer tablet with food or milk to decrease gastrointestinal distress.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8353221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ketorolac Tromethamine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/mL (1 mL): $2.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/mL (1 mL): $0.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/2 mL (2 mL): $1.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/10 mL (10 mL): $10.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ketorolac Tromethamine Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/mL (1 mL): $2.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/2 mL (2 mL): $0.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ketorolac Tromethamine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $102.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8352030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; observe for weight gain, edema; monitor renal function (serum creatinine, BUN, urine output); CBC and platelets, liver function tests; observe for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F8349372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum concentration: Therapeutic: 0.3-5 mcg/mL; Toxic: &gt;5 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Analac (TW);",
"     </li>",
"     <li>",
"      Bedoral (ZA);",
"     </li>",
"     <li>",
"      Dilox (CN);",
"     </li>",
"     <li>",
"      Dolac (BF, BJ, CI, ET, GH, GM, GN, ID, KE, LR, MA, ML, MR, MU, MW, NE, NG, RU, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Dolorex (PE);",
"     </li>",
"     <li>",
"      Dolten (AR, PY);",
"     </li>",
"     <li>",
"      Eleadol (UY);",
"     </li>",
"     <li>",
"      Eurolac (PH);",
"     </li>",
"     <li>",
"      Farpain (ID);",
"     </li>",
"     <li>",
"      Inco (TW);",
"     </li>",
"     <li>",
"      Kelac (IN);",
"     </li>",
"     <li>",
"      Keromin (KP);",
"     </li>",
"     <li>",
"      Ketanov (IN, PH);",
"     </li>",
"     <li>",
"      Keto (HK, ID, MY, PH, SG);",
"     </li>",
"     <li>",
"      Ketolac (TH);",
"     </li>",
"     <li>",
"      Ketomed (PH);",
"     </li>",
"     <li>",
"      Ketoracin (KP);",
"     </li>",
"     <li>",
"      Ketoro (TW);",
"     </li>",
"     <li>",
"      Ketron (CO);",
"     </li>",
"     <li>",
"      Kine (PE);",
"     </li>",
"     <li>",
"      Kortezor (PH);",
"     </li>",
"     <li>",
"      Ni Song (CL);",
"     </li>",
"     <li>",
"      Notolac (VE);",
"     </li>",
"     <li>",
"      Painoff (TW);",
"     </li>",
"     <li>",
"      Remopain (ID);",
"     </li>",
"     <li>",
"      Rolesen (EC);",
"     </li>",
"     <li>",
"      Scelto (ID);",
"     </li>",
"     <li>",
"      Supradol (DO, PA, SV);",
"     </li>",
"     <li>",
"      Tabel (KP);",
"     </li>",
"     <li>",
"      Taradyl (BE);",
"     </li>",
"     <li>",
"      Tarasyn (KP);",
"     </li>",
"     <li>",
"      Teromac (PH);",
"     </li>",
"     <li>",
"      Tora-Dol (CH);",
"     </li>",
"     <li>",
"      Toradol (AE, AU, BH, CL, CY, DK, EG, FI, GB, HK, ID, IQ, IR, IT, JO, KW, LB, LY, NO, OM, PH, PK, QA, SA, SE, SY, YE);",
"     </li>",
"     <li>",
"      Toragesic (BR);",
"     </li>",
"     <li>",
"      Torasic (ID);",
"     </li>",
"     <li>",
"      Torpain (ID);",
"     </li>",
"     <li>",
"      Trolac (ID, KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8349370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8349373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Analgesic: I.M.: ~10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Analgesic: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Analgesic: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed (100%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: ~13 L; poor penetration into CSF; crosses placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-6 hours; prolonged 30% to 50% in elderly; up to 19 hours in renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (92%, ~60% as unchanged drug); feces ~6%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, &ldquo;Clinical Experience With Ketorolac in Children,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(9):1009-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/7803871/pubmed\" id=\"7803871\" target=\"_blank\">",
"        7803871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clinch D, Banerjee AK, and Ostick G, &ldquo;Absence of Abdominal Pain in Elderly Patients With Peptic Ulcer,&rdquo;",
"      <i>",
"       Age Ageing",
"      </i>",
"      , 1984, 13(2):120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/6731166/pubmed\" id=\"6731166\" target=\"_blank\">",
"        6731166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerstenfeld LC, Thiede M, Seibert K, et al, &ldquo;Differential Inhibition of Fracture Healing by Non-Selective and Cyclooxygenase-2 Selective Non-Steroidal Anti-Inflammatory Drugs,&rdquo;",
"      <i>",
"       J Orthop Res",
"      </i>",
"      , 2003, 21(4):670-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/12798067/pubmed\" id=\"12798067\" target=\"_blank\">",
"        12798067",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jallad NS, Garg DC, Martinez JJ, et al, &ldquo;Pharmacokinetics of Single-Dose Oral and Intramuscular Ketorolac Tromethamine in the Young and Elderly,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1990, 30(1):76-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/2303585/pubmed\" id=\"2303585\" target=\"_blank\">",
"        2303585",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joishy SK and Walsh D, &ldquo;The Opioid-Sparing Effects of Intravenous Ketorolac as an Adjuvant Analgesic in Cancer Pain: Application in Bone Mestastases and the Opioid Bowel Syndrome,&rdquo;",
"      <i>",
"       J Pain Symptom Manage",
"      </i>",
"      , 1998, 16(5):334-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/9846029/pubmed\" id=\"9846029\" target=\"_blank\">",
"        9846029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Litalien C and Jacqz-Aigrain E, &ldquo;Risks and Benefits of Nonsteroidal Anti-inflammatory Drugs in Children: A Comparison With Paracetamol,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2001, 3(11):817-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/11735667/pubmed\" id=\"11735667\" target=\"_blank\">",
"        11735667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marret E, Flahault A, Samama CM, et al, &ldquo;Effects of Postoperative, Nonsteroidal, Antiinflammatory Drugs on Bleeding Risk After Tonsillectomy: Meta-Analysis of Randomized, Controlled Trials,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2003, 98(6):1497-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/12766664/pubmed\" id=\"12766664\" target=\"_blank\">",
"        12766664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maunuksela E, Kokki H, and Bullingham RES, &ldquo;Comparison of Intravenous Ketorolac With Morphine for Postoperative Pain in Children,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1992, 52(4):436-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/1424417/pubmed\" id=\"1424417\" target=\"_blank\">",
"        1424417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Munro HM, Reigger LQ, Reynolds PI, et al, &ldquo;Comparison of the Analgesic and Emetic Properties of Ketorolac and Morphine for Paediatric Outpatient Strabismus Surgery,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1994, 72(6):624-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/8024908/pubmed\" id=\"8024908\" target=\"_blank\">",
"        8024908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Obase Y, Matsuse H, Shimoda T, et al, &ldquo;Pathogenesis and Management of Aspirin-Intolerant Asthma,&rdquo;",
"      <i>",
"       Treat Respir Med",
"      </i>",
"      , 2005, 4(5):325-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/16137190/pubmed\" id=\"16137190\" target=\"_blank\">",
"        16137190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradhan BB, Tatsumi RL, Gallina J, et al, &ldquo;Ketorolac and Spinal Fusion: Does the Perioperative Use of Ketorolac Really Inhibit Spinal Fusion?,&rdquo;",
"      <i>",
"       Spine",
"      </i>",
"      , 2008, 33(19):2079-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/18698276/pubmed\" id=\"18698276\" target=\"_blank\">",
"        18698276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(1):44-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/1/21529/abstract-text/2199127/pubmed\" id=\"2199127\" target=\"_blank\">",
"        2199127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9152 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-210.101.131.232-F6895ED81D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21529=[""].join("\n");
var outline_f21_1_21529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8320258\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345791\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8347268\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349402\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349401\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349403\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8350484\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8350485\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8353206\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345793\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345784\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8352025\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349369\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345794\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8320263\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346958\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345801\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345802\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299558\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8347281\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349365\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345796\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345797\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345799\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8345800\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8350489\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8353221\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8352030\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349372\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961984\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349370\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349373\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9152\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9152|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/48/4872?source=related_link\">",
"      Ketorolac (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/59/41909?source=related_link\">",
"      Ketorolac (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/32/35332?source=related_link\">",
"      Ketorolac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/0/19460?source=related_link\">",
"      Ketorolac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/51/43827?source=related_link\">",
"      Ketorolac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/33/3606?source=related_link\">",
"      Ketorolac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/22/1385?source=related_link\">",
"      Ketorolac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_1_21530="Management of symptomatic carotid atherosclerotic disease";
var content_f21_1_21530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of symptomatic carotid atherosclerotic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21530/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21530/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21530/contributors\">",
"     Ronald M Fairman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21530/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21530/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21530/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21530/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/1/21530/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21530/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/1/21530/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/1/21530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location most frequently affected by carotid atherosclerosis is the carotid bifurcation, often with extension into the proximal internal carotid artery (ie, the origin). Progression of atheromatous plaque at the carotid bifurcation results in luminal narrowing, often accompanied by ulceration. This process can lead to ischemic stroke or transient ischemic attack (TIA) from embolization, thrombosis, or hemodynamic compromise.",
"   </p>",
"   <p>",
"    Carotid endarterectomy (CEA) is established as safe and effective by randomized controlled trials for reducing the risk of ischemic stroke in both symptomatic and asymptomatic patients with carotid artery atherosclerosis. Advances in medical management and percutaneous carotid angioplasty and stenting (CAS) are proposed alternatives to CEA that may impact the future use of surgical revascularization techniques for carotid disease.",
"   </p>",
"   <p>",
"    This topic will review the treatment of symptomatic carotid atherosclerotic disease. The management of asymptomatic carotid disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16922?source=see_link\">",
"     \"Management of asymptomatic carotid atherosclerotic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other aspects of carotid occlusive disease are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9608?source=see_link\">",
"     \"Pathophysiology of symptoms from carotid atherosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link\">",
"     \"Carotid endarterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF SYMPTOMATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic carotid disease is defined as focal neurologic symptoms that are sudden in onset and referable to the appropriate carotid artery distribution (ipsilateral to significant carotid atherosclerotic pathology), including one or more transient ischemic attacks characterized by focal neurologic dysfunction or transient monocular blindness, or one or more minor (nondisabling) ischemic strokes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/1\">",
"     1",
"    </a>",
"    ]. The definition is contingent on the occurrence of carotid symptoms within the previous six months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thus, although there is no precise time limitation, remote carotid symptoms should not be considered as indicative of \"symptomatic\" carotid disease.",
"   </p>",
"   <p>",
"    Vertigo and syncope are not generally caused by carotid stenosis. Therefore, patients with these symptoms in isolation should be considered as asymptomatic with regard to carotid disease even if they are found to have carotid artery stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAROTID ENDARTERECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials have established carotid endarterectomy (CEA) as safe and effective for reducing the risk of ischemic stroke in patients with symptomatic carotid artery atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the available data discussed below, we recommend CEA rather than medical management alone, and we suggest CEA rather than carotid angioplasty and stenting (CAS) for patients with recently symptomatic carotid stenosis of 70 to 99 percent and a life expectancy of at least five years who meet all of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A surgically accessible carotid lesion",
"     </li>",
"     <li>",
"      Absence of clinically significant cardiac, pulmonary, or other disease that would greatly increase the risk of anesthesia and surgery",
"     </li>",
"     <li>",
"      No prior ipsilateral endarterectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This recommendation applies only when the perioperative risk of stroke and death with CEA for the surgeon or center is &lt;6 percent. Some patients who do not meet these conditions may be appropriate candidates for CAS. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Carotid stenting'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (81 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    treatment is recommended for all patients who are having CEA. Aspirin should be started prior to surgery and continued for at least three months after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H93838520#H93838520\">",
"     \"Carotid endarterectomy\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beyond three months, continued antiplatelet therapy is indicated for most patients to prevent cardiovascular disease, particularly for those with a history of ischemic stroke or transient ischemic attack of atherothrombotic, lacunar (small vessel occlusive type), or cryptogenic type. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the prevention of cardiovascular disease in general is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Method of stenosis measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of CEA for patients with symptomatic carotid disease was established by clinical trials designed in the 1980s that employed conventional contrast angiography to determine the degree of carotid stenosis. Comparison of the two major trials of endarterectomy &mdash; the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST) &mdash; requires an understanding of how carotid artery stenosis was measured since these studies used different methodologies (",
"    <a class=\"graphic graphic_figure graphicRef58353 \" href=\"UTD.htm?11/36/11842\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NASCET measured the residual lumen diameter at the most stenotic portion of the vessel and compared this to the lumen diameter in the normal internal carotid artery distal to the stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ECST measured the lumen diameter at the most stenotic portion of the vessel, but compared this to the estimated probable original diameter at the carotid bulb [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The maximum stenosis is generally in the carotid bulb, a wider portion of the artery than the distal segment. As a result, a given stenosis would be more severe using the ECST method compared with that of NASCET. ECST methodology also requires an estimation of the true bulb diameter, which increases the risk of interobserver variability.",
"   </p>",
"   <p>",
"    Despite these differences, the results of different methods have a nearly linear relationship to each other and provide data of similar prognostic value. A 50 percent stenosis with the NASCET method is equivalent to a 65 percent stenosis for the ECST method, while a 70 percent stenosis with the NASCET method is equivalent to an 82 percent stenosis for the ECST method. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conventional contrast angiography is the gold standard for the evaluation of the true severity of internal carotid artery stenosis. However, noninvasive tests &mdash; carotid duplex ultrasound (CDUS), magnetic resonance angiography (MRA), and computed tomographic angiography (CTA) &mdash; are preferred in current clinical practice because contrast angiography is an invasive procedure associated with a risk of stroke and other complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link&amp;anchor=H22#H22\">",
"     \"Neuroimaging of acute ischemic stroke\", section on 'Conventional angiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The available clinical data suggest that the noninvasive tests (CDUS, MRA, and CTA) are sufficiently accurate and reliable that they can be used to select symptomatic patients with carotid stenosis who can benefit from endarterectomy or stenting. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H5#H5\">",
"     \"Carotid endarterectomy\", section on 'Preoperative evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     NASCET trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;NASCET was initiated in the mid-1980s to investigate the efficacy of CEA compared with medical treatment in patients with symptomatic carotid atherosclerotic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/5\">",
"     5",
"    </a>",
"    ]. This randomized, prospective, multi-center trial enrolled 659 patients who had had a hemispheric or retinal TIA or a nondisabling stroke within the 120 days before entry and had stenosis of 70 to 99 percent in the symptomatic (ipsilateral) carotid artery.",
"   </p>",
"   <p>",
"    The study was prematurely terminated because of evidence that surgery was beneficial in this selected group of patients. At the time of study termination, patients had been followed for a mean of 18 months. Although the risk of stroke and death was higher at 30 days in the patients treated with CEA (5.8 versus 3.3 percent with medical therapy), the following statistically significant benefits for CEA were observed at two years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A lower risk of any stroke or death (15.8 versus 32.3 percent)",
"     </li>",
"     <li>",
"      A lower risk of any ipsilateral stroke (9 versus 26 percent) (",
"      <a class=\"graphic graphic_figure graphicRef75669 \" href=\"UTD.htm?16/50/17197\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A lower risk of major or fatal ipsilateral stroke (2.5 versus 13.1 percent)",
"     </li>",
"     <li>",
"      A lower risk of any major stroke or death (8.0 versus 19.1 percent) (",
"      <a class=\"graphic graphic_figure graphicRef67964 \" href=\"UTD.htm?16/58/17325\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The trialists concluded that CEA was highly beneficial for patients with recent TIAs or nondisabling strokes with ipsilateral stenosis of 70 to 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent report, the NASCET trial demonstrated that CEA also had a moderate degree of benefit for patients with 50 to 69 percent symptomatic ipsilateral stenosis compared with those receiving medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the overall statistical significance favoring surgery was marginal; the five-year rate of any ipsilateral stroke for endarterectomy versus medical treatment was 15.7 versus 22.2 percent (p = 0.045). Patients with stenosis of less than 50 percent did not benefit from surgery.",
"   </p>",
"   <p>",
"    Follow-up of the NASCET cohort continued for an additional seven years. The benefits of CEA in patients with 70 to 99 percent stenosis continued to be evident after this prolonged period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subset analysis found that patients who were age 75 and older with 50 to 99 percent stenosis benefited more from CEA than younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/8\">",
"     8",
"    </a>",
"    ]. Others have reported similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/9\">",
"     9",
"    </a>",
"    ]. These findings suggest that CEA should not be withheld from appropriately selected, fit patients over the age of 75.",
"   </p>",
"   <p>",
"    Predictors of medical complications with CEA were a history of myocardial infarction or angina and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with a recent history of myocardial infarction, unstable angina pectoris, or heart failure were excluded from NASCET, perhaps in part explaining the low perioperative medical complication rate.",
"   </p>",
"   <p>",
"    The NASCET surgical results study examined rates of perioperative stroke and death at 30 days, stroke severity at 90 days, variables that influenced perioperative risk, and the durability of CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/11\">",
"     11",
"    </a>",
"    ]. Five baseline variables were predictive of increased surgical risk: hemispheric (versus retinal) TIA as the qualifying event; left sided procedure; contralateral carotid occlusion; ipsilateral ischemic lesion on CT scan; and irregular or ulcerated ipsilateral plaque.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ECST trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECST was a multi-center, prospective trial that randomly assigned 2518 patients with a nondisabling ischemic stroke, TIA, or retinal infarct due to a stenotic lesion in the ipsilateral carotid artery to medical therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/2\">",
"     2",
"    </a>",
"    ]. The first report included 374 patients with a mild stenosis (0 to 29 percent) and 778 patients with severe stenosis (70 to 99 percent). After a three-year follow-up, the following findings were noted in the interim report:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with mild stenosis had little risk of ipsilateral ischemic stroke; possible benefits of CEA were small and were outweighed by the early risks (",
"      <a class=\"graphic graphic_figure graphicRef65469 \" href=\"UTD.htm?4/57/5022\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      At 30 days, the incidence of stroke or death was 7.5 percent in the patients with a severe stenosis who underwent CEA; the risk of these complications was not related to the severity of the stenosis (",
"      <a class=\"graphic graphic_figure graphicRef75272 \" href=\"UTD.htm?4/51/4926\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      At three years, patients treated with CEA had significant reductions in the incidence of ipsilateral ischemic stroke (2.8 versus 16.8 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone) and in the total risk of surgical death, surgical stroke, ipsilateral ischemic stroke, or any other stroke (12.3 versus 21.9 percent). The risk varied with age and sex, with benefit being less likely in women and over a narrower range of carotid stenosis in younger patients (",
"      <a class=\"graphic graphic_figure graphicRef67785 \" href=\"UTD.htm?15/23/15728\">",
"       figure 6",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent final report from ECST, based upon an ultimate total of 3024 patients followed for a mean of six years, noted two major findings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CEA was beneficial for symptomatic carotid stenosis of 80 to 99 percent (",
"      <a class=\"graphic graphic_figure graphicRef52441 \" href=\"UTD.htm?0/5/89\">",
"       figure 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The risk of a major ischemic stroke ipsilateral to the unoperated carotid artery increased with the severity of the stenosis, particularly above 80 percent, but only for two to three years after randomization (",
"      <a class=\"graphic graphic_figure graphicRef52441 \" href=\"UTD.htm?0/5/89\">",
"       figure 7",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, the ECST confirmed the results of the NASCET trial, demonstrating a benefit with CEA in symptomatic patients with severe ipsilateral carotid stenosis, although age and sex were important considerations in a decision about surgery. The reduced risk of recurrent stroke associated with CEA was durable during at least 10 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in the areas where NASCET and ECST appeared to disagree (eg, in patients with less than 80 percent stenosis), a reanalysis of the data suggests that if the same measurement criteria were used, these differences would disappear [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Method of stenosis measurement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pooled analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of CEA in patients with symptomatic carotid disease has been calculated from a pooled analysis of the major trials that included data from the ECST, NASCET, and VA trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. Prerandomization carotid angiograms from ECST were reassessed by the NASCET method, and outcomes were standardized to achieve comparability among the trials. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CEA was beneficial for patients with greater than 70 percent symptomatic stenosis (but not near occlusion). The number needed to treat (NNT) to prevent one stroke over five years for this group was 6.3, with an absolute risk reduction (ARR) of 16 percent.",
"     </li>",
"     <li>",
"      No significant benefit of CEA with near occlusion of the internal carotid artery (ICA) was observed. (Near occlusion is defined by the angiographic appearance of a collapsed ICA distal to the stenosis, accompanied by faster filling in the external carotid artery, and preferential filling of the intracranial circulation from collateral vessels). The ARR over two years with CEA for near occlusion was 5.6 percent, but the lack of benefit became apparent over five years, when the ARR was negative (-1.7 percent).",
"     </li>",
"     <li>",
"      CEA was beneficial for patients with 50 to 69 percent symptomatic stenosis. The NNT to prevent one stroke over five years in this group was 22, with an ARR of 4.6 percent.",
"     </li>",
"     <li>",
"      CEA was not beneficial for symptomatic carotid stenosis of 30 to 49 percent, and CEA was harmful for symptomatic patients with less than 30 percent stenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Perioperative complication rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined morbidity and mortality that exceeds 6 percent for patients with symptomatic stenosis could eliminate the benefit gained from CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. However, the utility of this finding is limited in practice, since it may be difficult to obtain the appropriate perioperative complication rates for individual surgeons or centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Timing of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of CEA in patients with symptomatic carotid atherosclerosis has been the subject of considerable debate. Data from population-based and hospital-based studies suggest that the risk of early recurrent stroke is high following TIA or stroke associated with carotid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. While no prospective, randomized studies have specifically evaluated outcomes related to the timing of CEA after a recent stroke or TIA, some conclusions can be drawn from the pooled NASCET and ECST trial data and from observational studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     After mild stroke or TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pooled analysis of the NASCET and the ECST trials, representing the largest experience to date, found that CEA within two weeks of a nondisabling stroke or TIA significantly improved outcomes compared with later surgery (",
"    <a class=\"graphic graphic_figure graphicRef70338 \" href=\"UTD.htm?18/18/18734\">",
"     figure 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/9\">",
"     9",
"    </a>",
"    ]. The following observations were reported.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the subgroup of patients with 70 percent or greater carotid stenosis, CEA was associated with a 30.2 percent reduction in absolute risk of stroke in patients randomized within two weeks of their last event, compared with a 17.6, 11.4, and 8.9 percent absolute reduction in those randomized 2 to 4, 4 to 12, and more than 12 weeks from their last event.",
"     </li>",
"     <li>",
"      For patients with 50 to 69 percent stenosis, clinically important benefits from CEA were noted only in patients randomized within two weeks of their last event.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further analysis of the pooled NASCET and ECST data showed the following additional observations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decline in benefit of CEA over time was more rapid in women than in men",
"     </li>",
"     <li>",
"      Surgical benefit in women was confined to those who had CEA within two weeks after their last event, irrespective of the degree of stenosis",
"     </li>",
"     <li>",
"      CEA within two weeks of a nondisabling hemispheric stroke was not associated with an increased operative risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2009 systematic review identified 47 nonrandomized studies of CEA for recently symptomatic carotid stenosis that reported data on time from presenting event to CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/22\">",
"     22",
"    </a>",
"    ]. In neurologically stable patients with recent TIA or nondisabling stroke, there was no significant difference in the rate of perioperative stroke or death with early CEA (within the first two weeks) compared with later CEA (odds ratio [OR] 1.2, 95% CI 0.9-1.6). The results were similar when the analysis was restricted to patients with stable stroke (OR 1.3, 95% CI 0.7-2.5).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     After moderate to severe stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of CEA for patients with moderate to severe ischemic stroke has not been evaluated in randomized clinical trials, as patients who have disabling stroke were not eligible for NASCET or ECST. Given that there have been no prospective trials addressing the question of timing of surgery, it is difficult to generalize observations from the NASCET and ECST trials to all patients undergoing CEA. In particular, patients who have a large infarction with brain swelling, hemorrhagic brain infarction, or progressing stroke have long been thought to have high perioperative risk with early CEA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. On the other hand, delay in CEA may expose the patient to an increased risk of recurrent stroke.",
"   </p>",
"   <p>",
"    A number of retrospective studies have evaluated the timing of CEA after moderate to severe ischemic stroke, and a 1997 review of these reports made the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients undergoing CEA who have fixed neurologic deficits after a stroke probably represent a heterogeneous group whose risks vary according to clinical and radiological features.",
"     </li>",
"     <li>",
"      Several reports documented satisfactory outcomes in patients undergoing surgery within six weeks of cerebral infarction.",
"     </li>",
"     <li>",
"      Intracerebral hemorrhage after CEA is most likely due to postoperative hyperperfusion and can possibly be reduced by meticulous perioperative attention to blood pressure control.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An evidenced-based review of CEA published by the American Academy of Neurology (AAN) in 2005 identified six retrospective cohort studies comparing the timing of CEA (early versus late) in patients after stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/27\">",
"     27",
"    </a>",
"    ]. None of the studies found any differences in outcomes of perioperative morbidity or longer-term follow-up. All six studies were limited by small size.",
"   </p>",
"   <p>",
"    Limited retrospective data suggest that early CEA is safe for patients who have been treated with intravenous thrombolysis for acute ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H2#H2\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Intravenous thrombolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Very early or emergent CEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early CEA (eg, within two days of TIA or stroke) or emergent CEA for",
"    <span class=\"nowrap\">",
"     progressing/fluctuating",
"    </span>",
"    stroke or crescendo TIA may have a high operative risk, as suggested by the following observational reports:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In an analysis of data from a large Swedish registry, CEA for symptomatic carotid stenosis within zero to two days (n = 148) of the qualifying ischemic event was associated with a significantly increased risk of perioperative stroke or death (11. 5 percent, odds ratio [OR] 4.2, 95% CI 2.1-8.7) compared with a reference group (n = 804) who had CEA on days three to seven (3.6 percent, OR 1) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/31\">",
"       31",
"      </a>",
"      ]. There was no increased risk the group (n = 677) who had CEA on days 8 to 14 (4 percent, OR 1.1, 95% CI 0.6-2.0), while risk was increased for the group (n = 967) who had CEA on days 15 to 180 (5.4 percent, OR 1.9, 95% CI 1.1-3.2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A 2009 systematic review identified 18 nonrandomized studies of CEA for recently symptomatic carotid stenosis that reported data on time from presenting event to CEA, and further stratified CEA into emergent (stroke-in-evolution or crescendo TIA) and nonemergent indications. The rate of perioperative stroke or death was significantly higher with emergent CEA (14 versus 4 percent for nonemergent CEA, pooled relative odds 4.6, 95% CI 3.4-63) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other factors influencing benefit and risk with CEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to exclude from surgery those who are unlikely to benefit from CEA. These include patients with the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe comorbidity due to other surgical or medical illness",
"     </li>",
"     <li>",
"      An ipsilateral stroke associated with persistent disabling neurologic deficits",
"     </li>",
"     <li>",
"      Total or near total occlusion of the symptomatic ipsilateral internal carotid artery (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Pooled analysis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for morbidity and mortality associated with CEA should also be identified in order to avoid surgery in those who may face unacceptably high surgical risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/32\">",
"     32",
"    </a>",
"    ]. These risk factors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H5#H5\">",
"     \"Carotid endarterectomy\", section on 'Preoperative evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H93838506#H93838506\">",
"     \"Carotid endarterectomy\", section on 'Perioperative risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the perioperative complication rate and the timing of surgery, a number of additional factors appear to impact benefit and risk of CEA in patients with symptomatic carotid stenosis. These include gender, the presence of contralateral carotid stenosis or occlusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of CEA may be greater for men than for women [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/9\">",
"     9",
"    </a>",
"    ]. Results from the pooled analysis of three major trials (ECST, NASCET, and VA trials) and a second analysis of data from NASCET and the ACE trial provided the following observations regarding the benefit of CEA for symptomatic patients by gender [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/9,33\">",
"     9,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of stroke ipsilateral to a symptomatic carotid stenosis is significantly lower for medically treated women than men, while the perioperative risk of death from CEA is significantly higher in women than in men.",
"     </li>",
"     <li>",
"      CEA is beneficial for women with 70 to 99 percent symptomatic carotid stenosis, and the five-year absolute risk reduction in stroke is similar for men and women (17.3 and 15.1 percent, respectively). The number of patients needed to treat (NNT) with CEA to prevent one ipsilateral stroke in five years is also similar for men and women (six and seven, respectively).",
"     </li>",
"     <li>",
"      In contrast to men, CEA is",
"      <strong>",
"       not",
"      </strong>",
"      beneficial for most women with 50 to 69 percent symptomatic carotid stenosis. However, a proportion (29 percent) of women in the 50 to 69 percent group with the highest risk factor profile, as determined by a modified version of the Stroke Prognosis Instrument-II (SPI-II) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/34\">",
"       34",
"      </a>",
"      ], may have benefit from CEA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Retinal versus hemispheric ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with symptomatic carotid disease, transient retinal ischemia (ie, transient monocular blindness [TMB]; also called amaurosis fugax) portends a lower risk of ipsilateral carotid stroke than hemispheric TIA. In a subset analysis from NASCET, 198 medically treated patients with TMB had a three-year risk of ipsilateral stroke that was approximately one-half that of 417 medically treated patients with hemispheric TIA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Contralateral carotid stenosis or occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;CEA is likely to be beneficial for patients who have symptomatic ipsilateral carotid stenosis and coexisting severe contralateral carotid stenosis or occlusion. However, such patients are at higher perioperative risk than those without a severe contralateral carotid artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/36\">",
"     36",
"    </a>",
"    ]. These points were illustrated in a report from the NASCET cohort that analyzed medical versus surgical therapy in 659 patients with a recent ischemic event referable to a 70 to 99 percent stenosis of an ipsilateral carotid artery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/37\">",
"     37",
"    </a>",
"    ]. The contralateral carotid artery had a 70 to 99 percent stenosis in 8.6 percent and was totally occluded in 7 percent. After a two-year follow-up, the following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medically treated patients with an occluded contralateral carotid were twice as likely to have an ipsilateral stroke compared with those with severe or mild to moderate disease (hazard ratio 2.36 and 2.65, respectively).",
"     </li>",
"     <li>",
"      Among surgically treated patients, the perioperative risk of stroke and death was higher in those with a totally occluded or mild to moderately stenotic contralateral vessel (4 and 5 percent, respectively) compared with those without contralateral disease. Despite this increased risk, patients who had CEA still had a significantly better outcome than patients treated medically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Risk modeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since any benefit of CEA is dependent upon the absolute risk of adverse outcome with or without treatment, it is useful to systematically consider the risks and benefits of CEA based on individual patient characteristics whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/38\">",
"     38",
"    </a>",
"    ]. A risk model for patients with recently symptomatic carotid stenosis has been derived from the ECST trial data and validated by showing that the predicted stroke risk for patients assigned to medical treatment in the NASCET trial was close to the observed risk [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the model does not account for the risk and benefit of surgery, it may be useful for assessment of baseline stroke risk and patient selection for CEA.",
"   </p>",
"   <p>",
"    The baseline ipsilateral stroke risk for patients with recently symptomatic carotid disease is calculated based upon the following factors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient age",
"     </li>",
"     <li>",
"      Patient sex",
"     </li>",
"     <li>",
"      Degree of carotid stenosis",
"     </li>",
"     <li>",
"      Type of presenting symptomatic event (eg, ocular TIA, hemispheric TIA, minor stroke, or major stroke)",
"     </li>",
"     <li>",
"      Time since last symptomatic event",
"     </li>",
"     <li>",
"      Carotid plaque morphology (eg, smooth versus ulcerated or irregular) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9608?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathophysiology of symptoms from carotid atherosclerosis\", section on 'Clinicopathologic correlates'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These factors can be entered into the model to estimate the absolute risk of ipsilateral stroke for individual patients with symptomatic carotid disease who are candidates for CEA (",
"    <a class=\"graphic graphic_figure graphicRef71761 \" href=\"UTD.htm?14/36/14920\">",
"     figure 9",
"    </a>",
"    ). A version of the ECST stroke risk model calculator is available online (",
"    <a class=\"external\" href=\"file://www.stroke.ox.ac.uk/\">",
"     www.stroke.ox.ac.uk",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an example from the model, a 70 year old woman who presents with an ocular TIA, a 70 to 99 percent ipsilateral carotid stenosis, an ulcerated irregular plaque, and time greater than 12 weeks since the last symptomatic event has a predicted absolute five-year stroke risk of 15 to 20 percent. However, if the same patient presents with a cerebral (hemispheric) TIA and time less than two weeks since the last symptomatic event, the predicted absolute five-year stroke risk rises 35 to 40 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CAROTID STENTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid artery angioplasty and stenting (CAS) is the standard for endovascular carotid intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/32\">",
"     32",
"    </a>",
"    ]. Compared with carotid angioplasty without stenting, angioplasty with stenting reduces the risk of embolization, thrombosis, carotid artery recoil, and long-term restenosis.",
"   </p>",
"   <p>",
"    Accumulating data suggest that CAS and CEA provide similar long-term outcomes for patients with symptomatic carotid occlusive disease. However the periprocedural (30 day) stroke or death rate is greater with stenting than with endarterectomy. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Randomized trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Carotid endarterectomy remains the preferred treatment for most patients with symptomatic carotid atherosclerosis. Nevertheless, the use of stenting is attractive, since the procedure is less invasive than CEA and may offer equivalent or better outcomes with continued technical advances, particularly in subsets of patients that may be at increased risk for poor outcomes with CEA. However, there are conflicting data whether patients at high risk of poor outcome following endarterectomy can be reliably identified, and the very existence of a defined group of high-risk of patients has been challenged. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=see_link&amp;anchor=H93838506#H93838506\">",
"     \"Carotid endarterectomy\", section on 'Perioperative risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the available data discussed below, we suggest CAS rather than CEA, for select patients with recently symptomatic carotid stenosis of 70 to 99 percent who have any of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A carotid lesion that is not suitable for surgical access",
"     </li>",
"     <li>",
"      Radiation-induced stenosis",
"     </li>",
"     <li>",
"      Restenosis after endarterectomy",
"     </li>",
"     <li>",
"      Clinically significant cardiac, pulmonary or other disease that greatly increases the risk of anesthesia and surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This recommendation only applies when the periprocedural risk of stroke and death with CAS for the operator or center is &lt;6 percent. Patients with symptomatic carotid atherosclerosis who do not have any of these conditions may be better served by treatment with CEA. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Carotid endarterectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results from randomized controlled trials comparing CAS with CEA for the treatment of symptomatic carotid stenosis show that the periprocedural (30 day) stroke or death rate is higher with stenting than with endarterectomy; the increased periprocedural risk of CAS mainly affects patients &ge;70 years of age. Although less certain, the available evidence suggests that longer-term outcomes are similar for both CEA and CAS.",
"   </p>",
"   <p>",
"    Supporting evidence comes from a 2012 meta-analysis that identified seven trials comparing endovascular treatment with CEA in patients with symptomatic carotid stenosis and four trials comparing endovascular treatment with CEA in patients with both symptomatic and asymptomatic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/39\">",
"     39",
"    </a>",
"    ]. None of the trials specifically included patients considered to be at high surgical risk. The vast majority of patients assigned to the endovascular arms of the included trials were treated with carotid stenting. In the analysis of patients with symptomatic carotid stenosis, the following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with CEA, patients assigned to endovascular treatment had a significantly higher rate of periprocedural stroke or death at 30 days (8.2 versus 5.0 percent, odds ratio [OR] 1.72, 95% CI 1.29-2.31).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In subgroup analysis, patients &ge;70 years of age had a significantly increased risk of periprocedural stroke or death with endovascular treatment compared with CEA (OR 2.20, 95% CI 1.47 to 3.29).",
"     </li>",
"     <li>",
"      In contrast, there was no significant difference in the risk of periprocedural stroke or death for patients &lt;70 years of age (OR 1.16, 95% CI 0.80-1.67).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with CEA, the endovascular treatment group had a significantly higher rate of death or stroke during the periprocedural period or ipsilateral stroke during follow-up (10.4 versus 7.7 percent, OR 1.39, 95% CI 1.10-1.75).",
"     </li>",
"     <li>",
"      Compared with CEA, endovascular treatment was associated with significantly lower risks of myocardial infarction (OR 0.44), cranial nerve palsy (OR 0.08) and access site hematoma (OR 0.37).",
"     </li>",
"     <li>",
"      The rate of ipsilateral stroke after the periprocedural period was similar for the endovascular and CEA treatment groups (2.2 versus 2.4 percent, OR 0.93, 95% CI 0.60-1.45).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details of the larger published trials are provided in the sections that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     ICSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the ICSS trial (also known as CAVATAS 2), 1713 adults (age &gt;40 years) with recently symptomatic carotid artery stenosis were randomly assigned to treatment with either CEA or CAS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients considered unsuitable for CEA or CAS were excluded, as were those who had a major stroke without useful recovery of function, those who had a previous CEA or CAS procedure in the randomized artery, or those awaiting major surgery such as coronary artery bypass graft surgery. All patients had carotid stenosis that was &gt;50 percent by NASCET criteria on noninvasive imaging such as duplex ultrasound. Measurement using catheter angiography was not required. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Method of stenosis measurement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although three-year outcomes for ICSS are not yet available, the following observations were reported for the interim intention-to-treat analysis at 120 days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of patients who reached the combined endpoint of stroke, death, or myocardial infarction was significantly higher for the stenting group than the endarterectomy group (8.5 versus 5.2 percent, hazard ratio 1.69, 95% CI 1.16-2.43)",
"     </li>",
"     <li>",
"      The stenting group also had significantly higher rates for the endpoints of any stroke (7.7 versus 4.1 percent), any stroke or death (8.5 versus 4.7 percent), and all cause death (2.3 versus 0.8 percent)",
"     </li>",
"     <li>",
"      There was no significant difference between the stenting and endarterectomy groups for the endpoint of disabling stroke or death (4.0 versus 3.2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings by per-protocol analyses were similar to those reported by the intention-to-treat analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subanalysis of 231 patients in the ICSS who had brain MRI found that the proportion of patients with new ischemic brain lesions on diffusion-weighted MRI at a median of one day after treatment was significantly higher in the stenting group than in the endarterectomy group (50 versus 17 percent, odds ratio 5.2, 95% CI 2.8-9.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     SPACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SPACE trial was a multicenter European study designed to test the hypothesis that CAS is not inferior to CEA for the treatment of severe symptomatic carotid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/42\">",
"     42",
"    </a>",
"    ]. The trial randomly assigned 1183 patients with this condition to either CAS or CEA and excluded high-risk patients with uncontrolled hypertension or severe concomitant disease and a poor prognosis. Recurrent carotid stenosis after surgery or stenting was also an exclusion criterion. The trial was stopped after the second interim analysis, mainly due to recruitment and funding problems.",
"   </p>",
"   <p>",
"    At 30 days after the procedure, there was no significant difference between CAS and CEA in the primary composite outcome measure, death or ipsilateral ischemic stroke (6.8 versus 6.3 percent, respectively, absolute difference 0.51 percent, 90% CI -1.89 to 2.91 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/42\">",
"     42",
"    </a>",
"    ]. However, these findings failed to prove that CAS is statistically noninferior compared with CEA. In a post-hoc analysis, older age in the CAS group (but not the CEA group) was significantly associated with an increased risk of ipsilateral stroke or death [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There was no statistically significant difference between CAS and CEA in the composite endpoint of any periprocedural stroke or death and ipsilateral ischemic stroke up to two years after the procedure in both intention-to-treat (9.5 versus 8.8 percent) and per protocol (9.4 versus 7.8 percent) analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/44\">",
"     44",
"    </a>",
"    ]. However, recurrent carotid stenosis &ge;70 percent was significantly more frequent in the CAS group in both analyses (10.7 versus 4.6 percent by intention-to-treat).",
"   </p>",
"   <p>",
"    One criticism of the SPACE trial was that the use of embolic protection devices with stenting was optional, and such devices were used in only 27 percent of patients treated with CAS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/42\">",
"     42",
"    </a>",
"    ]. However, there was no significant difference in the primary outcome of death or ipsilateral ischemic stroke at 30 days between patients treated with and without embolic protection (7.3 and 6.7 percent, respectively, OR 1.1, 90% CI 0.53-2.25). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=see_link&amp;anchor=H4#H4\">",
"     \"Carotid artery stenting and its complications\", section on 'Embolic protection devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     EVA-3S",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like the SPACE trial, the multicenter French EVA-3S trial evaluated the hypothesis that CAS is not inferior to CEA for the treatment of severe symptomatic carotid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/45\">",
"     45",
"    </a>",
"    ]. EVA-3S randomly assigned 527 patients with this condition to CAS or CEA. The study excluded high-risk patients with unstable angina, uncontrolled diabetes, or uncontrolled hypertension, and patients with previous carotid revascularization (ie, recurrent carotid stenosis).",
"   </p>",
"   <p>",
"    The incidence of any stroke or death at 30 days, the composite primary outcome measure, was significantly higher with stenting than with CEA (9.6 versus 3.9 percent, relative risk 2.5, 95% CI 1.2-5.1). The trial was stopped prematurely due to an excess number of deaths in the CAS group.",
"   </p>",
"   <p>",
"    The prespecified main secondary outcome (any periprocedural stroke or death and any non-periprocedural ipsilateral stroke occurring in up to four years of follow-up) was also significantly higher with stenting than with CEA (11.1 versus 6.2 percent, hazard ratio 1.97, 95% CI 1.06-3.67) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/46\">",
"     46",
"    </a>",
"    ]. The difference favoring CEA at four years was largely driven by the higher periprocedural (within 30 days) risk of stenting. The risk of ipsilateral stroke after the periprocedural period was low, and similar in both treatment groups.",
"   </p>",
"   <p>",
"    In the periprocedural period, cranial nerve injury was significantly more common after CEA than after stenting. Major local complications were more common with CAS, and systemic complications (mainly pulmonary) were more common with CEA, but these differences were not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main criticism of EVA-3S centers on the heterogeneity of operator experience, stent types, and cerebral protection devices [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Interventional clinicians were required to have performed only two stenting procedures with any new device before its use in EVA-3S, while five different stents and seven different cerebral protection devices were used in the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/45\">",
"     45",
"    </a>",
"    ]. Another criticism is that embolic protection for patients assigned to CAS was optional early in the trial, and the 30-day outcome of any stroke or death was significantly lower in patients treated with (n = 277) than in those treated without (n = 20) embolic protection (7.9 and 25 percent, respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=see_link&amp;anchor=H4#H4\">",
"     \"Carotid artery stenting and its complications\", section on 'Embolic protection devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     CREST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CREST trial randomly assigned 2502 patients with carotid atherosclerotic disease to endarterectomy or stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/49\">",
"     49",
"    </a>",
"    ]. The proportion of enrolled patients with asymptomatic and symptomatic carotid disease was 47 and 53 percent, so the results are not directly comparable to the trials that enrolled only symptomatic patients. The CREST trial found that the overall effectiveness and safety of the two procedures (CAS and CEA) were similar, and the benefits were equal for men and women and for patients with asymptomatic and symptomatic carotid disease. The following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary endpoint for the trial, a composite of any stroke, MI, or death within 30 days following treatment plus any ipsilateral stroke during long-term follow-up (median 2.5 years), was similar for stenting and endarterectomy (7.2 versus 6.8 percent, hazard ratio [HR] 1.1, 95% CI 0.8-1.5).",
"     </li>",
"     <li>",
"      The rate of ipsilateral stroke occurring from 31 days post-procedure to four years of follow-up was also similar for stenting and endarterectomy (2.0 versus 2.4 percent).",
"      <br/>",
"      <br/>",
"      Nevertheless, some important differences emerged [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/49-52\">",
"       49-52",
"      </a>",
"      ]:",
"     </li>",
"     <li>",
"      For patients age 70 and older, the rate of the primary endpoint and adverse events increasingly favored surgery over stenting. As a result, CAS tended to have greater benefit at younger ages, while endarterectomy tended to have greater benefit at older ages [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The proportion of patients with stroke within 30 days of the procedure was significantly higher in the stenting than the endarterectomy group (4.1 versus 2.3 percent, HR 1.8, 95% CI 1.1-2.8).",
"     </li>",
"     <li>",
"      The frequency of myocardial infarction within 30 days of the procedure was significantly lower in the stenting group (1.1 percent versus 2.3 percent, HR 0.5, 95% CI 0.3-0.9).",
"     </li>",
"     <li>",
"      At one year after the procedure, quality of life was significantly diminished for patients who developed stroke, even a minor stroke, compared with those who developed myocardial infarction.",
"     </li>",
"     <li>",
"      A secondary analysis showed that for the subgroup of patients with symptomatic carotid disease, the periprocedural rate of stroke and death was significantly higher for those assigned to stenting compared with endarterectomy (6.0 versus 3.2 percent, HR 1.89, 95% CI 1.1-3.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A CREST substudy found that at one year, stroke had a large and statistically significant detrimental impact on quality of life, while both myocardial infarction and cranial nerve palsy had small impacts on quality of life that were not statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/51\">",
"       51",
"      </a>",
"      ]. However, despite the higher rate of stroke with stenting, there were no significant differences at one year after the procedure between the CEA and CAS groups in any quality of life measure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Early trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two early trials that compared CEA with CAS for symptomatic carotid disease were stopped prematurely because of significantly worse outcomes with the percutaneous technique [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], while another early trial reported that CAS and CEA had similar rates of adverse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SAPPHIRE trial found that CAS was not inferior to CEA in patients with symptomatic or asymptomatic carotid stenosis considered to be at high risk for carotid surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. However, more than 70 percent of patients in the trial had asymptomatic carotid disease. Thus, the results do not apply directly to patients with symptomatic carotid stenosis, particularly those considered to be at low to moderate risk for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Effect of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients have worse outcomes with CAS compared with CEA, even though older age was originally proposed to be associated with high risk for surgery and therefore a potential indication for carotid stenting rather than endarterectomy. In a 2012 meta-analysis (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Randomized trials'",
"    </a>",
"    above), the subgroup of patients &ge;70 years of age had an approximately two-fold increased risk of periprocedural stroke or death with endovascular treatment compared with CEA (OR 2.20, 95% CI 1.47 to 3.29), while no increased risk was noted for patients &lt;70 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/39\">",
"     39",
"    </a>",
"    ]. Similar findings were reported in a 2010 meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/58\">",
"     58",
"    </a>",
"    ] and in the CREST trial (see",
"    <a class=\"local\" href=\"#H23\">",
"     'CREST'",
"    </a>",
"    above). The risk of stroke associated with carotid stenting appears to increase linearly with patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/49,58\">",
"     49,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence that older age is a risk factor for periprocedural complications of CAS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=see_link&amp;anchor=H101621741#H101621741\">",
"     \"Carotid artery stenting and its complications\", section on 'Risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1236614\">",
"    <span class=\"h2\">",
"     Stenting in other subgroups",
"    </span>",
"    &nbsp;&mdash;&nbsp;In data drawn largely from registries and case series, subgroups suggested to have tolerated CAS with relative safety included patients with prior neck irradiation, high cervical carotid bifurcations and those with complete occlusion of the contralateral internal carotid artery. Further evidence from large controlled clinical trials is needed before drawing firm conclusions about the safety and effectiveness of CAS in these various subgroups. Factors that may affect periprocedural outcomes of CAS are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=see_link&amp;anchor=H101621741#H101621741\">",
"     \"Carotid artery stenting and its complications\", section on 'Risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is controversy about the appropriate management for patients who develop restenosis of the carotid artery following CEA, and the available data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Restenosis due to intimal hyperplasia is usually benign. For patients who develop symptomatic cerebral ischemia due to recurrent carotid stenosis caused by intimal hyperplasia or atherosclerosis, multispecialty guidelines note that it is reasonable to either repeat CEA or perform CAS using the same criteria as recommended for initial revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/61\">",
"     61",
"    </a>",
"    ]. Additional factors that should be considered in the decision include the degree of wound healing since surgery, the occurrence of local or cerebral perioperative complications with prior surgery, and the time since the prior surgery, since perioperative risk may change over time. In addition, patient preference is always important in such decisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time when most of the major CEA trials were underway (generally the late 1980s to mid 1990s), the best medical therapy for carotid disease was generally considered to be antiplatelet treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . Since the completion of these trials, newer medical regimens have emerged that reduce the risk of stroke. These therapies include aggressive treatment with statins, antiplatelet agents, and antihypertensive agents. As an example, statin treatment can delay progression and induce regression of atherosclerotic lesions both in native coronary vessels and in coronary bypass grafts. Statin treatment can also reduce the incidence of first and recurrent stroke. Guidelines issued in 2011 by the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    recommend optimal medical therapy for all patients with carotid artery stenosis and a TIA or stroke, including antiplatelet therapy, statin therapy, and risk factor modification [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/62\">",
"     62",
"    </a>",
"    ].(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Improvement in atherosclerosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link&amp;anchor=H10#H10\">",
"     \"Secondary prevention of stroke: Risk factor reduction\", section on 'Dyslipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unknown if these newer medical therapies would change the relative risk reduction afforded by CEA for carotid disease, but they might increase the number of patients needed to treat to prevent one stroke. This may be of particular significance for patients with asymptomatic carotid disease in whom the NNT is already high compared with symptomatic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16922?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of asymptomatic carotid atherosclerotic disease\", section on 'Carotid endarterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2734819\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines issued in 2011 by the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    for the prevention of stroke make the following recommendations for the management of symptomatic carotid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with recent TIA or ischemic stroke within the past six months and ipsilateral severe (70 to 99 percent) carotid artery stenosis, CEA is recommended if the perioperative morbidity and mortality risk is estimated to be &lt;6 percent.",
"     </li>",
"     <li>",
"      For patients with recent TIA or ischemic stroke and ipsilateral moderate (50 to 69 percent) carotid stenosis, CEA is recommended depending on patient-specific factors, such as age, sex, and comorbidities, if the perioperative morbidity and mortality risk is estimated to be &lt;6 percent.",
"     </li>",
"     <li>",
"      When the degree of stenosis is &lt;50 percent, there is no indication for carotid revascularization by either CEA or CAS.",
"     </li>",
"     <li>",
"      When CEA is indicated for patients with TIA or stroke, surgery within two weeks is reasonable rather than delaying surgery if there are no contraindications to early revascularization.",
"     </li>",
"     <li>",
"      CAS is indicated as an alternative to CEA for symptomatic patients at average or low risk of complications associated with endovascular intervention when the diameter of the lumen of the internal carotid artery is reduced by &gt;70 percent by noninvasive imaging or &gt;50 percent by catheter angiography.",
"     </li>",
"     <li>",
"      CAS may be considered among patients with symptomatic severe stenosis (&gt;70 percent) in whom the stenosis is difficult to access surgically, medical conditions are present that greatly increase the risk for surgery, or when other specific circumstances exist, such as radiation-induced stenosis or restenosis after CEA.",
"     </li>",
"     <li>",
"      CAS in the above setting is reasonable when performed by operators with established periprocedural morbidity and mortality rates of 4 percent to 6 percent, similar to those observed in trials of CEA and CAS.",
"     </li>",
"     <li>",
"      Optimal medical therapy, which should include antiplatelet therapy, statin therapy, and risk factor modification, is recommended for all patients with carotid artery stenosis and a TIA or stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multispecialty guidelines for the management of extracranial carotid and vertebral artery disease published in 2011 are generally concordant with the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines and incorporate the following additional recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/1/21530/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is reasonable to choose CEA over CAS when revascularization is indicated in older patients, particularly when arterial pathoanatomy is unfavorable for endovascular intervention.",
"     </li>",
"     <li>",
"      It is reasonable to choose CAS over CEA when revascularization is indicated in patients with neck anatomy unfavorable for arterial surgery. Conditions that produce unfavorable neck anatomy include but are not limited to arterial stenosis distal to the second cervical vertebra or proximal (intrathoracic) arterial stenosis, previous ipsilateral CEA, contralateral vocal cord paralysis, open tracheostomy, radical surgery, and irradiation.",
"     </li>",
"     <li>",
"      In symptomatic or asymptomatic patients at high risk of complications for carotid revascularization by either CEA or CAS because of comorbidities, the effectiveness of revascularization versus medical therapy alone is not well established. Comorbidities that increase the risk of revascularization include but are not limited to age &gt;80 years, New York Heart Association class III or IV heart failure, left ventricular ejection fraction &lt;30 percent, class III or IV angina pectoris, left main or multivessel coronary artery disease, need for cardiac surgery within 30 days, myocardial infarction within four weeks, and severe chronic lung disease.",
"     </li>",
"     <li>",
"      In patients with symptomatic cerebral ischemic and recurrent carotid stenosis due to intimal hyperplasia or atherosclerosis, it is reasonable to repeat CEA or perform CAS using the same criteria as recommended for initial revascularization.",
"     </li>",
"     <li>",
"      Carotid revascularization is not recommended for patients with chronic total occlusion of the targeted carotid artery.",
"     </li>",
"     <li>",
"      Carotid revascularization is not recommended for patients with severe disability caused by cerebral infarction that precludes preservation of useful function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=see_link\">",
"       \"Patient information: Carotid artery disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic carotid disease is defined as focal neurologic symptoms that are sudden in onset and referable to the carotid artery distribution within the previous four to six months. These symptoms may be transient ischemic attacks, episodes of transient monocular blindness, or minor (nondisabling) ischemic strokes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of symptomatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options for symptomatic carotid atherosclerotic disease include carotid endarterectomy (CEA), carotid artery stenting (CAS), and medical management. All recommendations regarding revascularization with CEA or CAS are made with the provision that that the perioperative risk of stroke and death for the surgeon, operator, or center is &lt;6 percent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Carotid endarterectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Carotid stenting'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Medical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with recently symptomatic carotid stenosis of 70 to 99 percent who have a life expectancy of at least five years, we recommend CEA rather than medical management alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Carotid endarterectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Pooled analysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Perioperative complication rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with recently symptomatic carotid stenosis of 70 to 99 percent who have a life expectancy of at least five years, we suggest CEA rather than CAS when the following conditions apply (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Carotid endarterectomy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A surgically accessible carotid lesion",
"     </li>",
"     <li>",
"      Absence of clinically significant cardiac, pulmonary, or other disease that would greatly increase the risk of anesthesia and surgery",
"     </li>",
"     <li>",
"      No prior ipsilateral endarterectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with symptomatic carotid disease, the perioperative risk of stroke or death for patients age 70 years and older is approximately two-fold higher with CAS compared with CEA. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Effect of age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For select patients with recently symptomatic carotid stenosis of 70 to 99 percent, we suggest CAS rather than CEA if any of the following conditions are present (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Effect of age'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1236614\">",
"       'Stenting in other subgroups'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2734819\">",
"       'Recommendations of others'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A carotid lesion that is not suitable for surgical access",
"     </li>",
"     <li>",
"      Radiation-induced stenosis",
"     </li>",
"     <li>",
"      Clinically significant cardiac, pulmonary or other disease that greatly increases the risk of anesthesia and surgery; however, it is not clear if revascularization with endarterectomy or stenting is better than medical management for this group",
"      <br/>",
"      <br/>",
"      For patients age 70 years and older in all these subgroups, the benefit-to-risk ratio of CAS is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with recently symptomatic carotid stenosis of 50 to 69 percent who have a life expectancy of at least five years, we suggest CEA rather than medical management (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). For women with recently symptomatic carotid stenosis of 50 to 69 percent, we suggest medical management rather than CEA (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Carotid endarterectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Perioperative complication rate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Gender'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend medical management rather than CEA or CAS for patients with symptomatic carotid stenosis that is less than 50 percent (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Carotid endarterectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Pooled analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with carotid stenosis and a nondisabling stroke or TIA, we recommend that CEA be performed within two weeks of the last symptomatic event rather than a later time (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Observational evidence suggests that CEA in the first 48 hours after symptom onset is associated with increased risk compared with CEA performed 3 to 14 days after symptom onset. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Timing of surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of additional factors may influence the benefit and risk of CEA for patients with symptomatic carotid stenosis (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Other factors influencing benefit and risk with CEA'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Older patients may have a greater benefit from CEA than younger patients",
"     </li>",
"     <li>",
"      Patients with hemispheric TIA appear to have greater benefit from CEA than patients with transient retinal ischemia",
"     </li>",
"     <li>",
"      Coexisting severe contralateral carotid stenosis or occlusion may increase perioperative risk but does not cancel out benefit from CEA",
"     </li>",
"     <li>",
"      CEA is",
"      <strong>",
"       not",
"      </strong>",
"      beneficial for patients with near occlusion of the symptomatic ipsilateral internal carotid artery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefit of CEA or CAS for patients with moderate to severe ischemic stroke has not been evaluated in randomized controlled trials, and patients with an ipsilateral stroke who have persistent disabling neurologic deficits are unlikely to benefit from revascularization. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other factors influencing benefit and risk with CEA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Timing of surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/1\">",
"      Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/2\">",
"      MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 1991; 337:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/3\">",
"      Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/4\">",
"      Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/5\">",
"      North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. Stroke 1991; 22:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/6\">",
"      Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998; 339:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/7\">",
"      Paciaroni M, Eliasziw M, Sharpe BL, et al. Long-term clinical and angiographic outcomes in symptomatic patients with 70% to 99% carotid artery stenosis. Stroke 2000; 31:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/8\">",
"      Alamowitch S, Eliasziw M, Algra A, et al. Risk, causes, and prevention of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery stenosis. Lancet 2001; 357:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/9\">",
"      Rothwell PM, Eliasziw M, Gutnikov SA, et al. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004; 363:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/10\">",
"      Paciaroni M, Eliasziw M, Kappelle LJ, et al. Medical complications associated with carotid endarterectomy. North American Symptomatic Carotid Endarterectomy Trial (NASCET). Stroke 1999; 30:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/11\">",
"      Ferguson GG, Eliasziw M, Barr HW, et al. The North American Symptomatic Carotid Endarterectomy Trial : surgical results in 1415 patients. Stroke 1999; 30:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/12\">",
"      Cunningham EJ, Bond R, Mehta Z, et al. Long-term durability of carotid endarterectomy for symptomatic stenosis and risk factors for late postoperative stroke. Stroke 2002; 33:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/13\">",
"      Rothwell PM, Gutnikov SA, Warlow CP, European Carotid Surgery Trialist's Collaboration. Reanalysis of the final results of the European Carotid Surgery Trial. Stroke 2003; 34:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/14\">",
"      Rerkasem K, Rothwell PM. Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev 2011; :CD001081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/15\">",
"      Gorelick PB. Carotid endarterectomy : where do we draw the line? Stroke 1999; 30:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/16\">",
"      Goldstein LB, Moore WS, Robertson JT, Chaturvedi S. Complication rates for carotid endarterectomy. A call to action. Stroke 1997; 28:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/17\">",
"      Barnett HJ. The inappropriate use of carotid endarterectomy. CMAJ 2004; 171:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/18\">",
"      Fairhead JF, Mehta Z, Rothwell PM. Population-based study of delays in carotid imaging and surgery and the risk of recurrent stroke. Neurology 2005; 65:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/19\">",
"      Ois A, Cuadrado-Godia E, Rodr&iacute;guez-Campello A, et al. High risk of early neurological recurrence in symptomatic carotid stenosis. Stroke 2009; 40:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/20\">",
"      Marnane M, Ni Chroinin D, Callaly E, et al. Stroke recurrence within the time window recommended for carotid endarterectomy. Neurology 2011; 77:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/21\">",
"      Rothwell PM, Eliasziw M, Gutnikov SA, et al. Sex difference in the effect of time from symptoms to surgery on benefit from carotid endarterectomy for transient ischemic attack and nondisabling stroke. Stroke 2004; 35:2855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/22\">",
"      Rerkasem K, Rothwell PM. Systematic review of the operative risks of carotid endarterectomy for recently symptomatic stenosis in relation to the timing of surgery. Stroke 2009; 40:e564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/23\">",
"      Blaisdell WF, Clauss RH, Galbraith JG, et al. Joint study of extracranial arterial occlusion. IV. A review of surgical considerations. JAMA 1969; 209:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/24\">",
"      BRUETMAN ME, FIELDS WS, CRAWFORD ES, DEBAKEY ME. CEREBRAL HEMORRHAGE IN CAROTID ARTERY SURGERY. Arch Neurol 1963; 9:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/25\">",
"      Rob CG. Operation for acute completed stroke due to thrombosis of the internal carotid artery. Surgery 1969; 65:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/26\">",
"      Pritz MB. Timing of carotid endarterectomy after stroke. Stroke 1997; 28:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/27\">",
"      Chaturvedi S, Bruno A, Feasby T, et al. Carotid endarterectomy--an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005; 65:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/28\">",
"      McPherson CM, Woo D, Cohen PL, et al. Early carotid endarterectomy for critical carotid artery stenosis after thrombolysis therapy in acute ischemic stroke in the middle cerebral artery. Stroke 2001; 32:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/29\">",
"      Bartoli MA, Squarcioni C, Nicoli F, et al. Early carotid endarterectomy after intravenous thrombolysis for acute ischaemic stroke. Eur J Vasc Endovasc Surg 2009; 37:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/30\">",
"      Crozier JE, Reid J, Welch GH, et al. Early carotid endarterectomy following thrombolysis in the hyperacute treatment of stroke. Br J Surg 2011; 98:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/31\">",
"      Str&ouml;mberg S, Gelin J, Osterberg T, et al. Very urgent carotid endarterectomy confers increased procedural risk. Stroke 2012; 43:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/32\">",
"      Brott TG, Brown RD Jr, Meyer FB, et al. Carotid revascularization for prevention of stroke: carotid endarterectomy and carotid artery stenting. Mayo Clin Proc 2004; 79:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/33\">",
"      Alamowitch S, Eliasziw M, Barnett HJ, et al. The risk and benefit of endarterectomy in women with symptomatic internal carotid artery disease. Stroke 2005; 36:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/34\">",
"      Kernan WN, Viscoli CM, Brass LM, et al. The stroke prognosis instrument II (SPI-II) : A clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke 2000; 31:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/35\">",
"      Benavente O, Eliasziw M, Streifler JY, et al. Prognosis after transient monocular blindness associated with carotid-artery stenosis. N Engl J Med 2001; 345:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/36\">",
"      Antoniou GA, Kuhan G, Sfyroeras GS, et al. Contralateral occlusion of the internal carotid artery increases the risk of patients undergoing carotid endarterectomy. J Vasc Surg 2013; 57:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/37\">",
"      Gasecki AP, Eliasziw M, Ferguson GG, et al. Long-term prognosis and effect of endarterectomy in patients with symptomatic severe carotid stenosis and contralateral carotid stenosis or occlusion: results from NASCET. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. J Neurosurg 1995; 83:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/38\">",
"      Rothwell PM, Mehta Z, Howard SC, et al. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet 2005; 365:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/39\">",
"      Bonati LH, Lyrer P, Ederle J, et al. Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev 2012; 9:CD000515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/40\">",
"      International Carotid Stenting Study investigators, Ederle J, Dobson J, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 2010; 375:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/41\">",
"      Bonati LH, Jongen LM, Haller S, et al. New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS). Lancet Neurol 2010; 9:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/42\">",
"      SPACE Collaborative Group, Ringleb PA, Allenberg J, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006; 368:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/43\">",
"      Stingele R, Berger J, Alfke K, et al. Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol 2008; 7:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/44\">",
"      Eckstein HH, Ringleb P, Allenberg JR, et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol 2008; 7:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/45\">",
"      Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006; 355:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/46\">",
"      Mas JL, Trinquart L, Leys D, et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol 2008; 7:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/47\">",
"      Furlan AJ. Carotid-artery stenting--case open or closed? N Engl J Med 2006; 355:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/48\">",
"      Qureshi AI. Carotid angioplasty and stent placement after EVA-3S trial. Stroke 2007; 38:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/49\">",
"      Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/50\">",
"      Silver FL, Mackey A, Clark WM, et al. Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). Stroke 2011; 42:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/51\">",
"      Cohen DJ, Stolker JM, Wang K, et al. Health-related quality of life after carotid stenting versus carotid endarterectomy: results from CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial). J Am Coll Cardiol 2011; 58:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/52\">",
"      Voeks JH, Howard G, Roubin GS, et al. Age and outcomes after carotid stenting and endarterectomy: the carotid revascularization endarterectomy versus stenting trial. Stroke 2011; 42:3484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/53\">",
"      Naylor AR, Bolia A, Abbott RJ, et al. Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial. J Vasc Surg 1998; 28:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/54\">",
"      Alberts MJ. Results of a multicenter prospective randomized trial of carotid artery stenting vs carotid endarterectomy [oral abstract]. Stroke 2001; 32:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/55\">",
"      Brooks WH, McClure RR, Jones MR, et al. Carotid angioplasty and stenting versus carotid endarterectomy: randomized trial in a community hospital. J Am Coll Cardiol 2001; 38:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/56\">",
"      Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004; 351:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/57\">",
"      Yadav JS. Carotid stenting in high-risk patients: design and rationale of the SAPPHIRE trial. Cleve Clin J Med 2004; 71 Suppl 1:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/58\">",
"      Carotid Stenting Trialists' Collaboration, Bonati LH, Dobson J, et al. Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet 2010; 376:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/59\">",
"      Attigah N, K&uuml;lkens S, Deyle C, et al. Redo surgery or carotid stenting for restenosis after carotid endarterectomy: results of two different treatment strategies. Ann Vasc Surg 2010; 24:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/60\">",
"      Bowser AN, Bandyk DF, Evans A, et al. Outcome of carotid stent-assisted angioplasty versus open surgical repair of recurrent carotid stenosis. J Vasc Surg 2003; 38:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/61\">",
"      Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Stroke 2011; 42:e464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/1/21530/abstract/62\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1106 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21530=[""].join("\n");
var outline_f21_1_21530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF SYMPTOMATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAROTID ENDARTERECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Method of stenosis measurement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NASCET trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ECST trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pooled analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Perioperative complication rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Timing of surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - After mild stroke or TIA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - After moderate to severe stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Very early or emergent CEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other factors influencing benefit and risk with CEA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Retinal versus hemispheric ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Contralateral carotid stenosis or occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Risk modeling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CAROTID STENTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - ICSS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - SPACE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - EVA-3S",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - CREST",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Early trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Effect of age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1236614\">",
"      Stenting in other subgroups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2734819\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1106\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1106|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/36/11842\" title=\"figure 1\">",
"      Carotid stenosis in NASCET and ECST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/50/17197\" title=\"figure 2\">",
"      NASCET endarterectomy stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/58/17325\" title=\"figure 3\">",
"      NASCET endarterectomy stroke death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/57/5022\" title=\"figure 4\">",
"      Endarterectomy mild stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/51/4926\" title=\"figure 5\">",
"      Endarterectomy severe stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/23/15728\" title=\"figure 6\">",
"      Benefit carotid endarterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/5/89\" title=\"figure 7\">",
"      Carotid endarterectomy stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/18/18734\" title=\"figure 8\">",
"      Outcome of carotid endarterectomy by time of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/36/14920\" title=\"figure 9\">",
"      Stroke risk medical treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/66?source=related_link\">",
"      Carotid artery stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/27/40378?source=related_link\">",
"      Carotid endarterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16922?source=related_link\">",
"      Management of asymptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9608?source=related_link\">",
"      Pathophysiology of symptoms from carotid atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/14/12512?source=related_link\">",
"      Patient information: Carotid artery disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_1_21531="Probabilities for thrombolysis";
var content_f21_1_21531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Baseline probabilities for thrombolytic decision tree (example for decision analysis)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"2\">",
"        <em>",
"         <strong>",
"          For illustration purposes only",
"         </strong>",
"        </em>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Probability that the patient is having a myocardial infarction (MI)",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        If the patient is having an MI, probability of death",
"       </td>",
"       <td class=\"sublist_other\">",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        If the patient is not having an MI, probability of death",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Probability of a patient having a severe or fatal complication of thrombolytic therapy",
"       </td>",
"       <td>",
"        0.40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In a patient having an MI, relative reduction in mortality from treatment with thrombolytic therapy",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Krumholz HM, Pasternak RC, Weinstein MC, et al, N Engl J Med 1992; 327:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21531=[""].join("\n");
var outline_f21_1_21531=null;
var title_f21_1_21532="Distrib nodal metastases";
var content_f21_1_21532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distribution of nodal metastasis",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Subsites",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"12\">",
"        Pathological node assessment (percent cases with positive nodes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Level I",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Level II",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Level III",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Level IV",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Level V",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        RP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"       <td class=\"subtitle3\">",
"        N0",
"       </td>",
"       <td class=\"subtitle3\">",
"        N+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyriform sinus",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pharyngeal wall",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RP: retropharyngeal.",
"    </div>",
"    <div class=\"reference\">",
"     1. McLaughlin MP, Mendenhall WM, Mancuso AA, et al. Retropharyngeal adenopathy as a predictor of outcome in squamous cell carcinoma of the head and neck. Head Neck 1995; 17:190.",
"     <br>",
"      2. Candela, FC, Kothari, K, Shah, JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck 1990; 12:197.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21532=[""].join("\n");
var outline_f21_1_21532=null;
var title_f21_1_21533="Platelet aggregometry";
var content_f21_1_21533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Platelet aggregometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 474px; background-image: url(data:image/gif;base64,R0lGODlhvgHaAcQAAP///4CAgAAAAMDAwH9/f0BAQKCgoBAQEPDw8CAgIGBgYFBQULCwsHBwcDAwMJ+fn9DQ0ODg4JCQkO/v7w8PDz8/P7+/vx8fHy8vL09PT8/Pz4+Pj6+vr9/f319fX29vbyH5BAAAAAAALAAAAAC+AdoBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztCIRAwEDtbupAwYBCw4CFAUNurzIZAgDzBIBz9DR0tPU1dbXDQUHAhgZBA8WyeJbt8/ZBdoC6hXsHgTv8PHy8/T19vcEFh3j/Fe+wMIoVPjwzoLBff0SNoIgIdu2bt/CKZz4iOGCAxS86aPI0ZFFjBk2aOhIclEEAxcz/4osyRLRgAYOVI5sSZMQg4sYPkisyTNQhAIXHiDsSdQPggACCEwoyrQPgwQVhjadeqcBBQ5Us9qJ4ACDVK1g3Qw48CGs2TcRDjw4y5aNg7Jt455pgEGuXTIMKHy9y1cLggRY+wreEqCCiw4bCGxYOrgxkQgC9qKooI6b48tBChB4wWHChAsCdmIejYPBBcYwQEsmzfrF38AwNgiA27p2jMIyPgjwYLv3C8irU2QQcKGg7+MpNMuorG4z8ucjTKOGTr2Gg7XimFVfA4ECv2fb1SignQx8+DMIIn8PcP6MhAz9zLcnAzg++/ljTCeUjx/Mgg373dffF5BNJw5/A3LRAP9vASb4xQEz2edgFwbUpRCCE16RAHYNZpjFABdQhKGHUxQA4EQjkgjFABQYuJ6KVijgHIoCwhhFgRylaOMSCjAoYo07NpFecAcCGeQSAfj445FOIHCAaDQy2YQEhpGko5RDJABllFgmYUCIJV3Z5Q8bsiTmmDxIYGGYRqL5g5NbLunmELi1dOacNsBJ05140tBjTXz2GQNwgLYp6A1/FnooDyy6aKWhi86gHE+BRqpCoz1VaikKDpxIKaSbtvBlUZqGOoKTsH1q6gwLwEcqqKuekJejdsIaKwmoNlVqqK1Otauls/pq6625CnsrC71S9euhwSo7rKnFOntsCslmtSz/ns1a+6yl0Wo7rQkFkOfttyOoSStT144JgQARgpUulgh0yta7UjZQ5Vn0HpmtWfnu2C2/w97CzDFEGFAABJeFK9edSFVmBC4ROGbuws8OIEABIvxy0wIIA4BSMQj8EoEEERtcgAQinKNAxxKg00A5EUQQAAPZ3IeAAgU8QzBV67Y7b8UXi1CAAAkIkwAASC0QQAIDDL3NSwI0sIAAKCcQQAMHHK1A1AE4gIsAzKiTjgEACNPA1tuSFK+ncfFpMcYADC2CMABkLQICCAyNgAhZPxP0S+kAMLXSuiAVNnsMCJCLAAoAYHHaHdnLl9tBxy2A0JdXjvkIRENjQOILMED3/83CCMCA4Y87rnjqqVNlQIuTByyBAF5bvvnUEgywQNOXizB1Lr8gNXMClyuQewNUo6646gGkxzTykE9kgACpUtxCw+rYbvvN2yTwU+8AcC/AAc0bTTzS2xzQANJgs768AdsMHX1C03N4V79IGMDM1AwwhcACVxkM/o6wtc4VJWQHyMC52jLA80BAAQfAQPX60sDqiI4CHvCZAOfXgmy4wIN2+UlQFhi7HbTuFy6QW1yOkhQSUvBZDwSZ43KxAI4BYGs589h9BoCzlUUAZzJU4VlCBhUiNeZOaXFAAA7gAPbl7AAHKBvRMCY3iykxZ00LwNYaJ0SwPDCCE2TNnWbXP//kQcBwAEDe4W4ngIgBoGQ4C1oXqXLBDD6HYWBj39cK177l2a6LyDOGHME3FRE+wIWjudO6dpeAKCJFAgyAoupCZ7vZKQAXARgaA6ZHRUIeEClK2Q6fDEA8ByAMKcRLQMecpr2ljY8BEIjfIKdCyqic51doZA0pLxBG6OAyj6N5SlD6U0G+TI9t8ymmXernIE0ZrGMyeCYtBWA/YkIulzKAGAA0VxNmTohPEFgAOvL4wwKsbIYMwFn/ANCyYsBselYb2X0CgDKOePObAYNiJsGWxCU6cnxDa+PWGtC1PSLvAAfbGgTW1TiKJK6aCRqjAMhmOEvuc49pBNvgcqHHbcL/zWINMCNHEoDMZg4LjYZDigKgIbM8Go506jhdHjXXyKLZE0wkupPFdje0AazLAQx4yRldCjbjQc0ZM2VaxBpWz4mUSUV8OqgwdCE6dTigpXzERfrWh1J1IAwyAtib9HCaUw72IHENdSpETeDTW5qVB1PbWT9IuYKhwk2Ub+3LBcimgoDetTrK1MoDjsaCt7l1Ox5o6qW4SZ3AZgUDckWBYcPjWKp4EgUMod0AxNrYvNrFAk1kQUDVEdnjVLYpG0irjU7LlAwoFkasLQoFoLlaz8ZFA1E8Umx7soEFMGm3PMEAX4MEXJrglrM7Km5LPKDa5Nr2LBOYrZSUW5IHhPa3/881y16xRN2ODLZL3eXIdrmbXcESlry+ie460dubDPh2TOFNCAcOgNzplrcpGqDAesF736JMAAPrc1N8x+GBv8K3v7ylL54GjAwNCIC2aGLwLqL72ggjmCYVaK6AL8ySDzigvhvGzAMOAOE5SVgWDzBdpE4MixQP91AsdoWLNxVjVsz4UNtgjsPscuNDIU/HAnhvXHp8KLDq+MVnIfKipqZjEGtlAh84wH4jlTjmCNksGsBAAZy8KOJVBslakU2FNzW7ynC5Ecso7Qp8gUgeTKACppxWetRxZUn8eMqFHZoHeumDB1CgAWfeVAHBDAkva7gFI0sABT6gQR10gAAUAP8quUSwrrBWInES2Eag64q1C2zAiDCwgAcYp+ZjOaDOkdjaDydamq1VgAAc2AgMJmABDhAAA+Rz46RJYABCO2LOBSilDkKWyXQI5NX1+EAFMGDVYvh615ewqCtLrINbnM4aQd00tDEhDLEGctvgDre4x03uMfW63FlJAKrRzZMqa5vdHAnomOFdEotZld49KaA6dI3vkhhZHQHud0n0rY7zCpwjTgJyqQ9+ICAzjuEcybGOcwvxjtS44pG4OMYfofGNN6LjHl8EyEOeiJGT/BAmP3khUq7yQbC85YF4Ocz/IPOZ96HmNt8DznOeh53z/A4+/3kdgi70ORC96HE4OtL/36CdpTv96VCPutSnTvWqW/3qWM+61rfO9a57/etgD7vYx072spv97GhPu9rXzva2u/3tcI+73OdO97rb/e54z7ve9873vvv974APvODrELxp4Hnwb9hlPSiwgHcjXgxEHCYKJpABKT+eOxDEwFpNwAEKPPvyXqhjo1OQ30ODvgsBoMAhZ/Dfxp/+C//DwOhdQPkPv54LEHCAAnPgARLf/kMHmFEORnz430OBpH32vPGpMKof5Dfgy3/CU51/AdNH/wjND8J/t3x9Jky/BRaYfQrebPvu54+sK9AAAQRwrxh4QJXmP0IBNn8CyrC/BlGmdvx7EAHYvcAC91cDI/Z5//uHA0kSAwDYfjPQeRy2f1qCgAFoA1nmegXIKOjHAhogGxhgAW02fhkQZxWoAzISA/anDnEiAwRgeSF4A04CakXAgCtoAwaggE4wgY4XgyWwAPS3BLWnfziYAgfggkmQgsX3g2y1JlWgZEZ4Ag0gLlSghEtIAg5wglIAhVHYf1xghUZoAK6yBVqIgzroBV8YgunRgVAwhgXIhWGAhvEXhmvIakZYhmPAhtGnhmRwbj94HVFIBiyyh2Qwgn4YBoQSiGBwgIQIBk9yiF9QIYroBa/RiKhHg5BoBYM4iVkwKZaIBRyQADeYiUnQAfrliT9QeDMzAwAmijwQefCgGzt4Av8ehoo6gBJBVk33xAIjxm+TODCb9QLn9gDPcAEJYABcFkm7twIpVoSHyBwHsHC8RhxWEwAEGD4AtIN0uIfZAz0vsEkyIEyrRwITIBvRSIjq0DXeUwSy6A3vMByUBIvbdDHE04AlQGzPIIzsyDm9kz31+ASkNTsGl49LwBwH448COQp4OJBOoG4G6QTulpBMIG8MqQT2RjsPmQQEh4sTGQT/FjUXWQQERzQbOQQJp2PM+JE2gD3MYX0keQMSp4wpSSfw2JIioHQ/KJM4SJMxaJMriJMhqJMVyJMF6JP7B5TxJ5TmR5TdZ5TXh5TRp5TLx5TG55S/B5W3J5WvR5Wn13T/MJmVWrmVXNmVXvmVYBmWYjmWZFmWZnmWaJmWarmWbNmWbvmWcBmXcjmXdFmXdnmXeJmXermXfNmXfvmXgBmYgjmYhFmYhnmYiJmYirmYjNmYjvmYkCkD6mOR08IQI0kTlbGOfkCK89iJQMAQ11ANudNWbGABBFABFKBul9kSOpYAEuCZaqB48qCO9IgEAyABKYGO+DCb7EAB6oBQBaA09DQwXNABHPABzOYADWAAlDkVDsc4PugG3Dh5D0CbsOkaBqAAwoABHrASOaABBpEYBOAB7MBszWZOz7ABBkGFzhee4wkaWHSdYhGa9Fmf9nmf+FkNz2lV4XgGx9QCE/AA/xVwAJeUiueonkwwMM6gRehQOtzQDrsZoenYm7+JDkojAdHJB5iUnxzaoR5an/tJoMiYBrXYAo8GjAHQnC5wm4PTjVqgoB86DaOZoXwBZCJKeNRUA6JGDPYZDx6QnApQm09XGTdqByU6A/KIn7ljdUUqBvIkpC5QkGI5PZVhYDLYnwMJGcsIAGe0AwiZlbMDfTqwkDApPD7gkDDJSSOgojAQkdfVksSTM+KUAxWZlRHAZK6JAxkppnLZkf0YlyHJHKu5KtLUAxBQAM9WDJ5gkpWBktOCTSbkRyLQOtDoCStJpLtWTueERiqDMLigOzbETi4TMbojQzcTnJJ6QxfDHv+VKjPpdDAMoKjhk0ma6QhWWRP9JEloZDVYczRI8URRNFAFBTrI41tmgzZSOEUepToXMz4JQDxk4wDkIww0Sgi3ShMW1VNoBDjb0FFqtFG68DvT9nCtM6l+9DfLU0WKsy45g6wc95IeolIsZTigU1Ud9VLaGVPyAw3uUyOtg67soa6LkzM6AwnX2hI/FVQNMFRfMzyX80iRFKzHQzWzszvp5CTPk6o71T8AazupA0X6IwFYGnPw6iFVRTtYFS9Ecz6oRDSntFUx6WW+BT/NCiSs1LECy6V4OqIrV7ImBkw54rMCBrRyopcHi3hHO3hJK3hLG3hNC3hP+3dR63dT23cnVct3V7t3Wat3WBmZXvu1YBu2Yju2ZFu2Znu2aJu2aru2bNu2BRgCADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of results of platelet aggregometry. The test substance is added to platelet-rich plasma at the point shown by the arrow. Time progresses to the right; an upward deflection of the curve represents a decrease in optical density due to platelet aggregation, allowing more light to pass through the solution. Three examples are shown: Curve A: A normal response to addition of adenosine diphosphate (ADP) is shown, with a first and second wave (phase) of aggregation. Curve B: Only a first phase of aggregation is seen. This pattern is seen in platelets taken from a patient with a storage pool defect after addition of an intermediate dose of ADP. Curve C: No response. This pattern is seen in platelets from a patient with Bernard-Soulier syndrome after addition of ristocetin or in patients with Glanzmann thrombasthenia after addition of all agonists except ristocetin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21533=[""].join("\n");
var outline_f21_1_21533=null;
var title_f21_1_21534="Sympathetic nervous system";
var content_f21_1_21534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Actions of sympathetic nervous system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 510px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemodynamic responses induced by the sympathetic nervous system after effective circulating volume depletion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21534=[""].join("\n");
var outline_f21_1_21534=null;
var title_f21_1_21535="Tongue protrusion measure";
var content_f21_1_21535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Measurement of tongue protrusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 577px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJBAesDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKSlphbmgB1FNzS0ALRmkzS0ALRSUuaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqfmZmcehq5WS77dQnX3H8hUyKirmgDS5qur08NRcLE2aXNRhqXNMLD80oNMzSigVh9LTQadTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVz90+NWuR7r/6CK6CuYvm/4nF1z0Zf/QFrOpsaU1dmgslSLJWcJOBT1l5qFIvlNJZPenh6zhL71KstUpE8pfDU4NVNJfepVcVSZLRZBp4NQK1SK1UmKxLmimA0/NMkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuPnlEmo3cgPWUr+Xy/0rptTu1sbGa4fkIvA9T2H4muKt2YRgscsTlj6k9TWNV7I3oxvdmiJPzpRJiqfmU5ZDxmsbm3KXBL71Isvb+tURJTg9O4uU0kl5qeOWspZMdTzUize9UpEuJsJLU6SVjrN71ahm6c1akZuJpq3rUoNUo5M1YR81omZtE4opgNPBqiQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACg8UVy/iPWN5ewsyf7ssqnp/sj39f84mUlFXZUIuTsin4h1FdQu1hgO63gOSw6O/T8hVAtgUxIxGgCjGKRzjmuSUm3dndGKirId5hzT1kPQ1XLdKA2c1NyrFsSU5ZKph6cH7U7isWxJ15pRNiqbScU1pfSncLGktxz1q1FPz1rDSXnrmrcUmO9NSJcTfhm9+avQy571z0M3StGCbpzWsZGMoGyjVKpqhDLnFW0atUzBonBopgNPFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFGaiubiK2haWdwiDua5nU9Smv8AdFEGite+fvSfX0Ht+fpUykolxg5E+t6y7M1tp7Y7PMP5L/jWGkYjXAHNTBQowBgVG/pXNKTk9TrhFRVkRNzULe/WpnxUD9azZoiNj703fzStUdIoeWwD61H5p9aa5+WqryYOKB2LrS5HWozJ2quHyKAcmgLFyJqtwv71nxdatR9qaJaNCN+ferkMhzis2PtVqLtmqTIaNi3lrRglrBhfBrQgk961jIwlE2UbNSKapQyZAq0jVsmYNEtFIDS1RIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVHPNHBE0krBEUZJNAElZWo6xFbOYoF8+ccFQcKv1P9Kzr3U570lLfdDB0z0Zv8P51XigSJflAGPSspVOiNo0+shk3nXcvm3bl2HQYwq/QUhXA4qZs1E2axZsiB6ib9etTPULipLRA55NQv7VO461A1Sy0Qv3qEk5xUr8ZqvIcVJaIriTAqg8hLU+6fJxVVTlqCi8hOBU8QLYzVaDkc1ehFMTJYxVmJajiXkVZjWmiGSxip17UxBUqiqRDJFOB1q1C+MZqovUetTxk1S0IZq279KvxP0rIt2IxV+B+laxZhJF9TTwagRqmBrVGTQ6iiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimSyJFG0kjBUUFmJ7CgCO8uorSEyzNhegx1J9BXM3Es2oTebPwin5IweF/xPvRczvqF15rgiMcRof4R6/U//AFqmChRxisJy5tEdEI8u+41VCLgflQetPPPWmmoLI2qNgeRUxHpUZFJjRAwqGQVaccVA44pMtFWTpVd+DViQVWkNQzRFeU1TnbC1akPFZ9y3apLRRmYk0kQyRQykv7VYgTkUiieBTir0S4AqGJMVcjWqRDJolq3EvAqKJOlW4lGKpIzbFVTjipAPWlWnKOaohsRV/CpUHTFIBUgFOwmyWKrkLYqmlTxnmqRm0acTVOpqjE1W0atosxaJwaWmqacKsgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsHxFcb5I7RDxw8gHfngfpn8BW9XHySCbUbiUnrIQPoOB/Ks6jsjSkru5YhQBcU+lQZA96G61ibDDSEUvc0m4ZoGIRx/Smkcc0u8Yyapz3qRdTQCJn61BJmq41ONj1p4mVxkHrUs0SIpBVWSrUuDzmqstQzSJTnIx0rOnOTV+4PB9aouN1QaIrqnzVcgT1qONOeauRJ0poGSxLxVqJfmFMiX2q1EnIqkZtk8S8dOBVlRUaAYqdV6c1aRk2KoFPC0oFOApk3EA6U9eKFHp9aeBTEAqRCetMFKDTQmW4mq5G1ZsbVbiarizOSL6GpAarRtU6mtUzJofRQKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAriYf8AWP7M3867auMuV8nULqP0kJ/Pn+tZVdjal1LsbZUUp6mq8UmBUocEdayNBTUTd8VMcGm7CaAKkm7aRWPfQu2etdGYh6VXmgB7dKTRSZxU0MiHIzS213LG2GziukuLRWB4rLnsRzxg1Jqncnt7jzFyKc+CSRVCFXhfBzVpmBGaTQ0ypcc1VAIbmrsnJqEpzWZqJGuatwrk1FGnPSrUK4qkS2TRrmrkKcDNQxLzVyMYFWkZyJEWpVH5UiCpAM1Rm2CjpTxSqMUoH40yQHtSj9KTGCKMc+9AhaM0tJQA5TViNulVRUqHmqTE0aETVZQ1nxNVuNq0izKSLQNOqNTUgrQzCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACua8TQeTdRXQB2SDY3sR0/r+VdLUVzBHcwPDMu6NhgipkrqxUZcruccMlMrUfnMp5q3d2c2muRIDJb9pcdP970/z9KrToHTcnpXO00dKaYsdx81aVu4btXmutf2wsxlhuXgAPCIBj8fWtnwp4ja5P2a+2pdqO3Aceo9/akmU46aHclQelRMme1LbXCuvWrGAwq7XMtjOkhB5qrLbhj0rYaMVXePnNJotSMS4sx6c1nzxlSa6K4UYrLnQMWxUtFxkZGc5FHcdajk+SU+me9SLyaxaOhMmjFWolziq8WOKvQqAKaJkSxLVpB0qONelWFH5VojJseo65qQDFNUVIoH51SM2ABp2P1pQOlKRTENxQfpTsUn60AN96Oc0EcZopAIetOU4+tN4FLkUAWI2xVuJ6z0arET4q0yGjSjaplNU4mqyhrVMyaJaKQUtUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIQCMHkVkX+iQyIzWZ+zTnoV+6fqvT8sVsUUmk9xptbHm17dra3n2LWoRbyt9yT/lnJ9DXP+IdF+YXNkxSRfmUqehr1HxTokOvaVJaygCQfNE5/hb/DtXj8NzeeH7t7G/Vzbo20q3Jj+nqK55xsddKXMjR0HxQ4It747LheM9A3/wBeurtddjJG5hXF6npcV0PNjx8wzkVlpb31s21WZox0zzis7tGnKmetLqcLL94Ukl/FtJDCvNIbq4AwQRVgXcxHU1XOyfZnW3+pooODWfbXhkJJ71hDe5zITircL+XxmlcrlsTak+GLCm277owR1qK8cPHnNR6Y+6MjOSDUSNY7Gvb9q0oBWbbdq1IB0oiTIsxj1qwo496ijHNTrWiMWOUfnUgAxTR0p4qiBRTscc0gFKaBCY5pD79af/OmmgBh9KTvxTj0prd6QwGPwpMdSBQaDyaAAHFTRtUHfmnK2D7UwZoQvzVuNqzI2xVyF81pFmckXlNPqBGqYGtEZMWiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5zxV4YtdbjMjt5M6j/WAZyPcd66OszxFci20i4bOGceWv1PH+NKVralQbT0PNYE8uNIgdwRQufpTygI5FOtk5dvU0+QAZrkO4qPFH1wKiIjHQVLL3FV3yeKRSEZwOBULOd1OINQOSDzQMmdiYGFR6S+J3U0gfKkVWt5PKvlHY1LKidXbnkVq2/asm2OQK1rf60RIkXEHeplqFM1Og7VojFkq9BThSAcUoFUSOHtS0gH5UuO9MQppCPWjNFADCPWmnrUhHFMIpANNN5px+tJSGN9qXPPrSGgnjvQMlQ81ahfFUQeRU8bc1SZLRqRtnFWENZ8L9KuRtWqZjJFgUU1TTqsgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4rxle+deLaxn5Yhz7sf8B/M11WqXi2NlJMQCw4VfVj0Fefwhp7l5HO5skknuTyTWVR6WNqMdeYasWyIVXkq9cjAxVNhWB0plSReahYYBq2656VEy5HFIq5TbuKqzdTV2RfmqtMnrQUiuuc1VucpIrjsatgYNRXa7k96kpHR6XIJIUYelblsa5Dw7P+78s9RXVWjYNNEyNJO2KsJiq8eMVYSrRgyZad2pq04GrIFoNHY0dqAFpO1FB4NACetIaU980hpANNMNSmmkUDI8U008imnrSGhM0+NufaozQMg0AXoXq9E3FZUTc1egfpWkWZyRooakFVo2qdTWqMWOooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopHO1GJ7DNAHJeLrwPN5IPywjJ/wB4j+g/nWTYIUtwW6tzWZeavBKPNcszlizIR3Jz1qKHXFdsOmxfUHOK5ZSu7ndGm1GxqXHXntVYjmp1dZlDKwI7EUwoRSGiu680xlqwQSfrSMnFIDPlXLe9V5Fzn6VoSoaryJ7UijOZfzppTcMEVbkj5PFR7MdaRRn2cn2a+HOFPFdpZvuUHNcdqMJADit3QboSwqCfmHBpDequdVCQRVpDz7Vn2z5q6hyB6VojCSLCmpM1Chp4PFUQx2aWm5pc4piHZpKSjP5UgFPrSdqCaTNACmkNFITQMafpTSKeaaaQEZFHenGmtQMepxVqF+RVJSQanjYZppiaNSJ+KtIazYH6VdjatYsxkiyDS01TxThWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMAVIPQilooA8F1q3lsNSubaUEeW5APqM1RgnAbrXp3xF0ZZYhfJHuH3JgP0P9PyryTUIJbKbIy0J6N6exrjnHldj1aM1ONzpLC+eAgqcqeq10NndR3SZQ/MOoPUVwFpeAgAmte1uirB0cqw6EVKYTgdfspjrnIqjY6qr4S4IVv746H/AArTIDDPY1Ri1bcpsuc1EyVbZeahK9aAuU5EyM1AU5q8y1GUpFJlOWHzIiMVT02RrW7w3CscVsbPas+/t8HcopMpPodRaygqD+NacT8Vymi3e5PLc/MP1rord8/TtTTIkjQU1KpyarI2RUgPNWZE4NITTAaXNAD80maYTSFuaYWH7qC1RlqTd+dK4WJS1ISKjBo3dqAsPzz1pCabmkzQApo7UmaKBij0NOU1HnjNLmgC5C3NXoXrKjbBq7A9XFmckakbVIKrRNxU6nIrZGDQ+igUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA2VFkjZJFDIwIIIyCDXlvifw++m3TbELWkh/dsecf7J/zzXqlQ3dtFdQPDOgeNhgg1E48yNaVR03c8EudMhySuYz/ALP+Famm+GHnsradJpQ08rKvAI2gHnGPUV0HiPQJLBzn95Ax+STH6H0P863fDUaDTNGH92SRf0eue1nZnZUq3inE4WfSbuwJ85PNjH8aDkfVf8M1JY3bQgbTvhP8Of5V6NqlkoYkDhq4xvD7PayT2p2yea+VP3W+Y/l9aLGcat/iJ4JI7hSY2yR1B6iiWMg8isFJZba42uHimXqp6j/EVt2moRzAJPhW/vdj/hSLcbaojZe1NC9qvyQc8DNV2jKnmgVyAjFV51DIRVthiq0vrQNGOS1tcBlPT9a6nTblZo1Za5+6j3g+tO0e5MMwRzwakt6o7OJ8jrUobv61ThbgEdKnzVGViwGp27I69arBqdu5607isTFqQtUW706Um6gLEhbFIG5qLd60Z5pDsS7qXdxUO6lzzRcLEwNGaiB6UpOcdaYrEu6kz9ajDUuaAsPyKTIzTc8UE80BYmRsGrUL9KoA/Wp4mppktGxA+cVbjNZls9X4m4FbRZhJFkUtNU06tDMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCK5giuYHinQPG4wVNcVq1re6G6i1kDWhkDxlhna3XH+etd1UdxDHPC8Uyh43GGU9CKmUeYuE+V+Rw174vlaHabFfMHfzOM/lWHJ40kstMuIzYh7lpC6EHCDPr361o+INIfT7gryYW5jc9x6H3Fc1cwgggjmud3T1O6FOEldHn+rapqdxqzX8kzfaD6cAD0x6V0Og+IUusQ3JEdx0/2WpNS04E5C1g3Wm8kgc1Jvyq1j0+y1J4CqyEvD6dSv09R7f/qrayk0QeMhlPIIryXS9amstsN7mSEcBv4l/wAa67TNUEYE1q6yQt95Qf19jRcynT7G/NGRVSTPQ1ehuYruMPGw5qGaLPTrQQjMk6n1qnOuxw61fnQiqzjcpFSykdDpNx51upzzitIHiuW0Sfy5imcA810qnNNEtDycGlDVGx60buKBWJd3FJuqPPFB+lA7D8+1Jk00E5oJouA/dRnBqMntQDzRcLEoPI9aXdjrUIPGfSnZ4oCxLnjmjPrUYPtSgg0CsSZ796TdyaZmgnigLEitz1qVGOarA1IhppiaNOB+RWlC2axIHxitS2etYsxmjSQ8VKKrxHipga2Rgx1FFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFXUbOK+tXhmHDdCOqn1FeZ6vYPZ3TxSjDqfwI7Ee1erVj+IdMXULU7QPPQfIx/l9DWc43VzejV5HZ7Hk9xGCDnFZVxbqe1bWpqYJirArzgg9j6VQljLjK85rmZ6UXc569tFYHisyKS40+YvbuR6jsa6O7WOMlWO5/7q8msu5hldSVhCj1Y80F2uX9K8Sokg839zIeuT8jfX0ruLG+S6hUkYJ9wcV49dwyKeWA+gqfR9butJmUrIZIO8Z9Pb0oRE6Vz16eMEHNZcyFHIp2j6xbanaq8LgjuD1U+4qW4+9g80HPqtylBJ5d0h7ZrrLZ9yDmuPuBtkBzXTaY+63TPXFIbL56dqQHj3peMU31xTJFz70Z5ptB7Uhi549qTd/8ArppOOKTPvQMcTzxS7qjBpwoAdmlB4pgOM+lKKAHg96cM1GCAKUHIoESUmRSZzge1ID2oAeDTlJqLNKOtMRbiatK2fkVjoelXbeTkVcWRJG7C3FW0NZtu+QKvRtW8WcskTiikFLVkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFMkHFPqG9uIrW1knncJFGMsTQCOI8U2dit/JNfYVCgfqRzyO3XoK42+CTFhaxC2tvYYd/qe1bus3Tapd/a7lNkaDEMR7D1Pua53UboLn0rkk9dD1aMWkrlUrFAuEUKKytQu0UEA0y/viA2DWDI0t1KEiV5HPRVGTSR0DL2fcTtrKkZtxrrLDwhqN2A0u2BT2PJ/z+Na8PgKFQDcXDOe46CmJyR5/YancaZdrPbPhh1Xsw9DXqOg61Bq9mJIW+YcMh6ofSq48F6aq8xqT6kk/1rPm0lNFnE9gAjDqAThh6GkzOSUjortCVrV0GbMJVuorOspUvrFJF7jp6HuKs6WNkjKKRl5HQqwIyKcaii6D0qXFIkaenvTTzTz1PtUZ4NIY3PPFGOaPejkUDDHrS57UnagcGgB2cijPPtSCgUCHDmnfSmijv1pgPzxSZpo6+1LQIcDSg00/XFA9TQBKrDNWIH+brVQevapY25poTNq1k6VpwtkVg2z4xWvbvkCt4M5po0VORTqijNSitjBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABriPEupfb7t7aNv9Dtz8+P+Wjj+g/n9BW94n1E2Vj5cBxdT5SPH8I7t+H88VwN9ILeIRL2HNZVJW0OrD07vmZS1a8wCB0rj9SuwpJduau6xfDfsjy8hOAo7mtfwz4SLul9rI+b7ywnkD6+9YbnoXUFdnOaL4cvdacSyhoLQ87iPmYe1d1p2iWGlR7YYl3HqTyT9a1rmdETZCAqisi5nIPWmZ8zmWJpgucYArNuLwDODUd1IdnJ61kTORGfWpuaRiXW1DB+9WNq97vQ89agldsZzWJqt6qggt0pXNOQ3vA168l7c2zHKld4HoQQP6/pXaWq7Ljgda4r4a2bO9xesCFcbEPqO/wDSu6I2TA9KZzVFaVjYjHyj2pxB5ApIuYwcVJ+NBkRNxTGqYjt3qNhSGiIj0pCPSnkfnTSKQxOxo6UtITQMOSaXP50lKF45oEL/ACpO9BpelMAoyD9aOgo470AKKUHim/Wlzz1oEOye3Snqx61FnpTgaALsDcitW1k6CsSJsVo2smCK0izKaub0LZAqwpqhbvwKuoeK6Is5ZIkoooqiQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoNFQ3kwtrSadvuxIzn6AZoA4zWrkXGqXVwTmOH9zH+H3v8Ax7P5CuC8R6j5aFU+aR+AB1rptQk8rSEZjkldzH1Ncz4TsDq+sveT828B+UHu3/1q5JO7PVpJQjd9DS8HeHfJA1HUhmZvuqf4f/r10N5cckZwBUt3OANo4ReMVzuo3ZyQDRsTrN3YXt1+8AzxVKWXLZqtM5aQc0rZwD3pG6jYklfeuKzLxwowKtl8Zz1rEv5/mbmkaRRU1K6WKEgHmuVSGXVtTS2jzhjlj6CrmqXBJPP0rqfB2j/ZrcXEqfv5efoOwpFt2R2/huwS102JUGFUYAq3c/60VpW0QiskUDoozWZdH94DTtY89y5m2atrzCvNTEcVX09g0IyatkZFBJERTTUhHNMPSgaImycj0ppFSHpSHnoKQyPH1ox9OtPI6elFAxuMdqQ9TTieOelNxQAY/KijpzRn86AEo+tBpCeeKAFGRRmmk+vWj1oAfn/69HbmmZ5pQcdKBEqNjFXbd+RWeDViJ8GqQmjoLSTNaUTZxWFaSYIrXgbIFbwZyzReHSlpiGn1qYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVDX0aXQtQjjGXa3kAHqdpq/SMMjBoGnZ3PJPFU6/8I6JUPGwdKt+GIF0/RIIgBvZdzH3PNYfjCJtMa60ifIVGEkDHo8ZORj6dPwrVivVaCMDsAOD7VxvRnqWvFWJ9Qm2ofesC4yzfWruoTgnrWTcXA56UGkIinAbrRLcqi4JrLmuwuTmqEt3uJyaRqol6e7ADc1zup3aqGYmk1DUVRSAaZomlTaxcLNcqVtAcgH+OkVoibwtpMl/dC9uUPkLzGD/EfWvTdEtvMuFyPlTms62hSFAigKqjA9hXT6Nb+RB5jDEj9j2FJaswrVLIvzthMViXWc9a1pvums6dM9qtnKi5pDZjxmtEj0rH0xtkmK2cUCe40j1qM/XipWFRtzmkMiNHSnYNNI4NAxDSGlxgU09cUhjSaQ8U6k6UAJSUUlAB25pCfzoznk03oKQxcmkJ96DSZ5oAUGgUmaXdxTAcOKljaoR71IhHGaBGlavWzaycCuft3wRWtaScitYMxmjbjOanFU4GyBVpTXQmcrHUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO+NtK0/UtEmOpQ7/KUtG6nDK3bB9zivEJri+0SQ292GK9Ukxww9q9W17xDp+stFBpF7b3lvE+ZXgkDrvHRSR3HXH0rF1p1W1IkA5HTrXNVs2ehhm4x9Tzi4153xhuT2FVmu7yTlIpSD6Ia0b+8W3u4HUYCSK3T0Oa9DutStVQxxnzJMdEGcf4fjUJXN6ldwdlE8pistVvlLwW7lM4y2F5/Gqt9o+sxKPMiWMHgEuOf616Lbzaj9mMUapAhdm3feYAkn6Dr71GloqMZHLSSnq7nJpNpFRnUk9bJHE6J4TkdxNqjb+4jB4/GuxgiWEBUUADgAVakwKda27XE4Vc89fYVO5blZXZb0i08+XfIMop/M10Q+VaZbwrBEqKMADApzHrirSscU5czuNfvVVxmrDkYqE/eFAkMjXbJntWxEcqM1mY6HFXrZsrg0CZKwqNh/OpW9KjbpQNEWPypp61Ie5qNutIoax7Uw04/jSE9qQxpzmk5peKa1ACE/lTWPPvSnn6UhPFAxOR9KCe1B70h9KAEJ4xR3o7+lHQcUgAZpaQ0UxDh704cGoxjNPB6UAWITg4rStZKykPNXLdsECqiyJI6K2kyBV6M1jWj9q1IWyK6Is5ZotiimqeKdWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU2RlRGZiAoGST2p1ZXimZodCuShwz7Y/wZgD+hNJuyuOKu0j51+ATqNH1dyeuoSEZ7fKtd/fCbUXMVmuFzgyN+teAeEfHNv4V8N6larC81/NeO8a4wgG0DJP1HQV3lv8W9Lg8DAR3Eg8QfZP8An1bYJtvTpjGa55QbZ3QqRjFdyP426LFpvgbzxI8k5uoxvPHZugr0TRY4k0XTwFHNvGTj12ivEPHXxHtvGHgI2k1u9tqkc8bugBMbAZBKnt9D+te16Qf+JLYf9e8f/oIpSXLGzKhLnm3ctzSAKQBxVCSQABvwNSXUuwAn1rKnn/eeWOd3YVi2dUUWgWkkCIMkniup0uzFtFyPmbkmqOhacIYg8o/ee/atzcAMCrirHNVnzOyFJ4qM+ppTz+NJiqMSNsnmmfhUpWgp+dIojXrVqEYNQbcGpozQItHp05qNv0pVPFIx5oBDTnqDUbfpTz1phxj3pFIYfemnk09qYe9A0NPJppzSmkpDGt7U2nkU3jNACYpppzU3PFAwz9KTNGSaSgBetFB/WkFADhTgc0we9OX9aBEqnmp4mwetVx1qVTjFNCZrWknI9q2bd+BXPWz4xWvaP2rWDMJo14zkVIKrQtVgVujnaFooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArD8ZcaHIT0EiE/nW5WV4phM+gXigZKpv/75Ib+lTLVMum7STPl/4O6RY654b1az1S2jubdr58q46HavIPUH3FennQbf/hEh4eEswsxa/ZN+Rv2Yx16Zx7Vy3wt0C68M2V5b38kDvNctKpiJIAIA5yBzxXdPMvUmuaUtdD0IwtFXR5V8X9F07QfhmLPSrVLeBbqLO0cscNyx6k+5rvdPlEei2Bz/AMu8f/oIrB+KOkXHibw1/Z1jLBHN5ySbpmIXAz6A881MskkdnbWoO6SOJYzt6ZAApSleJUINTb6Et9dlyUUZY9K1dA00xt51wAZD0B7U3SNJ8thNP8znoPSt9AFGAKhLqOpUvoi0rhQAKVWyeagTnrUyiquc5KpzUqjIznmo1BqZRimIaV4NG04xUue2DRt9qYiBhxjvSDIqcqOajdeKQxUb2p+ciq/P6VIGoGOPpTCKcevHWmk0DGkUw8U4ntTT70hjD1pO+KcaaaQxDTSeKU+1NNACdTSGg0hPFIYE4ppOKDxSGgA706m96XimA7PNOB560wGlHrQIlU809DzUS/e5qRelMRcgbtWnav0rHjPI9a0LZsGrizOSN6BuBVxTxWZbPwOa0IjkV0RZzSRMKKQUtUQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTXUOjKwypGCPWnUUAeP6zYvpWqz2zA7AcofVT0NZl1dlSOa9n1HTbTUYwl5CsgHQ8gj6Ec1z83gTTHJKSXCN2ywYD9K5pUHfQ9CGLjb3lqeWBprptiKcHua2bDT4oQHb5n9a6LU/Bd1bpvsJVuAP4CNjfhzg/pXMiaWGVo5VZHU4IIwQaycXHct1fabGunFSrVKCfdjIq9H83IoIZIgz0qdFpiKetWY0OKokVV9KmA4HNAHbtTwvHSgkbtpwHan7eKAPwpgRkY68UxxkVMR0xUbDg0AVnGKF4NSsvtTccUihDSGg02kMQ9M009OaX600+9AxCaaeDSk0w0hgTxTc8UGkpDE/lSUpNNJ5oAQ8UhOTRmkNABmjPFNJGaAaAJM56U4HpUYNKD60wJQeaepP4VEpp6mmIsIePertu2DVCM/nVqE9KpEM3LVulacJ4rDtX6VsW7ZFbxZzTRcWnVGpp4rQyFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArhfHWlJ9tivEGDMNr4/vDp+n8q7qsPxhGH0pWxykqkfjkf1qKivFmlJ2kjgYbYjGavQIQanhjz1qwkGRXKkdbYRICBVhF5p0cRA6VIq+1URcYq9KlVPanquKdjBosK4z3pD0p7U00wGN0FRH3qRqjIpDGZ6io27nFPY8VGxpFIaTz0puaU0wmkMQmkJozTTSKA0wmlamnvk0hiE5prUpNNJ/KgAOTTScUEimMRQMUmmE0jGm559qBi5pQaZmgnrQIkyaUNzUWSadnNAiZTUinNQA4709WGeKYi0hqzCapxk1aiPNWiGaVscEVsWrdKxLc9K17U9K1iYTNOM1KKgiPAqcdK1RixaKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsfxX/yCWHq6/zrYrF8W/8AIKH/AF1WplsyofEjnYVBAq5GOMiqtvyBVyP865kjrZIBwDSgHFOA9BSgUyBFGKKUikJ4oAb9aYx605jTGPHNA0MY5zUbfdpx/WmMeKRQwnvURp7fpUZx1PWkMQnmo88U5jTCaRSEJpuR060MeaaTikMGxmkJprHI60wtxSKHFhzTGamMeaaT3FAx270pme1ITSdKQC9abS4pMUwFFBGfc0d6Td2oEKetKDTCeaTNAEoanofzqBevNSqTTEWkNW4TmqKE8VbhNUiGadv2rVtSBjmsi2PStKEgAGtomEjYi6VOBxUcCbY1z1xUtaowYUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZXidN+jTnH3SrfkwrVqG8hFxazQnpIhX8xSaurDi7O5xlt0FXYxxWbaHjB+8OD9a0IzXKjrZYHSikU0uaZIUjcZpcimkjPWgBrVGTz7U88jGKjPU0ikMPU+lQsc5zUhPGaif2oGhjHj3qNu3pTmPFMY4qSkNaomPr0p7H0PFRNQUhGbmm7veg+9N7mkMCeaYSaXPUUw96QxGpuaU5/Cm9KQw/nS9qaaX6UwDvQTSGkP4UCDPNITSE8YpN1ABnvSg803+VAxTEPUk1Ip4qFTg9aerc0AWozVqJveqSsAKu6dbTXs3lQJuPf0A9Sapa7EM0LUs7qqAsx4AHeuosLIQqHl+aX9Fo0vTo7GIAfNKR8z+v/ANar1dMY23OSc77BRRRVmYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcXrVubLVnIH7qf94v1/iH58/jRE+cV0euWP26xZUA85PmjPv6fjXH28pyQQQw4IPBBrnnHlZ0wlzI1VbgU8HpVVGyODUu/P1xUlEuQTyaRj05pmffikLUAKTycVGSaC1Rs/XFIYjH1qJiDQ7ZyKjc0ikDYqM9aGNNYmkMaxqM+1OJODTT+tBSGE+pppOKceKY31pDENNNFIaQxDTG9qefSmGgBM8mjPFIaQ0AKTSE0hNJnmgAJpDTWdVJywBAyR7VTvJ3ksZ/sLfvzGTESOC23IxnrTAuk015EjALsqgkKMnHJ6CuObUXinOomQu8aKjt0BAycEdtwOPZ1xTLmeeSO90q6aaaWQLLbt1JJfIIPYcA89MHtinYm52u7ml3gViCHUGxDNdp5CnmRFIlceh7D6j8MV3vh3wtJdhbnUQ0cB5WLozfX0H604xcnZClJRV2U9C0m41WXKfJbg4aUjj6D1NegadYwWEAit0wO5PVj6mp4Yo4IkjiRURBhVUYAFPrphBROOpUcwoooqzMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArmvEulMxN7aJlxzKi9x6j3rpaKUoqSsyoycXdHn1vOCAQQasiQVc8Q6I0bPeWK5U8yRKOnqR/hWHDcbhiuZpxdmdUWpK6NLzPX8KN/vVTzM0b/ekOxZZxyKjZ/eofM4zTGfNAErt71GzdTmmF/emF6RQ8t3phNMLU0tSGPLUhI9ajLUmaBiscUxmoZvxphbNIYpOTTd1IW5puetAxxb3ppPqc00txSE0AOJGKaTTScd6aXAoAryajbJcGEyYcMFJ2naCegLYwD7ZqtdXzRXbqGARQEbeOFY/df12k5B9xUWmbJtKZZVDCVpPNB7ksc1iTrNfzzQJPu+yL5ZwcNcqTypbt025/vA9KYtStbXl3Nq2+6Ci5VmgjlZcFHDFlRsdmUkZ75HcZqzc3lxdTTR2scrzxyJPCxOfIkPDI3tw34H6Vfg05Btab5n2eWw7OqtlCf9oADke9benabd6jMVsbdpG/iYDAH1PSi99hWstWc+ulyXV1cz3pFuZ1VHitnysijOSxIzzntg4710Og6FJcMYdJtFRScsyjao9ya7LSPA6Jtk1ObzD3ij4H4nqf0rsba3itoVigjWONeiqMCtY0m/iMZ14r4TD8PeGbbS9s02J7ofxkcJ/uj+tdDRRW6SSsjllJyd2FFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABrmNe8OiXdcacAs3Vougf6ehrp6KTipKzKjJxd0eXCV4pGjlVkkU4KsMEVIJgR1rv9U0u11OPbdR5YfddeGX6GuO1Hwtf2zlrMi6i7DIVx+B4P+eK55U2tjpjVjLfQz/N6UgkqjO0ts5juI3ifoQ4INNFwD3rM1saO/imliRVETjuad549aLhYslqQsRVfz6QzDPWgdixmmFqgM4ppnA70DsWSaaTzxVY3HvTGuPekFiyzU0nk81VNwMdajaegdi2XAzUbTACqbTe/FMUtIwCAsT2ApXHYtNPxULSk960rHw1q94FaO0dEP8UpCD9ef0rptN8BICG1G6LHvHCMD8z/AICqUJPoRKrCPU85a0YzP5FxNFHKdzxpjknqQcZGfat/SPBd5eNbyRW/2WKJSqs5K/Ke2Op9a9S03SLHTRizto42xgtjLH8TzV+to0e5zyxH8qOW0zwXp9qFa63XUnX5uF/If1rpoYo4Y1jiRUReAqjAFPorZRS2MJSct2FFFFMkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCG5tobmPZcRJKh7OoNYV74P0y4yYlkt2PeNuPyNdHRScU9ylJx2Zwd14FmUf6JfI3oJEK/qM1j3PhXWoPuwLKo7xuD+nWvVKKh0os0VeaPF7iyv7b/AI+LWeMerIRVMynpzmvdKrzWVtMf31vDJ/vIDUOh2ZosT3R4l5x9aYZjXtR0fTT1sLX/AL9L/hQNH00f8uFp/wB+V/wqfYPuV9ZXY8UMrN05+lTw2t5ccQWs8hP9xCa9qis7aL/VW8Kf7qAVYHFNUO7JeJ7I8ftPC2tXJGLNox6ysF/Q81t2fgG5fBvLyOP1CAsf6V6LRVqjFEPETexytl4I0yDDTGSdh/eOAfwFb9lptnZD/RbaKL3Vefzq3RVqKWxk5yluwoooqiQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tongue is protruded as far as possible. The measurement (in millimeters) is taken from the lower incisors to the tip of the tongue, as illustrated above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_1_21535=[""].join("\n");
var outline_f21_1_21535=null;
